Constraints on the CD8 T cell response in chronic HBV infection by Das, A.
1 
 
 
Constraints on the CD8 T cell response in chronic HBV infection 
 
A thesis presented to University College London 
for the degree of Doctor of Philosophy by 
Abhishek Das 
 
September 2008 
Department of Immunology and Molecular Pathology, 
Division of Infection and Immunity, 
University College London 
United Kingdom 
 
  2 
 
 
 
Declaration 
 
'I, Abhishek Das, confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been indicated in 
the thesis.' 3 
 
Abstract 
The inflamed liver in chronic hepatitis B virus infection (CHB) is characterised by a large 
influx of non-virus specific CD8 T cells, which we hypothesize could provide insights into 
mechanisms of failure of viral control and liver damage in this setting. We compared the 
effector function of total circulating and intrahepatic CD8 T cells in CHB patients and 
healthy donors. We demonstrated that CD8 T cells from CHB patients, regardless of their 
antigen specificity, were impaired in their ability to produce IL-2 and proliferate upon TCR 
dependent stimulation. By contrast, these CD8 T cells had preserved production of the 
proinflammatory cytokines IFN-γ and TNF-α.  
We provide evidence that this global CD8 T cell impairment of IL-2 production and 
proliferation may be partially attributable to a) downregulation of the proximal TCR 
signalling molecule CD3ζ (zeta), secondary to L-arginine depletion within the inflamed 
hepatic microenvironment and b) exhaustion of CD8 T cells associated with a terminally 
differentiated phenotype and shortened telomeres following long-term exposure to high 
level viraemia.  
In addition, we implicate IL-10 as a regulatory cytokine in CHB, and show preferential 
suppression of HBV-specific CD8 T cells compared to responses for other viruses by IL-
10 blocking experiments. Circulating IL-10 levels were elevated in patients and correlated 
temporally with viral load and ALT (surrogate marker of liver inflammation) during 
spontaneous flares of CHB. B cells were shown to be a potent source of this cytokine upon 
CpG stimulation, and these ‘regulatory’ cells, identified as CD24
highCD38
high transitional, 
were selectively enriched in CHB and correlated with disease flares. Depletion of this 
subset rescued HBV-specific responses, implicating a pathogenic role in suppressing T cell 
function and viral persistence in this setting.  
Collectively, our data imply that impairment of CD8 T cell function during CHB is likely 
multifactorial, and that these polarised CD8 T cells may then both impede viral control, 
whilst contributing to the pro-inflammatory cytokine environment. 
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Layout of Thesis 
The introduction (Chapter 1) of this thesis describes the structure of the hepatitis B virion, 
and the epidemiology, clinical course and treatment of chronic HBV infection. A broad 
overview of innate and adaptive immune responses against viral infections is provided, 
with more focussed sections detailing the immune response during acute and chronic HBV 
infections.  
Chapter 2, materials and methods, contains details of protocols and reagents used. 
A large influx of non-antigen specific CD8 T cells is recruited into the livers of patients 
with liver inflammation and high viral load, however, their role in CHB is unknown. In 
chapter 3, we analyse the functional characteristics of CD8 T cells from the periphery and 
liver of patients, and demonstrate a global CD8 T cell dysfunction in IL-2 production and 
proliferation. In the following chapters, potential mechanisms for dysfunction within both 
global and virus-specific CD8 T cells are studied. 
Chapter 4 provides evidence that downregulation of proximal signalling molecules, 
CD3zeta and CD28, are associated with impaired CD8 T cell function. Furthermore, 
downregulation of CD3zeta is linked to L-arginine depletion, and this is heightened within 
the HBV infected liver where we detect higher expression of the enzyme arginase-1, which 
catabolises L-arginine.  
Chapters 3 and 4 have been published this year (Das et al. 2008) and therefore will be 
presented concisely in this thesis. The introduction and discussion sections for chapters 5 
and 6 however are more thorough. 
In chapter 5, we investigate whether chronic viral stimulation during CHB may drive CD8 
T cells prematurely towards a terminally differentiated, immunosenescent state. We show 
that there is an accumulation of highly differentiated end stage cells in young patients with 
high viral load, and these cells have the shortest telomere length.  
Finally, in chapter 6, we analyse whether global CD8 T cell hyporesponsiveness could be 
partially mediated by the immunosuppressive cytokine IL-10, and whether a subset of 
transitional B cells may regulate the immune response via production of this cytokine. 19 
 
1 Introduction 
Viruses do not themselves possess the adequate machinery to replicate, and are therefore 
dependent on their host cells for survival and transmission. It is not in the interest of the 
host cell however to harbour such microbes, which compete for cellular resources, mediate 
cell damage and immunopathology and may have oncogenic potential. This conflict of 
interest is the basis for a dynamic host-virus interaction, the balance of which determines 
whether viral infection is cleared or persists.  
On the one hand, viruses have developed a multitude of evasion strategies to hide from or 
directly attack the immune response against them. On the other hand, the immune response 
has co-evolved to mount a series of timed defensive strategies to block viral entry and 
actively suppress replication. The innate immune response is the first line of defence, and 
through production of anti-viral type I interferons (IFNs) and NK cell mediated lysis of 
infected cells, attempts to rapidly control viral replication at the local site of infection. 
Viral control may also be mediated by other innate mechanisms, for example, by 
intracellular anti-viral restriction factors belonging to the APOBEC (apolipoprotein 
BmRNA-editing  catalytic polypeptide) and TRIM (tripartite motif) family of proteins 
(Takaori-Kondo 2006;Towers 2007). Professional antigen presenting cells including 
dendritic cells are primed at this stage, and provide a critical bridge to initiate the following 
adaptive arm of the response. Although CD4 T cell help and production of neutralising 
antibodies by B cells are required for an efficient adaptive response, it is generally 
accepted that CD8 T cells are the main mediators of viral clearance. Since the discovery by 
Doherty and Zinkernagel that CD8 T cells can recognise foreign viral particles in the 
context of self-MHC (Zinkernagel & Doherty 1974a;Zinkernagel & Doherty 1974b), many 
studies have characterised how these cells recognise and combat virus infected cells, 
through both cytolytic destruction and non-cytolytic clearance of virus with curative 
cytokines. A strong, multi-specific CD8 T cell response is associated with disease 
resolution, however a weak mono-specific response can result in viral persistence. 
Why the immune response controls infection in some individuals but not in others is as yet 
unclear. Further studies are required therefore, to understand the underlying basis for 
immune dysfunction in the setting of chronic viral infection. This will facilitate the 
development of novel immunotherapeutic strategies which are in great need to reduce the 
global burden of disease associated with persistent viruses.  20 
 
1.1 Epidemiology 
Chronic hepatitis B virus infection (CHB) affects over 400 million individuals worldwide, 
and confers a high risk of liver cirrhosis and hepatocellular carcinoma which result in over 
one million HBV related deaths per year (Beasley 1988;McMahon 2005). The 
geographical areas of highest disease prevalence include Sub-Saharan Africa, China and 
parts of South-East Asia, whereas Western Europe and the United States are classed as 
low-endemic areas. Perinatal transmission from mother to baby is the most common 
method of virus transmission, however in highly endemic areas, virus may also be spread 
horizontally through close personal contact with individuals, or through sexual contact. 
Infection at birth confers a 90% risk of subsequent chronic infection, possibly due to early 
tolerance of the neonatal immune system by HBV antigens. The risk of chronic infection 
declines however with increasing age (0-5 yrs risk = 25-30%; >5yrs risk = 5-7%) 
(McMahon 2005). In the U.K., the incidence of chronic HBV infection is rapidly rising, 
with an estimated 7000 new cases between 1996 and 2000 (estimation based on 
mathematic modelling and WHO estimates of chronic disease in different countries). 
Although a proportion of these cases were secondary to hetero/homosexual encounter or 
through sharing of intravenous needles, the large majority (96%) were in fact seen in the 
migrant population (Health Protection Agency 2006). This may be a by-product of 
globalisation, frequent international travel and immigration, which have increased in recent 
times.  21 
 
1.2 Hepatitis B virus 
Hepatitis B virus is a hepatotropic and non-cytopathic virus, which is a member of the 
hepadnaviradae family. These viruses somewhat resemble retroviruses, because they 
replicate through reverse transcription of an RNA intermediate, the pregenomic RNA. 
However, unlike retroviruses, hepadnavirions contain DNA and not RNA (Beck & Nassal 
2007).  
HBV virions (Dane particles) are 40-42nm particles, with an outer lipoprotein envelope 
encasing an inner nucleocapsid or core. Contained within this inner core is a relaxed-
circular, partially double-stranded (full length negative strand, and an incomplete plus 
strand) DNA genome consisting of approximately 3200 nucleotides, and the polymerase 
protein required for synthesis of viral DNA (Rehermann & Nascimbeni 2005).  
The genome incorporates four overlapping open reading frames; surface, core, polymerase 
and X genes. The X open reading frame encodes the viral X protein (HBx), and the P 
coding region encodes the viral polymerase required for RNA encapsidation and DNA 
synthesis. By initiation of translation at three different in-frame initiation codons in the 
preS-S region, the genome can encode three different proteins; S protein/HBsAg, M/preS2 
protein and the L/preS1 protein. PreS1 may be required for the binding of virus to the host 
cell. Finally, the preC-C region can encode the HBV core antigen (21kD), a structural unit 
of the viral capsid, or if translation is instead initiated at the upstream AUG codon, a larger 
preC protein (24kD) is formed. The extra portion of the preC protein includes a sequence 
that directs it into the secretory pathway where it is cleaved by proteases in the Golgi to 
generate the 16-kD HBeAg (Ganem & Prince 2004). 22 
 
 
Figure 1a: HBV genome and the HBV virion (Dane particle) structure. Modified from 
(Ganem & Prince 2004;Rehermann & Nascimbeni 2005). 23 
 
1.3 Hepatitis B virus replication 
HBV virions bind to (as yet unknown) cell surface receptors and are internalised. HBV 
nucleocapsids then transport the genomic HBV DNA to the nucleus where the relaxed 
circular DNA is transformed into covalently closed circular DNA (cccDNA), which is the 
template for the transcription of four viral RNAs of varying lengths by the enzyme RNA 
polymerase II. Viral RNAs are then transported to the cytoplasm where they are used as 
mRNAs for the translation of HBV surface, core, polymerase and X proteins. 
Nucleocapsids are then assembled in the cytoplasm, into which a strand of pregenomic 
RNA is encapsidated with the polymerase protein, and is reverse transcribed inside the 
nucleocapsid. Pre-genomic RNA is reverse transcribed to minus-strand DNA, which is 
then used to synthesize plus-strand DNA by DNA polymerase.  Resulting core particles 
may either bud into the endoplasmic reticulum and be enveloped with L, M and S surface 
antigens and released as virions, or a smaller proportion are transported back to the nucleus 
where newly formed DNA genomes are converted to cccDNA, to maintain the pool of 
transcriptional templates. In addition to whole virions, large amounts of 20nm sphere and 
filamentous HBsAg particles are also generated, which outnumber virions by a factor of 
10
4-10
6. High circulating concentrations of HBsAg are found in microgram quantities in 
patients with HBV, which is not seen in other human viral infections (Ganem & Prince 
2004;Rehermann & Nascimbeni 2005). 24 
 
 
Figure 1b: HBV Replication Cycle. Adapted from (Fung & Lok 2004). 25 
 
1.4 Animal models of HBV 
Study of the pathogenesis and immunology of HBV infection has been hampered by the 
lack of suitable animal models and tissue culture systems for HBV. Data on acute HBV 
infection have come mainly from chimpanzees experimentally infected with HBV, or 
humans accidentally exposed to it, although in the early 1950’s, studies were conducted in 
172 male inmates of U.S. Federal Penitentiaries experimentally inoculated with pooled 
plasma samples harvested from patients with hepatitis B (Murray 1955). Mice are not 
susceptible to HBV infection, however transgenic mouse models in which HBV can be 
expressed in the liver have proved useful, although they do not spontaneously develop 
hepatitis in the liver, and require infusion of T cells from non-transgenic mice. 
Furthermore, in these animals, cccDNA is not produced like in human infection (Wong & 
Pamer 2003). Recent advances however have been made by study of animal models with 
related hepadnavirus infections, including pekin duck and woodchuck HBV. Infection of 
woodchucks with woodchuck hepatitis virus (WHV) can result in persistent infection, 
chronic hepatitis and hepatocellular carcinoma much like in human CHB. Study of these 
animals has been facilitated by the set-up of woodchuck breeding colonies, and the 
constant development of immunological tools to study them. Infection of neonates has also 
helped in understanding early events which may later determine viral clearance or 
resolution. In addition, these models may further be used to evaluate the safety and 
efficacy of novel drugs, vaccines and immunomodulators (Menne & Cote 2007;Menne & 
Tennant 1999).  26 
 
1.5 Clinical course of acute and chronic HBV infection 
Primary infection with HBV can be either symptomatic or asymptomatic. 95% of adults 
clear the infection and develop lifelong immunity, however in less than 5% of individuals, 
persistent infection is established which can progress to chronic hepatitis. 1% of 
individuals may develop fulminant hepatitis associated with large-scale tissue damage and 
may require a liver transplant with or without antiviral therapy (Dusheiko & 
Antonakopoulos 2008). Approximately 20% of patients who develop chronic hepatitis 
progress to liver cirrhosis, and the chance of developing hepatocellular carcinoma is also 
increased by 100-fold (Beasley 1988). The development of chronic hepatitis is much 
higher if infection is acquired by vertical transmission. Babies born to HBeAg positive 
mothers have a 70-90% risk of contracting the virus and 90% develop chronic hepatitis. If 
the mother is HBeAg negative however and is able to partially control viral replication, the 
risk of infection is reduced to 10-40% and rate of chronicity is also reduced (40-70%) 
(Alter 2003). 
Chronic infection has a dynamic course which varies greatly between patients. Patients 
may be divided broadly into 3 categories of disease; HBeAg positive CHB, HBeAg 
negative CHB or HBeAg negative inactive carrier state (Dusheiko & Antonakopoulos 
2008). HBeAg positive patients are characterised by a high level of HBV replication 
sustained over a long period of time. They may or may not have raised ALT. Individuals 
who are infected at birth go through an immunotolerant phase, characterised by elevated 
HBV DNA (>10
5 copies/ml) and presence of HBeAg in the serum, in the absence of liver 
inflammation (Figure 1c(a)). This may be due to HBeAg mediated tolerance of the immune 
response, which subsequently fails to control HBV replication, and does not mediate 
damage to HBV infected cells via cytolytic killing which would normally cause liver 
inflammation. In most patients, there is a decline of serum viral load titre over time, and 
HBeAg to anti-HBe seroconversion occurs at a rate of 5-10% per year (Figure 1c (b)). Rate 
of clearance of HBsAg however, is much more rare at 0.5%/year. As mentioned above, 
HBeAg negative patients may fall into two groups. The first group are patients with anti-
HBe positive chronic hepatitis. In these individuals, absence of HBeAg from the serum is 
due to viral mutations in the preC region which prevents its expression. These patients are 
susceptible to active flares of liver disease associated with acute increases of HBV DNA 
and ALT. Necroinflammation and varying stages of fibrosis can be seen on liver biopsy 27 
 
(Ganem & Prince 2004). The second group have seroconverted to anti-HBe status, and 
typically have normal ALT and HBV DNA <10
5 copies/ml (Figure 1c (c)) (McMahon 
2005). These individuals are termed anti-HBe positive inactive carriers. It may be difficult 
to distinguish patients in these two groups, and this may require longitudinal follow-up of 
viral load and ALT as well as analysis of liver biopsy tissue.  
 
Figure 1c: Clinical course of acute and chronic HBV infection. Fluctuations of serological 
markers, serum viral load and liver inflammation (ALT) over the typical course of acute 
and (vertically transmitted) chronic HBV infection. Modified from (Rehermann & 
Nascimbeni 2005). 28 
 
1.6 Vaccine and Antiviral therapy 
A safe and effective vaccine against the hepatitis B virus surface antigen has been available 
since 1982 (Lavanchy 2004). Its efficacy has been shown in countries like Taiwan where 
introduction of the vaccine into routine immunisation schemes has reduced the prevalence 
of HBV infection by 93% in under 15 year olds (Namgyal 2003). However, despite its 
success and a recommendation by the WHO in 1991 that all countries implement the 
vaccine into their routine immunisation schemes by 1997, overall uptake has been poor 
(116/215 countries took part in 2000), due to a number of limitations (Alter 2003). The 
main obstacle is cost, which has hindered its introduction in many low income countries 
such as India and Sub-Saharan Africa, though some progress has been made by the Global 
Alliance for Vaccines and Immunization (GAVI) in funding vaccination programs in some 
of the 74 poorest countries in the world which it supports (Global Alliance for Vaccines 
and Immunization). However additional hurdles remain, including lack of infrastructure in 
developing nations, poor compliance with the full course of immunisation (3-4 
intramuscular doses) and suggested, though uncomfirmed case reports, that link the 
vaccine to Rheumatoid Arthritis (Duclos 2003) or demyelinating diseases such as Guillian-
Barre Syndrome (Khamaisi et al. 2004) that further hinder implementation of vaccination 
programs.  
Despite the availability of a vaccine which can effectively prevent the development of 
chronic hepatitis in 95% of cases (Lavanchy 2004), there is still a huge burden of patients 
with chronic HBV infection worldwide for whom the prophylactic vaccine is of no use. 
For these patients, anti-viral therapy is used to reduce morbidity and mortality; however 
existing treatment is rarely curative and therefore of limited efficacy, with ongoing 
problems of toxicity, intolerance, viral resistance and expense. Finite treatment regimens 
are not suitable for the majority of patients, and the endpoint goal of treatment may be 
more focussed on preventing progression to liver cirrhosis, hepatocellular carcinoma and 
end stage liver disease. Due to the heterogenous nature of disease which varies between 
individuals, treatment regimens vary from monotherapy to combination therapies with 
different drugs. Licensed drugs include the immunomodulator IFNα, and nucleoside and 
nucleotide analogues, which interrupt viral replication. Lamivudine, a potent nucleoside 
analogue reverse transcriptase inhibitor, has been the main first line treatment because it is 
inexpensive, has a good safety record, and can suppress HBV DNA in the serum reliably 29 
 
by 2-4 log10. However, drug-resistant viral mutations emerge quickly due to the rapid 
error prone replication of HBV (Ling et al. 1996). Furthermore, ‘immunotolerant’ patients 
who characteristically have a low level of liver inflammation but high viral load, have a 
poor response to lamivudine. No resistance is developed against IFNα treatment, however 
this therapy is generally of limited efficacy and is very poorly tolerated. Other commonly 
used therapies include Adefovir (nucleotide analogue that blocks reverse transcription) and 
Entecavir; a guanosine analogue which blocks the HBV polymerase at three stages; base 
priming, reverse transcription of the negative strand from pregenomic RNA, and synthesis 
of the plus strand of HBV DNA by DNA polymerase. New emerging drugs in the U.K. 
include Tenofovir (not yet licensed), which has a similar mechanism to Adefovir however 
is thought to be less nephrotoxic, and may be more suitable for patients with highly 
replicative HBV or HBV/HIV coinfection (Dusheiko & Antonakopoulos 2008).  
Although new emerging drugs and treatment regimes may successfully suppress HBV viral 
load for longer and with fewer side effects or further clinical sequelae, it is unlikely that 
this therapy alone will provide a definitive cure which can be delivered cheaply and 
efficiently to millions of individuals in developing countries suffering with chronic 
infection today. Clearance of viral infection and disease resolution will probably require a 
synergistic boost to the host’s own immune response, and this approach in addition to 
suppression of virus load with antiviral agents, may tip the balance in favour of viral 
clearance. There is a great need therefore to better understand the mechanisms of disease 
and why the immune system fails in some, but not other individuals. This knowledge will 
facilitate development of novel immunotherapeutic strategies to aid viral clearance and 
reduce the global burden of disease- the ultimate aim of research into viral infection. 
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1.7 The immune response against viral infection 
1.7.1 Innate immune response 
The immune system is equipped with a sequence of defensive manoeuvres which are 
revealed at different points over the course of viral infection. The innate response is 
initiated almost immediately after inoculation, and aims to rapidly contain viral spread. 
The hallmark of this response is production of Type I IFNs, which can inhibit viral 
infection but also have immunoregulatory effects including induction of NK cell function 
(Lanier 2008), Dendritic cell maturation (Dalod et al. 2003) and priming of CD8 T cell 
responses (Tough et al. 1996). Production of other cytokines such as IL-12, IL-6 and TNF 
may also contribute to viral control (Pichlmair & Reis e Sousa 2007). NK cell IFNγ 
production or direct lysis of infected cells too is important during the innate response. 
These cells may recognise altered levels of MHC-I on infected cells, or become activated 
by stress-induced molecules (Moretta et al. 2005).  
Type I IFNs can be produced by all nucleated cells in response to viral infection. Their role 
as factors which interfere with viral replication was first demonstrated by Isaacs and 
Lindenmann in 1957 (Isaacs & Lindenmann 1957). Infection of mice with Lymphocytic 
Choriomeningitis Virus (LCMV), an RNA virus which in some cases is hepatotropic and 
can induce acute hepatitis, is a useful model to study both the innate and adaptive immune 
response, as it is possible to reliably induce either self-limiting or persistent infection by 
altering the strain/dose of virus or the inoculation procedure. Despite the presence of 
adaptive immunity, mice that lack normal IFNα and IFNβ signalling pathways were 
unable to clear virus infection (Muller et al. 1994;van den Broek et al. 1995). 
Depending on which cellular compartment the virus occupies within an infected cell, 
distinct cytosolic or endosomal pathways can ‘sense’ viral nucleic acids and induce type I 
IFN production, although leakage of viral nucleic acids between compartments allows for 
cross-talk. In the cytosolic pathway, viral RNAs are recognised by MDA5 (melanoma 
differentiation factor-5) and RIG-1 (retinoic acid inducible gene I) resulting in a 
downstream cascade of events leading to the phosphorylation of transcription factors IRF3 
(interferon regulatory factor 3) and IRF7 which induce Type I IFN production. 
Alternatively, the virus may be taken up into endosomes where their nucleic acids are 
exposed to Toll-Like Receptors (TLR), a type of Pattern Recognition Receptor which 31 
 
detect pathogen-associated molecular patterns (PAMPs) found in a variety of bacteria, 
viruses, fungi and protozoa (Kawai & Akira 2006). In plasmacytoid dendritic cells, major 
producers of IFNα, detection of viral nucleic acids by TLR 7,8 and 9 leads to MyD88 
mediated phosphorylation of transcription factor IRF7 which regulates expression of Type 
I IFN. TLR’s can also be found on the surface of cells including hepatocytes, and TLR4 for 
example, can induce IFNα and IFNβ via the TRIF pathway (Pichlmair & Reis e Sousa 
2007). 
Binding of Type I IFNs to their receptor initiates a signalling cascade which upregulates 
the expression of IFN stimulated genes (ISGs). These genes code for proteins involved in 
viral control, including the TRIM and APOBEC proteins; restriction factors which target 
incoming retroviral capsids and deaminate retroviral genomes respectively. Other ISG’s 
include MX1 (myxovirus resistance 1), IFN-inducible double-stranded-RNA-dependent 
protein kinase (PKR) and IFN-regulatory factor 1, and are equally important in antiviral 
function (Pichlmair & Reis e Sousa 2007). Apart from their direct effects on gene 
transcription, type I IFNs are also important in priming the adaptive immune response and 
initiating NK cell production of IFNγ (Lanier 2008). The role of NK cells in innate 
immunity will be further discussed in the context of acute HBV infection in a later section. 
Therefore, early exposure to cytokines, an inflammatory environment and varying doses of 
viral particles may affect how the adaptive response is primed, and the overall outcome of 
infection. 
1.7.2 Early innate response to HBV 
It has been difficult to study the very early immune events after HBV infection in humans, 
due to the fact that patients usually present with clinical symptoms which only develop 10-
12 weeks after inoculation, past the point where the burden of viral load has already been 
cleared. However, data from chimpanzees experimentally infected with HBV and limited 
data in humans accidentally infected with HBV have provided some information on the 
early control of this disease. 
In order to survive and be successfully transmitted to another host, most viruses replicate 
rapidly upon entry in an attempt to overwhelm the immune response. This can be shown in 
the mouse model of LCMV for example, where inoculation with a high dose or rapidly 
replicating strains of virus results in impairment of the adaptive virus-specific CD8 T cell 32 
 
response and leads to persistence of infection (Moskophidis et al. 1993). Fast viral spread 
is also true for hepatitis C virus (HCV) infection where virus in the serum was detectable 
1-2 weeks post inoculation, in 5 health care workers accidentally infected with HCV 
through needle-stick injury (Thimme et al. 2001), and a similar kinetic of viral load was 
observed in acutely infected chimpanzees (Major et al. 2004).   
Hepatitis B virus however does not behave in this manner, and instead both viral load and 
HBeAg/HBsAg particles are undetectable within the liver and serum of patients for 4-7 
weeks (Guidotti et al. 1999b). Previous studies have speculated that this may be due to 
inefficient replication in hepatocytes or habitation of immunopriveleged sites apart from 
the liver such as the brain (Bertoletti & Gehring 2006). Alternatively, one could postulate 
that suppression of replication could also be immune mediated. IFNα and IFNβ have been 
shown to non-cytolytically inhibit HBV replication in a transgenic mouse model, and this 
was associated with a ten-fold decrease in viral capsids containing HBV pregenomic RNA 
(McClary et al. 2000;Wieland et al. 2000). Furthermore, HBV infected hepatocytes may 
produce type I IFNs (Chang & Lewin 2007) and PH5CH8 cells (derived from non-
neoplastic hepatocytes) produced IFNβ in vitro upon stimulation with poly (I:C) or Sendai 
virus by TLR3 or RIG-1 mediated pathways respectively (Li et al. 2005a). However, novel 
gene profiling studies provided strong evidence against this argument, and showed instead 
that the type I IFN response was absent during the early stages of HBV infection. Wieland 
et al showed that in serial liver biopsies isolated from 3 HBV infected chimpanzees, there 
was no intrahepatic gene expression during the entry and incubation phases (Wieland et al. 
2004). In contrast, 27 genes were upregulated upon HCV infection, many of which were 
regulated by the type I IFNs (Su et al. 2002). HCV infection is accordingly associated with 
induction of a strong Type I IFN response, whereas HBV has been described as a stealth 
virus as it is able to evade the innate immune response altogether.  
After an initial quiescent phase, there is a rapid exponential rise in viral load, to the point 
that serum levels may reach 10
9-10
10 copies/ml and almost all hepatocytes may be infected. 
This initiates an acute phase response characterised by a robust activation of TNF and 
IFNγ, which is associated with clearance of up to 80% of virus load. This occurs prior to 
the influx of both virus specific and non-virus specific lymphocytes into the liver, which in 
chimpanzees and humans, appears 2-3 weeks later and correlates with liver inflammation 
and clinical symptoms in patients (Guidotti et al. 1999b;Webster et al. 2000). These data 33 
 
imply two things; 1) clearance of the majority of HBV DNA is non-cytolytic and tissue 
sparing as it precedes liver inflammation and 2) production of IFNγ at this early stage is 
not likely to be from CD8 T cells. Candidates for this IFNγ production are NK and NKT 
cells. NK cells account for a large proportion of resident intrahepatic lymphocytes, and 
resting mature NK cells constitutively express transcripts for IFNγ (Lanier 2008). In 
transgenic mouse models, NKT cells have been shown to efficiently inhibit viral 
replication via IFNγ upon α-galactoceramide stimulation (Kakimi et al. 2000;Kakimi et al. 
2001a). Furthermore, study of ex vivo NK cell frequencies in presymptomatic patients 
(infected during a single source outbreak), revealed that highest circulating numbers of NK 
cells were detectable during the peak of viral load, although whether NK cell frequencies 
fluctuate in the liver remains to be defined (Webster et al. 2000). Thus NK cells are a 
potential source for the initial burst of IFNγ, however what activates them to do so is 
unclear. Usually type I IFNs are known to activate NK cells in this setting, and may also 
induce IL-15 production required for their proliferation (Zhang et al. 1998). However, in 
the absence of type I IFN induction during the incubation phase of HBV, it may be that 
direct recognition of viral particles or stress signals on infected hepatocytes may be enough 
to activate these cells.  
 
Figure 1d: Kinetics of HBV replication and the immune response during acute HBV 
infection.  
Dendritic cells provide a vital bridge between the innate and adaptive immune responses. 
They mature in response to innate signals including Type I IFNs and interaction with NK 34 
 
cells (Bertoletti & Ferrari 2003), and subsequently, are highly efficient at priming CD8 T 
cell responses in lymph nodes draining the site of infection, within hours of onset of 
infection. Defective dendritic cell function may therefore perpetuate chronicity by 
hampering an effective adaptive response, onset of which correlates with clearance of 
HBV in patients who resolve infection. Whether or not DC function is altered during HBV 
infection is unclear; some studies have suggested that plasmacytoid and myeloid dendritic 
cells were functionally impaired during CHB (van der Molen et al. 2004), however the 
stimulatory effects on T cell priming seemed minimal. 35 
 
1.7.3 Adaptive immune response 
A strong multi-specific CD8 T cell response, with adequate CD4 T cell help and co-
ordinated humoral immunity, provides a solid adaptive immune defence against virus 
infection (Bertoletti & Gehring 2006). The main cellular components of this response 
include B and T lymphocytes. In this section, I first discuss the development of these cells, 
with a particular emphasis on development of peripheral B cell subsets, as in chapter 6 we 
investigate the ability of ‘transitional’ B cells to modulate the immune response during 
CHB.  
The adaptive immune response to viral infection is then described in the context of HBV 
infection, and comparisons are made with the immune response against other similar 
viruses which may develop persistence; particularly HIV and HCV. Prior to this, a brief 
section describes how viral peptides are recognised by CD8 T cells, in the context of MHC 
class I mediated presentation. Other topics concerning CD8 T cells; memory development, 
T cell signalling and CD8 T cell differentiation are covered during the introduction 
sections of chapters four and five.  36 
 
1.8 Lymphopoesis 
1.8.1 B cell development 
B cell development takes place in the foetal liver and in the bone marrow after birth. It is 
characterised by a series of checkpoints which decide lineage commitment and cell fate. 
Successful rearrangement of genes at the immunoglobulin heavy and light chain loci is 
required for successful expression of a B cell receptor. This receptor must be mono-
specific to one non-self antigen. Checkpoints such as allelic exclusion and negative 
selection are in place to ensure this (Martensson & Ceredig 2000). 
The earliest cell committed to the B cell lineage is the Pro (progenitor) B cell derived from 
the Common Lymphoid Progenitor Cell. This lineage commitment is thought to be 
mediated by transcription factors such as PU.1, E2A and EBF, which suppress lineage 
inappropriate genes and initiate D to J recombination at the heavy chain locus (Hagman & 
Lukin 2006;Pongubala et al. 2008). Once the lineage is determined, further maturation 
stages occur which can be defined by expression of cell surface markers and 
immunoglobulin gene rearrangement (see figure 1). Hardy et al. made use of multicolour 
flow cytometry in the early 1990's to divide these cells into fractions A, B and C dependent 
on expression of markers CD43 (mucin leukosialin), BP-1 and CD24 (heat stable antigen) 
(Hardy et al. 1991). Rowlink and Melchers further contributed by identifying that CD25 
and c-kit are expressed at certain maturation steps (Rolink et al. 1994). Their classification 
system describes that a Pro B cell progresses through Pre-B1, large Pre-BII, small Pre BII 
steps before exiting into the blood stream as an immature transitional B cell. 
The bone marrow environment is critical for early B cell development. Common 
Lymphoid progenitors and Progenitor B cells develop on a stromal cell framework and 
adhere to these cells intially via integrins (VLA-4 binds to VCAM-1). Stromal cells then 
provide survival signals to the B cells via soluble factors (IL-7 which induces proliferation 
of pro-B cells) and surface bound stem cell factor which binds to c-kit and also induces 
proliferation. Blockade of integrin binding intercepts the survival signal blocking further 
maturation. In addition to external signals, internal factors such as expression of 
transcription factors are also critically important. Recombinase Activating Gene (RAG 1 
and 2) encodes enzymes required for the rearrangement of the immunoglobulin genes. 37 
 
Pax5, another transcription factor, promotes lineage commitment like E2A and EBF by 
initiating transcription of CD19, a B cell specific signalling molecule. 
B cell development produces a wide repertoire of B cells specific to a variety of antigens. 
This wide antibody repertoire is possible because of gene rearrangment. Multiple V 
(variable) D (diversity) and J (joining) genes can combine in the process of VDJ 
recombination of the Ig heavy chain at the Pro B cell stage.  The Ig heavy chain 
rearrangement occurs first and if successful results in the formation of the mu heavy chain. 
This is temporarily expressed at the cell surface in conjugation with surrogate light chain 
(VpreB and lambda5) as the pre-B cell receptor. This is a vital checkpoint. Signalling 
through the pre-BCR initiates proliferative expansion and inhibits further rearrangement on 
the Ig heavy chain (Melchers et al. 1995). Immunoglobulin light chain rearrangement 
occurs later during the Pre B cell stage. Different combinations of heavy and light chains 
may then combine together to form the B cell receptor. Further diversity is added at any of 
these recombination stages because of imprecise joining, and the action of enzyme 
Terminal Deoxynucleotidyl Transferase (TdT) which can add nucleotides at VDJ 
junctions. These mechanisms exponentially increase the variety of potential B cell 
receptors, however only B cells which can receive survival signals through their receptors 
will survive. 
Immature B cells exit the bone marrow through the venus sinus into the blood stream. At 
this stage they are functionally immature 'transitional cells' and have a short half life of 3 
days. At these secondary sites, they can undergo positive selection if they encounter an 
appropriate antigen and have the potential to mature into memory or plasma cells.  
1.8.2 Peripheral B cell subsets in mouse and man 
Peripheral B cells can be broadly characterised into 3 main groups; transitional, mature 
(which are both naïve subsets) and memory. In both mice and humans, these subsets can be 
distinguised from one another by their phenotype and tissue localisation. 
Transitional cells are 'functionally immature' B cells which have newly egressed from the 
bone marrow. In humans they are the major component of the B cell compartment in cord 
blood (50%) however their frequency declines through infancy. In adults they account for 
4% of peripheral B cells (Marie-Cardine et al. 2008). In mice, transitional cells are divided 
into T1 or T2 cells. T1 (IgM
bright, IgD
neg, CD24
high, CD21
low,CD23
low) migrate to the white 38 
 
pulp of the spleen and can be found in the outer PALS (peri-arteriolar lymphatic sheath). 
T2 (IgM
bright, IgD
bright, CD24
high, CD21
high, CD23
high) are found in the surrounding 
lymphoid follicles where mature cells are also present. However, unlike the mature, the T2 
cells are confined to these follicles whereas the mature are free to recirculate through 
lymph and blood (Carsetti et al. 2004;Martensson & Ceredig 2000). Human transitional B 
cells are thought to have similar tissue distribution and marker expression as in mice. 
Carsetti et al. recently showed that dependent on expression of two developmentally 
regulated markers CD24 and CD38, peripheral human transitional cells could be accurately 
identified by their high expression of both CD24 and CD38. They have also been shown to 
lack CD27 (mainly present on memory cells) and to co-express IgM, IgD, CD21, CD23 
and L-selectin (Carsetti et al. 2004). 
Transitional 1 and 2 B cells are precursors for mature B cells, an active process in the 
spleen of mice. Transition from T1 to T2 to mature B cells is thought to be a linear process. 
Loder et al have shown that intravenous transfer of T1 cells into RAG 2 knockout mice 
results in development of T2 and mature B cells by 48 hours (Loder et al. 1999). In 
addition, it was shown in patients followed up post Haemopoeitic Stem Cell transplant 
(HSCT) that by 1-2 months post HSCT all detectable CD19+ cells were transitional, but by 
9 months these populations declined and the mature fraction increased to 80% of total B 
cells (Marie-Cardine et al. 2008). However, it cannot be ruled out that T1 cells directly 
differentiate to mature B cells without a T2 intermediate stage.  
Only 1-3% of transitional cells that exit the bone marrow will mature. The exact signals 
which induce this maturation step are as yet unknown, however there is suggested 
involvement of antigen and BCR signaling. Loder et al. have shown, for example, that 
mice with deletions in elements involved in the B cell receptor signaling cascade are 
arrested at the T1 or T2 developmental stage (Loder et al. 1999). Mature B cells are long-
lived IgM+IgD+ cells which are can recirculate in lymph and blood and enter lymphoid 
follicles of spleen and lymph nodes where they can encounter antigen on follicular 
dendritic cells. 
On recognition of specific antigen, B cells may then enter the long-lived pool as memory 
or plasma B cells. These cells, unlike the mature, respond rapidly to secondary antigenic 
stimulation with production of high affinity antibodies. On binding antigen via the B cell 
receptor in the secondary lymphoid follicle, the antigen is internalised and presented on 39 
 
MHC II to T cells. This, along with co-ligation of CD40L (on T cells) to CD40 (on B cells) 
can induce class-switching. B cells may then proliferate in germinal centres and undergo 
somatic hypermutation to form highly efficient antibody-producing plasma cells. Memory 
B cells in humans are mostly in the resting state, and are CD24bright, CD38dull and 
CD27positive.  
1.8.3 T cell development 
Lymphoid progenitor cells exit the bone marrow and migrate in the blood to the thymus 
where T cell lymphopoiesis occurs. This involves a series of maturation steps which 
require interaction with stromal and epithelial cells of the thymic architecture (Zuniga-
Pflucker 2004). Early thymocyte progenitors committed to the T cell lineage do not 
express the T cell receptor (TCR), or the co-repectors CD4 or CD8, hence are termed 
double negative thymocytes (CD4-CD8-). These cells may be further subdivided into four 
stages of differentiation based on expression of CD25 and CD44. 
 DN1  (CD44+CD25-) ----- > DN2 (CD44+CD25+) -----> DN3 (CD44-CD25+)--- > DN4 
(CD44-CD25-) 
 
Figure 1e: Development of T cells within the thymus. DN = double negative. DP = double 
positive. Adapted from (Germain 2002). 40 
 
DN3 thymocytes express the pre-TCR which is made up of a non-rearranged pre-TCRα 
chain and a rearranged TCR-β chain. Signalling through this receptor is required for 
further maturation, and induces 6-8 cycles of cell division in DN4 cells which give rise to 
double positive (DP) CD4 and CD8 expressing cells which are the precursor pool from 
which single positive CD4 and CD8 are derived. In DP thymocytes, the pre-TCRα-chain is 
replaced by a rearranged TCRα-chain, thus allowing for expression of a complete αβ TCR 
which can then interact with MHC-class I or MHC-class II loaded with self peptides on the 
surface of cortical epithelial cells (Germain 2002). The strength of this signal interaction 
determines the fate of the DP thymocyte. If the strength of interaction between the TCR 
and MHC/self-peptide complex is too low, cells do not receive a survival signal and die by 
neglect. Those that can bind MHC/self-peptide with sufficient strength are positively 
selected.  If the strength of binding with self peptide and MHC is too high however, these 
potentially autoreactive cells are later subjected to negative selection upon encounter with 
dendritic cells in the thymic medulla (Kisielow et al. 1988;von Boehmer et al. 1989). T 
cells that survive these selection processes may exit the thymus and populate the peripheral 
T cell pool. 
Successful maturation requires the co-receptor CD4 or CD8 to have the same MHC class 
specificity as the corresponding TCR. There are a number of models as to how this CD4-
CD8 lineage commitment might occur. The ‘instructional model’ proposes that the 
biochemical signal through the TCR differs depending on whether MHC class I is co-
recognised by TCR and CD8, or MHC class II is co-recognised by TCR and CD4. Each 
qualitative signal provides an instruction which induces the correct lineage commitment, 
and switches off genes associated with the other pathway (Germain 2002). One idea that 
has been put forward is that the intensity and duration of the signal through the TCR 
determines the lineage; short duration results in CD8 T cell development, and prolonged 
signals induce CD4 T cell development. This may be internally regulated partially by 
mitogen-activated protein kinase 1 (MAPK1); higher activity of which has been shown to 
preferentially induce CD4 T cell development (Wilkinson & Kaye 2001). MAPK1 
phophorylates LCK at a serine residue, which protects it from becoming dephosphorylated 
by SHP1. This results in prolonged action of LCK and prolonged TCR signalling which 
favours CD4 T cell development.  41 
 
Alternatively, the ‘selection model’ suggests that DP thymocytes may make a random or 
stochastic choice as to which lineage to commit to, which does not take into account the 
specificity of the TCR. This may result in choosing an incorrect co-receptor, which does 
not provide optimum antigen responses with the TCR of that particular cell. These cells are 
likely negatively selected during later antigen encounter, at which point they fail to receive 
survival signals due to inability to express the appropriate co-receptor (Germain 2002).  
Recent data have shown that signalling through the Notch/Notch-ligand pathway controls 
many cell fate decisions during thymopoesis including that of T cell commitment (Maillard 
et al. 2005). In mammals, there are four highly conserved transmembrane receptors (Notch 
1-4) which can interact with five ligands (Jagged 1+2, Delta-like 1, 3 + 4), which are 
highly expressed in the thymic environment. Binding to the ligand initiates proteolytic 
processes in the Notch transmembrane domain and release of ICN (intracellular Notch). 
This translocates to the nucleus and associates with DNA binding protein CSL, and results 
in eventual transcription of Notch target genes (Tanigaki & Honjo 2007). Deletion of 
Notch/Notch ligand genes is embryonically lethal, and inactivation of Notch 1 results in 
complete blockade to T lineage commitment, which cannot be compensated by signalling 
through the other Notch receptors (Radtke et al. 1999). This pathway is thought to regulate 
the early T vs. B cell fate decision, commitment to the αβ-T cell lineage over the γδ T cell 
lineage, rearrangement of the TCR β gene and the CD4 vs. CD8 cell fate decision (Zuniga-
Pflucker 2004).  42 
 
1.9 MHC Class I presentation pathway 
In the normal state, cells present thousands of peptides complexed to MHC class I on their 
surface, which are derived/processed from virtually all proteins synthesized in the cell. 
This allows CD8 T cells to constantly ‘survey’ the intracellular protein content of cells. In 
the event of  a microbial infection, or if intracellular proteins are mutated in cancer, 
peptides derived from these non-self proteins are also complexed with MHC class I and 
presented to CD8 T cells (Hammer et al. 2007;Zinkernagel & Doherty 1974a;Zinkernagel 
& Doherty 1974b). Once CD8 T cells with the appropriate T cell receptor bind to these 
new complexes, they are alerted to the presence of non-self peptides, and rapidly mount 
either a cytolytic or non-cytolytic effector response to eliminate the infected or tumour cell 
(Xu et al. 2001).   
The process of antigen presentation begins in the cytoplasm, where recently synthesized 
proteins are degraded into a mixture of peptides of variable lengths by the multi-catalytic 
proteosome, or other proteases and chaperones. These peptides are then transported into 
the endoplasmic reticulum (ER) by transporter associated with antigen processing (TAP), 
where the pMHC I repertoire is customised. This is achieved firstly by formation of the 
peptide-loading complex (PLC) which promotes the retention of MHC I in the ER, and its 
association with high-affinity peptides. Within the PLC, associated chaperone proteins help 
fold the heavy and β2 microglobulin chains of the MHC I molecule together so that it is in 
a peptide-receptive state (Hammer et al. 2007).  Peptides which have then been cleaved to 
an optimum length by the ER aminopeptidase associated with antigen processing enzyme 
(ERAAP or EARP1 in humans) may associate into the MHC groove. ERAAP trims extra 
N-terminal residues from peptides, but does not alter the C-terminal end (Blanchard & 
Shastri 2008).  
During viral infection, CD8 T cells may be primed by dendritic cells or other antigen 
presenting cells which present viral peptides complexed with MHC class I. These viral 
peptides may be derived from endogenously produced viral proteins, or from phagocytosed 
infected apoptotic bodies or endocytosed soluble viral antigens (Xu et al. 2001). During 
HBV infection, hepatocytes may have the capacity to present viral peptides on MHC class 
I directly to virus-specific CD8 T cells, however in a TCR-transgenic mouse model it was 
shown that TCR/MHC/peptide interaction without appropriate co-stimulation resulted in 
CD8 T cell tolerance (Bertolino et al. 1998).  43 
 
1.10 Adaptive Immune response against HBV 
HBV-specific CD8 and CD4 T cells are critical mediators of viral control in patients with 
self-limited infection. Viral clearance is dependent on the ability of these T cells to mount 
a strong, multi-specific response to all viral proteins; failure to do so results in viral 
persistence and chronic hepatitis (Maini & Bertoletti 2000).  
CD8 T cells in particular have been singled out as the main effector cells involved. 
Thimme et al. showed that in chimpanzees acutely infected with HBV, depletion of CD8 T 
cells (starting from week 6 when the exponential phase of viral replication is expected to 
occur) resulted in extended peak levels of HBV DNA. Furthermore, on reappearance of 
CD8 T cells by week 13, there was a concurrent fifty-fold decrease in HBV DNA levels 
and this correlated with the appearance of virus-specific T cells and mRNA for CD3, CD8 
and IFNγ in the liver. In contrast, depletion of CD4 T cells with a monoclonal antibody at 
week 6 did not alter duration or course of infection compared to the control antibody 
(Thimme et al. 2003). However, CD4 T cells have been shown to have important 
immunoregulatory function during the early course of infection, particularly the production 
of Th1 cytokines and IL-2, which are required to induce and maintain CD8 T cell function 
(Penna et al. 1997). Therefore, had these cells been depleted at an earlier stage, one might 
expect that this could alter the expansion and functional ability of the CD8 T cells. The 
importance of early CD4 T cell priming of CD8 T cell responses has been shown during 
primary CMV infection, where early CMV-specific CD4 T cell responses preceding CD8 
T cell responses were associated with asymptomatic infection, whereas delayed CMV-
specific CD4 responses were associated with symptomatic disease (Gamadia et al. 2003). 
These data imply, therefore, that inefficient CD4 T cell help of CD8 T cells and humoral 
responses could lead to viral persistence, although in this setting, CD4 were not required 
just for help, and could also independently induce CMV clearance through production of 
IFNγ. 
The requirement of CD4 help for an effective cellular immune response against HBV is 
supported firstly by early studies which consistently found vigorous CD4 T cell responses 
towards HBV antigens in HBV infected subjects who developed acute self-limiting 
hepatitis, however this responsiveness was significantly impaired in patients with chronic 
HBV infection (Ferrari et al. 1990;Jung et al. 1991). Furthermore, strong multispecific 
CD4 responses with a Th1 profile were found in the blood of patients with acute self-44 
 
limited infection (Penna et al. 1997). In these patients, during the incubation phase, 
expansion of virus-specific CD8 and CD4 T cells was noted prior to viral clearance 
(Webster et al. 2000).  
Consistent with a role for CD4 T cells in protective immunity, dysfunction of CD4 T cells 
has been shown to impair viral clearance in other examples of chronic infection. Adult 
CD4 knockout mice failed to clear LCMV infection, whereas in wildtype mice, virus was 
cleared from most tissues by 2 months (Zajac et al. 1998). During HCV infection, loss of 
virus-specific CD4 responses (in patients who initially mounted a strong response resulting 
in virus elimination; HCV PCR negative) was associated with a resurgence of HCV 
viraemia and recurrence of infection (Gerlach et al. 1999). In HIV infection, poor viral 
control in viraemic patients with high viral load was associated with an impaired capacity 
of HIV-specific CD4 T cells to proliferate in response to antigen. Antigen-specific CD4 T 
cells from aviraemic patients, however, maintained proliferative capacity and were 
additionally capable of producing IL-2 in vitro (Younes et al. 2003). The frequency of IL-2 
producing HIV specific CD4 T cells was further shown by Harari et al. to negatively 
correlate with viral load (Harari et al. 2004), and preferential loss of IL-2 by HCV specific 
CD4 T cells was found in patients with chronic HCV, but not in those who resolved 
infection (Semmo et al. 2005). 
In addition to producing IL-2 and supporting the proliferation of cytotoxic CD8 T cells, 
CD4 T cells are also required to prime humoral immune responses, and may additionally 
have a regulatory role in HBV infection. Production of HBeAg specific antibodies, for 
example, is dependent on CD4 T cells, and in acute HBV infection, a strong CD4 response 
against nucleocapsid antigens occurs at around the same time as clearance of enveloped 
antigens from the serum (Bertoletti & Ferrari 2003). As regards to their regulatory role, 
there is confliciting evidence as to the contribution of these cells in HBV (for a full 
background on regulatory T cells please refer to chapter six). Some studies have found no 
increase in classical regulatory CD4+CD25+ cells in CHB (Franzese et al. 2005), however 
others have found an enrichment of these regulatory T cells in the periphery and livers of 
patients with severe CHB infection (Peng et al. 2008a;Xu et al. 2006). In both the above 
studies however, depletion of CD4+CD25+ T cells increased the function of HBV-specific 
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In addition to T cells, B cells have an important role in inducing a humoral immune 
response. The importance of antibody production is highlighted by the fact that production 
of HBsAg-specific antibodies are neutralising (Rehermann & Nascimbeni 2005) and 
production of anti-envelope antibodies correlates temporally with clearance of HBV 
(Alberti et al. 1978). Furthermore, HBsAg-specific and HBcAg-IgG antibodies persist for 
life and provide protective immunity in the host. In addition to antibody production, B cells 
in mice have also been shown to regulate immune responses through production of 
cytokines such as IL-10 (Fillatreau et al. 2002;Mauri et al. 2003;Mizoguchi et al. 2002). 
The capacity for B cells to regulate immune responses during viral infection through 
production of IL-10 in humans is not yet documented, however has been investigated in 
this thesis.  46 
 
1.11 Mechanisms of viral control 
In earlier studies, it was assumed that clearance of HBV was proportional to the number of 
virus-specific CD8 T cells which could recognise viral peptide complexed to MHC-I on 
infected hepatocytes, and directly lyse these cells. However, it was realised that this could 
not be the sole mechanism of viral clearance as 1) upto 10
11 hepatocytes may be infected 
with HBV (Guidotti et al. 1996), thus cytolytic damage of each cell would result almost 
certainly in irreversible tissue damage and fulminant hepatitis which is clinically only seen 
in 1% of patients, 2) hepatocytes have been shown to be relatively resistant to perforin 
mediated lysis (Kafrouni et al. 2001) and 3) during acute HBV infection in chimpanzees 
and humans, clearance of the majority of viral load is achieved in the absence of liver 
inflammation, suggesting that non-cytolytic mechanisms must be in play (Guidotti et al. 
1999b;Webster et al. 2000). An elegant study in the transgenic mouse model of HBV 
revealed that upon adoptive transfer of virus-specific CD8 T cells into the livers of mice, 
HBV gene expression and replication was abolished with only minimal killing of HBV-
infected hepatocytes. This non-cytolytic clearance was mediated by ‘curative’ cytokines 
IFNγ and TNF released directly by virus-specific CD8 T cells and also macrophages and T 
cells, which became activated. These cytokines could activate virocidal pathways in 
hepatocytes leading to destabilisation of viral RNA and elimination of HBV nucleocapsid 
particles with replicating genomes. Furthermore, injection of mice with HBsAg-specific H-
2
d-restricted CD8 CTL clones derived from HBsAg-primed perforin knockout mice, 
resulted in disappearance of HBV DNA replicate forms and hepatocellular cytoplasmic 
HBcAg, without hepatocyte damage or elevation of ALT (Guidotti et al. 1996).  
Non-cytolytic clearance of LCMV, another non-cytopathic infection, is also partially 
mediated by IFNγ production (Guidotti et al. 1999a). However, in this case, there is a clear 
co-dependence for both cytolytic and non-cytolytic mechanisms. Walsh et al. highlighted 
the need for cytolytic mechanisms by demonstrating that perforin knockout mice failed to 
clear certain strains of LCMV infection (Walsh et al. 1994). At the same time, Mueller et 
al. showed that knocking out the effect of IFNγ by generating IFN-γR knockout mice, 
resulted in uncontrolled LCMV replication, even though cytolytic function was preserved 
(Muller et al. 1994).  47 
 
1.12 Mechanisms of liver pathogenesis 
Hepatitis B virus is non-cytopathic, and it is the immune response against it which 
mediates immunopathology and liver damage. It has been assumed that cytolytic killing of 
infected hepatocytes by HBV-specific CD8 T cells was responsible for the majority of 
liver damage, partially based on work in HBV transgenic mice which showed that adoptive 
transfer of HBsAg specific CD8 T cell lines and clones into the liver resulted in 
development of acute necro-inflammatory liver disease (Ando et al. 1993;Moriyama et al. 
1990). However, the finding that activated HBV-specific CD8 T cells are present in the 
livers of patients with no inflammation who successfully control HBV replication, may 
suggest a more complex scenario. In this study, Maini et al. showed that the absolute 
intrahepatic frequencies of HBV-specific CD8 T cells were similar in patients with or 
without liver inflammation. However, in the latter group, these HBV-specific CD8 T cells 
were diluted in amongst a massive non-antigen specific lymphocytic infiltrate, which was 
not detected in the absence of inflammation (Maini et al. 2000). How this infiltrate is 
recruited and what role it may have in the liver has been studied in the transgenic mouse 
model of HBV. In two consecutive studies, it was shown that recruitment of non-antigen 
specific lymphocytes was mediated in part by IFN-γ induced release of chemokines 
CXCL9 and CXCL10 from hepatocytes and non-parenchymal cells (Kakimi et al. 2001b), 
but also adoptively transferred virus-specific CD8 T cells could amplify this recruitment by 
inducing matrix metalloproteinase activity in GR1+ cells (neutrophils, macrophages, 
plasmactyoid dendritic cells), which further recruited non-antigen specific GR1- cells 
(NK/NKT/B/T lymphocytes, macrophages, dendritic cells) into the liver (Sitia et al. 2004). 
Most importantly, blocking of chemokines or depletion of GR1 cells reduced the influx of 
non-antigen specific lymphocytes and was associated with reduction in the severity of liver 
disease without affecting non-cytolytic clearance of the virus. Studies in humans have 
shown that NK cells may be a candidate cell type for mediating liver pathology, as they are 
abundant in the cellular infiltrate and account for 30-40% of resident intrahepatic 
lymphocytes (Norris et al. 1998). In a recent study, Dunn et al showed that these cells 
could mediate hepatocyte killing through the TNF-related apoptosis-inducing ligand 
(TRAIL) pathway. Furthermore, induction of cytokines IFNα and IL-8 during HBeAg 
negative flares of HBV, promoted NK TRAIL mediated apoptosis of hepatocytes, which in 
vivo could further aggravate liver pathology (Dunn et al. 2007). Other components of the 48 
 
lymphocytic infiltrate may also contribute to this liver pathology, and the potential role of 
non-antigen specific CD8 T cells will be discussed further in this thesis. 
1.13 Dual role for virus-specific CD8 T cells in viral control and liver damage 
Data by Maini et al. showed that the absolute frequency of HBV-specific CD8 T cells was 
similar in the liver of patients who controlled virus replication with no liver inflammation, 
and patients with high viral load and liver inflammation (Maini et al. 2000). This suggested 
two intriguing concepts: 1) the frequency of HBV-specific CD8 T cells does not 
necessarily correlate with viral control 2) HBV-specific CD8 T cells can mediate viral 
clearance in the absence of liver inflammation. 
With regards to the first point, studies in Human T-cell Lymphotropic Virus (HTLV-1) 
infection showed that frequency of tetramer positive HTLV-1 specific CD8 T cells was 
similar between patients with HTLV-1 associated myelopathy/tropical spastic paraparesis 
(HAM/TSP) and asymptomatic carriers (Jeffery et al. 1999), despite 16 fold greater 
proviral load in the former group (Nagai et al. 1998). This suggested that viral control was 
not related to the frequency of virus-specific CD8 T cells, but rather their responsiveness. 
This was further supported by use of a mathematical model which predicted that 
differences in the equilibrium proviral load was related to the rate of CTL proliferation in 
response to antigen, and the rate that a CTL killed a virus-infected cell (Nowak & 
Bangham 1996).  
The second observation that virus-specific CD8 T cells can control infection without 
significant immunopathology is supported by data in HCV infected chimpanzees. Cooper 
et al. showed that intrahepatic HCV-specific CD8 T cells isolated from non-inflamed livers 
had cytotoxic capacity, however, the same populations isolated from highly inflamed livers 
had no detectable intrahepatic CTL activity  (Cooper et al. 1999). These data suggested 
that liver damage and viral control may be independent of each other. Theoretical 
mathematical models have been applied to study the role of virus-specific CD8 T cells 
during persistent viral infection with HTLV-1. Asquith and Bangham proposed a model 
whereby the threshold of proviral load could be used to predict whether the virus-specific 
CD8 T cell response was harmful or resulted in viral clearance. Individuals who mounted a 
strong, efficient CD8 T cell response against the virus, were able to suppress antigen load 
below a certain threshold which was sufficient to ligate T cell receptors and induce lysis of 49 
 
infected cells, but was not sufficient to induce production of IFNγ. However, in poor T cell 
responders, antigen levels were not sufficiently suppressed, and consequently reached a 
threshold sufficient to induce pro-inflammatory IFNγ production. This could induce a ‘role 
switch’ whereby the net effect of CTL effector function favoured tissue damage and 
inflammation over anti-viral cytolytic effector function (Asquith & Bangham 2000). This 
is consistent with a study in a TCR-transgenic mouse model of influenza infection, where 
high frequencies of virus-specific CD8 T cells were protective at low viral doses, but 
caused pathology and mortality in mice upon challenge with high viral doses, and this 
could be blocked through IFN-γ (Moskophidis & Kioussis 1998). 
1.14 Characteristics of the virus-specific T cell response during CHB 
It is widely accepted that HBV-specific CD8 T cell responses are strong and multispecific 
in patients with self-limited infection, however are characteristically weak, transient and 
barely detectable in patients who develop CHB (Bertoletti & Maini 2000). This was first 
shown in the early 1990’s following stimulation with synthetic peptides derived from 
HBcAg and HBeAg in vitro (Bertoletti et al. 1991;Penna et al. 1991), and has since been 
confirmed by ex vivo quantification of these cells using tetramers (Maini et al. 2000), 
intracellular cytokine staining (Webster et al. 2004) and ELISPOT analysis after 
stimulation with either HLA-A2 restricted viral peptides, or overlapping pools of peptides 
spanning the entire HBV genome (Boni et al. 2007). Furthermore, microarray studies have 
confirmed that the gene profile of HBV-specific CD8 T cells differs in patients with CHB 
and resolved infection, and upregulation of apoptotic genes may contribute to attrition of 
the HBV-specific response in the former group (Lopes et al. 2008).  
In addition to both quantitative and qualitative dysfunction of virus-specific populations in 
CHB, an epitope hierarchy exists within HBV-specific T cell responses which can be 
altered if virus persists. During acute HBV infection, ex vivo characterisation of HBV-
specific CD8 T cells showed that the frequency of core 18-27 tetramer positive cells was 
much higher than polymerase 575-583 or envelope 335-343 epitopes (Maini et al. 1999a), 
although in some cases polymerase and envelope responses may dominate the CD8 T cell 
response (Webster et al. 2004). In patients who develop chronic hepatitis, above a certain 
threshold of viral load (HBV DNA>10
7copies/ml), core 18-27 specific responses could not 
be detected ex vivo or following in vitro expansion, and the frequency of these responses 
in the liver was shown to correlate inversely with viral load (Webster et al. 2004). Instead, 50 
 
envelope responses with altered tetramer binding (Reignat et al. 2002) and polymerase 
responses could sometimes be detected in these individuals.  
The ability to visualize virus-specific CD8 T cell populations with HLA Class I tetramers 
and simultaneously determine their functional capacity with intracellular cytokine staining, 
has facilitated the study of these cells in a wide range of chronic viral infections in mice 
(LCMV), primates (Simian Immunodeficiency Virus (SIV)) and man (HCV, HIV). These 
studies have consistently shown that, akin to CHB, a strong multispecific CD8 T cell 
response against a variety of viral epitopes is favourable for viral clearance and disease 
resolution, whereas mono-specific responses associated with functional loss allow viral 
persistence. Accordingly, marked constraints on virus-specific CD8 T cell responses have 
been documented when the virus is able to persist. 
The observation that high frequencies of virus-specific CD8 T cells can persist in 
individuals with chronic SIV or HIV infection, but fail to clear the virus, suggested that 
these cells may be qualitatively inadequate/inefficient. Vogel et al showed that early after 
infection of monkeys with SIVmac239, the majority of virus-specific tetramer positive 
CD8 T cells were able to produce IFNγ. However, after four months of viral persistence, 
the ratio of IFNγ+ to tetramer+ cells was reduced to 0.66, suggesting that these cells 
became dysfunctional upon viral persistence (Vogel et al. 2001). A similar functional loss 
has been described during HIV infection, where Shankar et al. showed that less than 25% 
of tetramer+ HIV-specific CD8 T cells produced IFNγ upon stimulation with the relevant 
gag or reverse transcriptase peptides, and in addition, freshly isolated CD8 T cells were not 
cytolytic against HIV infected CD4 T cells (Shankar et al. 2000). This is supported by 
Appay et al. who demonstrated that HIV-specific CD8 T cells were perforin low and 
cytolytically impaired compared to CMV-specific CD8 T cells from the same chronically 
infected individuals (Appay et al. 2000).  
Qualitative dysfunction within the HCV-specific CD8 T cell response has also been 
documented in chimpanzees who failed to resolve acute HCV infection and developed 
chronicity. In these animals, Cooper et al. observed  strong, multi-specific response CTL 
responses against  at least 6 viral epitopes in resolved chimpanzees, however responses 
were narrow and weaker in those who developed chronic infection (Cooper et al. 1999). 51 
 
During HCV infection in humans, virus-specific CD8 T cells may be ‘stunned’ by high 
viraemia early after acute infection resulting in transient impairment of IFN-γ production 
(Lechner et al. 2000), or exhibit a longterm ‘stunting’ of function associated with poor 
TNF and IFNγ production on stimulation with specific peptides or with mitogens 
compared to CMV/EBV-specific CD8 T cell responses (Gruener et al. 2001;Klenerman et 
al. 2002). The prolonged dysfunction during chronic infection may be partially attributable 
to hyperexpression of PD-1, a negative regulator of the immune response, on both 
circulating and intrahepatic HCV-specific CD8 T cells. Blockade of PD-1 was shown to 
recover function in circulating but not intrahepatic HCV-specific CD8 T cells, which were 
phenotypically even further exhausted (CD127
low, CD28
low, CTLA4
high) (Nakamoto et al. 
2008;Radziewicz et al. 2007). 
During chronic LCMV infection, Zajac et al. demonstrated that CD8 T cells specific to 
certain dominant viral epitopes (GP 33-41) persisted indefinitely in mice and had an 
activated phenotype, however CD8 T cells specific for other dominant epitopes (NP 396-
404) were deleted. The persisting GP33-41 specific CD8 T cells were impaired in their 
ability to release IFNγ and kill infected cells, and this antiviral function was completely 
abolished in the setting of CD4 deficiency. The level of unresponsiveness of these cells 
was found to be proportional to the duration of exposure to viral antigens; this could be 
modulated by inoculating mice with different strains of virus. With short periods of 
infection (1 week) induced by the Armstrong strain, all GP-33 CD8 T cells were 
functional, however upon infection with the Clone 13 virus which results in a highly 
disseminating, persistent chronic infection with high viral load, approximately 80% of GP-
33 specific CD8 T cells were rendered unresponsive for a prolonged period. These data 
indicated that different immunodominant viral peptides may activate T cells to varying 
degrees resulting in either anergy or deletion to ‘silence’ the immune response during 
chronic infection (Zajac et al. 1998). In patients with CHB, where a similar epitope 
hierarchy exists within HBV-specific CD8 T cells, it is feasible that similar mechanisms 
may apply, and that core responses could be more susceptible to deletion than envelope or 
polymerase responses-possibly by excessive tolerance by large quantities of secreted 
HBeAg in patients with CHB.  In support of this, it was found that HBcAg specific T cells 
were tolerised in HBeAg transgenic mice (Milich et al. 1990). 52 
 
How persistence of virus could impact the immunodominance of virus-specific responses 
or impair functional responses was questioned in a follow-up study by Wherry et al, who 
studied the functional attributes of virus-specific CD8 T cells longitudinally during chronic 
LCMV infection induced by the Clone 13 strain of virus. They showed that there was a 
hierarchical loss of effector function within virus-specific CD8 T cells, driven by antigen 
load; IL-2 production and proliferative capacity were lost first, followed by capacity to 
produce TNFα then IFNγ. Cells which were functionally ‘exhausted’ beyond this point 
were physically deleted. This study not only characterised distinct phases of functional 
exhaustion defined by effector function, but also provided a valuable model of how 
persistent viruses may impact effector function and impair viral control (Wherry et al. 
2003a). 
1.15 Mechanisms of viral persistence 
Viruses have developed a number of evasion strategies against the innate and adaptive 
immune system. ‘Hiding’ strategies include ability of some viruses to mutate frequently, 
preferentially occupy immunoprivileged sites, and to persist in a ‘latent’ state with minimal 
protein expression. Additionally, HBV may evade Toll Like Receptor detection due to the 
fact that viral replicative intermediates of ssRNA or viral DNA may be shielded within its 
nucleocapsid (Bertoletti & Gehring 2006). Other strategies may be more aggressive, and 
directly target the host’s anti-viral defence mechanism. The HSV (Herpes Simplex Virus) 
Immediate-early protein ICP47 physically associates with TAP in cells, inhibits peptide 
translocation to the ER, and therefore prevents peptide loading of MHC class I molecules 
(Fruh et al. 1995). Similarly HIV nef protein can reroute surface MHC class I into clathrin-
coated pits for endosomal degradation (Collins et al. 1998), and HCMV genes US3 and 
US6 code for proteins which retain class I molecules in the ER and block TAP mediated 
peptide translocation respectively (Tortorella et al. 2000). These various strategies which 
interfere with presentation of viral peptides by MHC-I are mechanisms to evade the potent 
cytolytic and non-cytolytic anti-viral CD8 T cell response.  
In addition viruses use a host of additional strategies; inhibition of apoptosis of virus 
infected cells, expression of MHC class I homologues to evade NK cell mediated lysis and 
direct suppression of cytokine pathways including the early innate cytokines IFNα and 
IFNβ (Tortorella et al. 2000). It is likely that HBV has evolved to incorporate more than 
one of these evasion mechanisms to escape immune control. 53 
 
1.16 Possible mechanisms of HBV persistence 
1.16.1 Immune tolerance by virus/viral antigens 
Chronic HBV infection is characterised by persistence of high dose antigen over many 
decades. In the mouse model of LCMV, high dose antigenic load has been shown to 
progressively drive CD8 T cells towards functional exhaustion and deletion (Wherry et al. 
2003a). Therefore the quantitative and qualitative deficiencies observed in HBV-specific 
CD8 T cells, particularly in patients with high viral load, may be partially attributable to 
sustained attrition following repeated cycles of TCR mediated activation without 
appropriate rest cycles. Alternatively, tolerance of these immune responses over time could 
be secondary to exposure to viral antigens. One feature unique to HBV infection is the 
production and secretion of large amounts of surface and core antigens during viral 
replication which do not contain the HBV genome. HBeAg, the secretory form of the core 
antigen, in particular has been shown to have no role in viral replication, and instead may 
be required to induce tolerance in utero (Milich et al. 1990). This is supported by 
epidemiological data which show that children born to HBeAg negative mothers were less 
likely to develop chronic infection (Alter 2003). A tolerogenic role for viral antigens is 
also documented in patients with HCV. The HCV core protein can inhibit T cell 
proliferation by binding to gC1q receptor (Kittlesen et al. 2000) and may have an 
immunomodulatory role as it can also bind to the cytoplasmic tail of Lymphotoxin-β 
receptor, involved in development of peripheral lymphoid tissue and germinal centres 
(Matsumoto et al. 1997). Since the expression of these receptors is not confined to virus-
specific cells, it is likely that tolerance by these antigens may provide a non-specific 
mechanism for T cell suppression affecting the global CD8 T cell population. 
1.16.2 Viral escape 
Mutation of immunodominant viral epitopes is a common evasion strategy to bypass 
immune detection, however this usually requires the virus to be under selection pressure by 
a strong narrowly focussed cytotoxic T cell (CTL) response. Because HCV polymerase 
lacks proof-reading capacity, and HIV reverse transcriptase is similarly error prone, high 
viral replication, in the setting of a strong CTL response, generates many possible 
mutations. However, this evasion strategy is uncommon during chronic HBV infection, 
where there is a characteristically weak CD8 T cell response, and low selection pressure on 54 
 
the virus. Despite this, Bertoletti et al. showed that HBV isolates from two chronically 
infected patients had naturally occurring mutations within the immunodominant core 
epitope. Complexing of this variant peptide with MHC class I could then antagonise 
binding of the wildtype core peptide/MHC I with the T cell receptor. This could reduce the 
CTL response against the immunodominant wildtype core epitope, and may also allow 
preferential survival of cells expressing the variant peptide (Bertoletti et al. 1994). The 
ability of HBV to mutate can also be shown in patients on lamivudine treatment, in whom 
it is extremely common for viral mutations to develop within 3-5 years due to the rigorous 
selection pressure applied by antiviral therapy (Dusheiko & Antonakopoulos 2008).  
1.16.3 Regulation of immune responses 
The role for CD4+CD25
highFoxp3+ regulatory T cells in chronic HBV infection is as yet 
unclear, however, some studies have suggested that they are present at higher frequencies 
in the livers of patients with severe HBV infection (Xu et al. 2006), and depletion of these 
cells in vitro recovers HBV-specific CD8 T cell function (Franzese et al. 2005;Stoop et al. 
2005). In addition to the classical CD4+CD25
highFoxp3+ regulatory T cell, we explore here 
a role for a novel subset of ‘transitional’ B cells, which have been shown to modulate 
immune responses through production of IL-10 (Fillatreau et al. 2002;Mauri et al. 
2003;Mizoguchi et al. 2002), although it is likely that these cells are part of a regulatory 
framework through which their effects could be amplified. Thus, there is a potential for 
these cells to impair HBV-specific CD8 T cell responses in vivo through production of 
immunosuppressive IL-10 or contact dependent mechanisms.  
1.16.4 Liver environment 
The liver is a multi-purpose organ and one of its major roles is to process food antigens 
derived from the gut. In order to avoid immune responses against these non-pathogenic 
antigens, the liver is naturally an immunotolerant site (Calne et al. 1969;Crispe 2003). 
Recent studies have shown that this tolerance may partially be maintained by a constitutive 
production of IL-10 by resident Kupffer cells in response to gut derived bacterial antigens 
(Tu et al. 2008b). In addition, activated CD8 T cells have been shown to be preferentially 
sequestered to the liver where they undergo activation induced cell death (Crispe et al. 
2000). Antigen-specific CD8 and CD4 T cells may be primed in the liver by hepatic 
stellate cells (Ito cells), hepatocytes and liver sinusoidal epithelial cells (LSECs). Ito cells 55 
 
are liver resident, and were shown to resemble professional antigen presenting cells as they 
could present peptide on MHC-I and MHC-II to antigen-specific CD8 and CD4 T cells 
respectively, which mediated protection against bacterial infection (Winau et al. 2007). 
Priming by LSECs and hepatocytes on the other hand had a tolerogenic influence on T cell 
function. Naïve CD4 T cells primed by LSECs failed to produce Th1 cytokines (Knolle et 
al. 1999), and priming of naïve CD8 T cells in the liver by hepatocytes, which have a lower 
expression of surface MHC class I and lack co-stimulatory molecules found on 
professional antigen presenting cells, induced only transient cell activation and eventual 
CD8 T cell death by apoptosis (Bertoletti & Gehring 2006;Bertolino et al. 1998). 
Interestingly, upregulation of the pro-apoptotic molecule Bim in HBV-specific CD8 T cells 
from patients with chronic but not resolved infection (Lopes et al. 2008), was speculated to 
perhaps be a result of defective intrahepatic cross-presentation of antigens to CD8 T cells, 
as Bim is required for deletion of auto-reactive T cells following cross-presentation of 
soluble antigen (Davey et al. 2002).  Thus a combination of Bim-mediated deletion, 
inefficient priming of effector responses by hepatocytes, and exposure to 
immunosuppressive IL-10 may contribute to impairment of CD8 T cell responses within 
the liver and perpetuate viral persistence.  56 
 
2 Materials and Methods 
2.1 Study Cohort 
Patients were recruited from three sites; Mortimer Market Clinic (London), the Royal Free 
Hospital (London), and Adenbrooke’s Hospital (Cambridge). Full ethical approval was 
obtained and each patient gave informed consent. HBV DNA viral load was determined by 
the Roche Amplicor Monitor Assay, and a commercial enzyme immunoassay was used to 
detect HBeAg/ anti-HBe antibody status (Murex Diagnostics). All patients were negative 
for antibodies to HIV-1 and HIV-2 (Ortho Diagnostics). All patients on antiviral therapy 
were excluded from the study unless otherwise stated. Healthy volunteers, both staff and 
students at University College London, kindly donated blood for the study. 
Chronic hepatitis B virus is a heterogenous disease, and serological markers can be used to 
classify patients into different disease groups. Presence of HBV surface antigen (HBsAg) 
for a period greater than six months is diagnostic of chronic HBV infection. HBeAg, the 
secretory form of the HBV core antigen, is a marker of active HBV replication. Patients 
can clear HBeAg from the serum and this correlates temporally with the appearance of 
anti-HBe antibodies in the serum. HBeAg to anti-HBe seroconversion occurs early in 
patients with acute HBV infection, but may be delayed by years to decades in those with 
CHB, and occurs at a rate of 5-10% per year. Additionally, a group of patients with 
‘HBeAg negative hepatitis’ do not have HBeAg present in their serum because of a viral 
mutation in either the basal core promoter or preC region of the HBV genome which 
prevents its expression. Patients with CHB may be further subdivided by their HBV DNA 
(IU/ml) and ALT levels, where ALT is a marker of liver inflammation (>50 IU/ml is 
abnormal). Patient tables with details of clinical characteristics can be found in the results 
sections of the relevant chapters. 
Patients who have resolved after past infection with HBV can be identified by the presence 
of anti-HBs and IgG anti-HBc antibodies in their serum. In patients who are immune 
following vaccination, only anti-HBs antibodies are detectable. 
2.2 Separation of Peripheral Blood Mononuclear Cells from whole blood 
Venous blood was collected in EDTA tubes, layered on top of Ficoll-Hypaque at a 2:1 
ratio, and centrifuged for 22 minutes at 2000 RPM with no brake. The top plasma layer 57 
 
was then discarded, and the visible PBMC layer was removed with a Pasteur pipette into 
RPMI 1640 medium for washing. After two wash cycles, cells were resuspended in RPMI 
complete medium with 10% fetal bovine serum for counting. 
2.3 Cell Counting 
A 10μl aliquot of cells was diluted in 90μl of trypan blue and the suspension was counted 
on a Neubauer haemocytometer under a light microscope. The number of cells per 
millilitre of the original cell stock was determined by the following formula: 
Number of cells/ml = number of cells counted in central grid x dilution factor (10) x 10
4  
2.4 Freezing/Thawing of cells 
Peripheral blood mononuclear cells that were not used for direct ex vivo experiments were 
resuspended at a concentration of 5 million cells/ml in freezing medium (90% fetal bovine 
serum and 10% DMSO) and rapidly aliquoted into 1.5ml cryovials (Nunc). These were 
stored at –80
oC in Mr. Frosty Chambers (Fisher Scientific, UK) for a maximum of 7 days, 
following which they were transferred to liquid nitrogen tanks for long-term storage. 
When required, cryovials were thawed in a 37
oC waterbath and the cell suspension was 
rapidly transferred to RPMI medium to buffer the toxic effects of DMSO. Following two 
wash cycles each time spinning the cells for 8 minutes at 1600rpm, decanting the medium 
and resuspending the cells in RPMI, cells were then ready for counting. 
2.5 Processing Liver samples 
Liver samples were obtained from patients with chronic HBV infection or patients with 
non-viral liver disease undergoing diagnostic liver biopsies or from resected tissue. Liver 
tissue was suspended in RPMI 1640 (Sigma) and macerated with a plunger from a 25ml 
syringe and a scalpel in a Petri dish. The cell suspension was then passed several times 
through a 70μm cell strainer (BD biosciences), each time washing the filter with fresh 
RPMI to minimise cell clumping and loss. The cell suspension was then washed three 
times and resuspended in RPMI complete medium with 10% fetal bovine serum for 
counting. Lymphocytes were identified under a high magnification by their size, shape and 
granularity. 58 
 
2.6 Antibodies and Reagents 
CD107a FITC  555800  BD Pharmingen 
CD19 Pe-Cy7  25-0199-73  eBioscience 
CD19 PerCP  345790  BD 
CD24 PE  555428  BD Pharmingen 
CD27 FITC  340424  BD 
CD28 FITC  555728  BD Pharmingen 
CD3 PerCPCy5.5  332771  BD 
CD38 FITC  555459  BD Pharmingen 
CD45RA APC  MHCCD45RA05  Caltag Laboratories 
CD8 APC  555369  BD 
CD8 biotin  0264  Coulter Immunotech 
CD8 PE  R0806  DAKO 
CD8 Pe-Cy5  555368  BD 
CD8 PerCPCy5.5  341050  BD 
HLA-A2 FITC  MCA2090F  Serotec 
IFN-γ APC  341117  BD 
IFN-γ FITC  IC285F  R&D 
IFN-γ PE  IC285P  R&D 
IL-10 APC  554707  BD Pharmingen 
IL-2 FITC  IC202F  R&D 
Ki67 FITC antibody set  556026  BD Pharmingen 
Mouse IgG1-PE  PN IM0670  Coulter Immunotech 
Normal affinity C18-27-specific  
tetramer PE 
Alison Turner, Paul  
Klenerman, Oxford 
Streptavadin Cy3  CLCSA1010 Cedarline  lab. 
TCR ZETA PE  PN IM3169  Coulter Immunotech 
TNF-α PE  559321  BD Pharmingen 59 
 
 
anti-CD28 555725  BD 
anti-CD3 (OKT3)  Kind gift of Peter Beverley and Arne Akbar 
anti-IL-10 Receptor (CDw210)  556011  BD Pharmingen 
β-Mercaptoethanol 31350010  Gibco 
Bovine  Serum Albumin  A-7906  Sigma 
Brefeldin A  B7651  Sigma 
BS3 Bis(Sulfosuccinimidyl) suberate  21580  Perbio Science 
CD19 MicroBeads  130-050-301  Miltenyi Biotec 
CFSE V12883  Molecular  Probes 
Copper(II) sulfate pentahydrate  C-7631  Sigma 
CpG ODN 2006  tlrl-hodnb  InVivoGen 
Cytoperm/Cytofix 554722  BD 
DMSO D2650  Sigma 
EDTA E-7889  Sigma 
Essential amino acids  11130.036  Gibco 
Fetal Bovine Serum  10108-165  Invitrogen 
Ficoll-Paque PLUS  17-1440-03   GE Healthcare 
Formaldehyde F8775  Sigma 
Formamide 444475W  BDH 
Functional grade anti-IL-10 16-7108-85  eBioscience 
γ-
33 P-ATP  NEG602H  Perkin Elmer 
HBcAg  kind gift from  Rhein Biotech 
Hepes 15630056  Gibco 
Human IL-10 ELISA Kit  950.060.096  Diaclone 
Human IL-10 High Sensitivity Elisa kit  850.880.096  Diaclone 
Human IL-2 Quantikine Immunoassay   D2050  R & D 
Human T cell nucleofector Kit  VPA-1002 AMAXA  Biosystems 60 
 
human-CD8 T cell isolation kit II 130-091-154 Miltenyi  Biotec 
IL-2 Human  11 011 456 001  Roche 
Ionomycin I0634  Sigma 
L-arginine A8094  Sigma 
Manganese chloride  M3634  Sigma 
Monensin M5273  Sigma 
Non-essential amino acids  11140.035  Gibco 
Penicillin/streptomycin 15070.063  Gibco 
Phorbol 12-Myristate 13-Acetate  P8139  Sigma 
Phosphate Buffered Saline  P4417-100 TAB  Sigma 
PMSF P7626  Sigma 
PNA probe  4330098  Applied Biosciences 
Potassium sodium tartrate tetrahydrate  S-2377  Sigma 
Protease inhibitor cocktail P8340  Sigma 
RPMI 1640  R8758  Sigma 
RPMI 1640 modified w/o L-arginine 81230-1000M2268  JRH  Biosciences 
Saponin S-4521  Sigma 
Sodium Chloride 5M solution  S-5150  Sigma 
Sodium Hydroxide  S-5881  Sigma 
Sodium pyruvate  11360.039  Gibco 
Sodium tungstate dehydrate  T-2629  Sigma 
Telomerase PCR ELISA
PLUS 12013789001  Roche 
TRAPEZE telomerase Detection Kit  S7700  Chemicon 
Tris T1503-1Kg  Sigma 
TRIS-HCl 1M Stock  T-2538  Sigma 
Trucount Tubes  346334  BD 
Trypan Blue  T8154  Sigma 
Tween 20  161-0781  BIO-RAD 
Zenalb 20 (Human Albumin 20%)  Bio Products Lab. 61 
 
Chapter 3 Materials and Methods 
2.7 Detection of IFN-γ/IL-2/TNF-α production 
PBMC were incubated at 37
oC in a humidified incubator with 5% CO2 for 16 hours in the 
presence of either: 
1.  Reagents which act via the T cell receptor: 1μg/ml anti-CD3mAb [OKT3 clone 
kindly provided by Peter Beverley and Arne Akbar] and 5μg/ml anti-CD28mAb 
(BD biosciences). 
2.  T cell receptor bypassing reagents: Phorbol Myristic Acetate (PMA, 3ng/ml) and 
Ionomycin (1μg/ml) 
3.  Negative  control: RPMI complete medium with 10% fetal bovine serum 
 
 
Figure 2a: Stimulation of T cells with either TCR-dependent or TCR-bypassing mitogens. 
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Brefeldin A (10μg/ml, Sigma-Aldrich) was added 1 hour into the incubation time to 
suspend protein transport from the endoplasmic reticulum to the Golgi apparatus, hence 
preventing extracellular release of cytokines. PBMC were then washed in PBS, stained 
with anti-CD8–Cychrome (PE-Cy5) mAb (30 minutes) and then permeabilized and fixed 
with Cytoperm/Cytofix (BD Biosciences) at 4
oC (30 minutes). After a further wash in 
PBS, cells were dual stained with anti-IFN-γ-PE mAb (R&D systems) and anti-IL-2-FITC 
mAb (R&D systems) or anti-TNF-α-PE mAb (BD Pharmingen) alone in PBS containing 
0.1% saponin at 4
oC for 30 minutes. After 2 further washes cells were fixed (PBS, 1% 
formaldehyde, 1% FBS) and acquired immediately on a FacsCalibur flow cytometer using 
Cell Quest Software. 
2.8 CFSE proliferation assay 
PBMC were washed 3 times in PBS, resuspended at 1 x 10
6 cells/ml in PBS and incubated 
for 10 minutes at 37
oC with 0.5 μM carboxyfluorescein succinimidyl ester (CFSE, 
Molecular Probes). An equal volume of FBS was added to quench the reaction. Cells were 
subsequently washed twice in RPMI complete medium supplemented with 10% fetal 
bovine serum and then transferred into a 96 well plate with pre-coated anti-CD3 mAb 
(1μg/ml). Soluble anti-CD28 was added (5μg/ml) in addition. At day 6, cells were 
harvested, stained with anti-CD8–Cychrome (PE-Cy5) and then acquired on the flow 
cytometer. 
2.9 CD107 degranulation assay 
PBMC were stimulated for 16 hours at 37
oC in the presence of anti-CD3 and anti-CD28 in 
addition to anti-CD107a-FITC. Monensin was added 1 hour into the incubation time. Cells 
were then surface stained with anti-CD8-Cychrome (PE-Cy5) (BD biosciences) and 
acquired on the FACS Calibur Cytometer. 
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2.10 Stimulation with synthetic viral peptides 
The following peptides representing HLA-A2 restricted viral epitopes were used in this 
study:  
 
Peptide  amino acid sequence 
HBV env 183-191  FLLTRILTI 
HBV env 335-343  WLSLLVPFV 
HBV env 338-347  LLVPFVQWFV 
HBV env 348-357  GLSPTVWLSV 
HBV pol 455-463  GLSRYVARL 
HBV pol 502-510  KLHLYSHPI 
HBV core 18-27  FLPSDFFPSV 
HCMV pp65 495-504  NLVPMVATV 
EBV BMLF-1 259-267  GLCTLVAML 
INFLUENZA A MP 58-66  GILGFVFTL 
 
Table 2.1: Details of viral peptides used in this study. All peptides were obtained from 
Proimmune. 
 
Overnight stimulation 
PBMC were stimulated with 10μM peptide for 12 hours and incubated at 37
oC in the 
presence of Brefeldin A (added 1 hour into the incubation). 
Short-term culture 
1μM peptide (or a pool of the seven HBV peptides) were added to 0.25x10
6 PBMC in a 96 
well plate with 50 IU IL-2 in RPMI complete medium for 10 days at 37
oC. IL-2 and 
medium were refreshed on day 4 of culture. On day 10, PBMC were restimulated with 
1μM peptide for 5 hours, in the presence of Brefeldin A (added 1 hour into the incubation). 64 
 
Chapter 4 Materials and Methods 
2.11 Detection of CD28 and intracellular CD3ζ 
PBMC isolated ex vivo were plated (2.5 x10
5/well) in a 96 well round bottomed plate and 
incubated at 4
oC for 30 minutes with saturating concentrations of anti-CD3 PerCP mAb, 
anti-CD8 APC mAb and anti-CD28 FITC mAb. After a wash step in PBS, cells were fixed 
and permeabilized according to the manufacturers protocol with Cytoperm/Cytofix for 30 
minutes (4
oC) after which intracellular staining was carried out using anti-TCRζ-PE mAb 
(Coulter Immunotech) or its corresponding isotype control, IgG1-PE mAb in PBS 
containing 0.1% saponin to permeabilise the cells. Washed cells, resuspended in a solution 
of PBS, 0.1% formaldehyde and 10% Fetal Bovine Serum, were acquired on a Becton 
Dickinson Facs Calibur using Cell Quest Software and data files were analysed using 
FloJo software (Tree Star). 
2.12 Transfection with chimeric receptors 
The CD3ζ/CD28 fusion chimeric receptor was used in this study. The receptor was cloned 
into an expression vector derived from pQBI-AdCMV5 (QBIOgene) and subsequently 
plasmid DNA preparation was done with p500 columns (Qiagen). Plasmid DNA was 
kindly gifted to us by Dr. Alastair Lawson and Dr. Helene Finney (Celltech). 
5 x 10
6 PBMC were washed in PBS then resuspended in 100μl of nucleofector solution for 
T cells. 3-6μg of plasmid DNA (or PBS as a negative control) was added. The suspension 
was subsequently electroporated using program U-13 in the nucleofector device (Amaxa 
Biosystems), and then removed into prewarmed RPMI complete with 10% fetal bovine 
serum. Transfected cells were rested overnight at 37
oC, and the proportion of cells 
expressing the chimeric receptor was determined using anti-CD33 (FITC) by flow 
cytometry.  
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Figure 2b: The CD3ζ/CD28 fusion chimeric receptor. 
 
2.13 Detection of IL-2 production by ELISA 
Transfected cells were rested overnight at 37°C, following which 2.5x10
5 cells were seeded 
into appropriate wells in a 96 well flat bottomed plate pre-coated with either CD33 antigen 
(5μg/ml), anti-CD3 (1μg/ml), both anti-CD3 and CD33 antigen together, or neither as a 
negative control. Soluble anti-CD28 was added to the appropriate wells (5μg/ml). Cells 
were then left in the incubator at 37°C for 48 hours following which supernatants were 
harvested. Enzyme linked immunosorbent assays were then conducted in duplicate using 
the supernatants collected, according to the manufacturer’s instructions (human IL-2 
quantikine immunoassay, R&D systems). 
2.14 Detection of CD3ζ following culture in L-arginine free medium 
PBMC (2.5x10
5)
 were seeded into a 96 well round bottomed plate and incubated at 37
oC 
for 6 days in either L-arginine free medium (GRH biosciences) or L-arginine free medium 
supplemented with L-arginine (Sigma-Aldrich) (0.2g/l). CD3ζ expression in CD8 T cells 
was then measured using the protocol detailed above. 66 
 
2.15 Proliferation of HBV-specific CD8 T cells with or without L-arginine 
In order to examine the proliferative capacity of HBV-specific CD8 T cells, PBMC were 
stained for CFSE as above, then stimulated with HBV c18-27 peptide, and on day 7, HBV-
specific CD8 T cells were detected by costaining with anti-CD8-Cychrome (PE-Cy5) and 
an HLA-A2/c18-27-specific tetramer (PE) (kindly provided by Alison Turner and Paul 
Klenerman, Oxford). PBMC were cultured in L-arginine free medium, with or without the 
addition of L-arginine at the range of concentrations indicated. 
2.16 Detection of serum L-arginine levels 
L-Arginine levels were determined by electrospray mass spectrometry. Samples (50µl) 
were deproteinized with acetonitrile, chromatographed (acetonitrile:water, 1:1, with 
0.025% formic acid) on a Teicoplanin guard column 10mm x 2.1mm ID (Chirobiotic T, 
ASTEC Ltd, Congleton, UK), and analysed using a SCIEX API4000 (Applied Biosystems, 
Warrington, UK) in positive ion multiple reaction monitoring mode. Arginine quantitation 
was done by R. Neil Dalton and Charles Turner of the WellChild Laboratory, Evelina 
Children’s Hospital at St Thomas’s Hospital, London. 
2.17 Detection of arginase activity in serum 
Arginase-I breaks down L-arginine to urea and ornithine. In this assay, a saturating 
concentration of substate (L-arginine) was added to a serum sample and the amount of urea 
produced in a given amount of time was used as a measure of the arginase activity in that 
sample. 1μM Urea made/hour/L serum is often abbreviated to IU/L serum as the units for 
measurement of arginase activity.  
Solutions: 
To initiate reaction: 
•  MnCl2 manganese chloride solution (Sigma) 10mM 
•  TRIS HCL buffer: 0.1M TRIS, 1M HCL, 1% Saponin (Sigma) pH 7.4 
•  L-arginine solution (Sigma) 50mM 
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To stop reaction: 
Stop solution: 0.22g Tungstic acid 
9ml water 
100μl concentrated Hydrochloric Acid 
100μl concentrated Sulphuric Acid 
 
20μl of serum was combined with 20μl of MnCl2 solution, 150μl of Tris Buffer and 100μl 
of L-arginine solution. Tubes were closed and mixed rapidly after addition of L-arginine, 
and then incubated for 30 minutes at 37
oC following which the reaction was stopped with a 
Tungstic acid solution. Epindorph tubes were then spun at 5000 RPM for 10 minutes in a 
centrifuge precooled to 4
oC to pellet the unwanted particulate matter. 200μl of clear 
solution was then carefully removed into COBAS tubes for detection of urea on the 
COBAS INTEGRA 400 (Roche). To subtract background serum urea levels, each 
experiment was exactly duplicated with the exception that 100μl water was added in place 
of L-arginine substrate. 
2.18 Detection of arginase activity in liver tissue 
Liver tissue was weighed then added to TRIS/HCL buffer containing protease inhibitor 
cocktail (Sigma) and trypsin inhibitor phenylmethylsulphonyl fluoride (PMSF) in a 1:4 
ratio at the bottom a glass mortar. A pestle was then used to macerate the liver into a cell 
suspension. This was transferred to an epindorph, exposed to three 15 minute freeze thaw 
cycles at –80
oC and then centrifuged at 5000 RPM for 10 minutes to pellet the cellular 
debris. The clear homogenate was then removed for determination of arginase activity as 
described above. 
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2.19 Detection of total liver protein content by Biuret test 
The Biuret test can be used to measure protein content. In principle, Copper II ions are 
reduced to Copper I ions which subsequently bind to peptide bonds in an alkaline solution 
and this results in a colour change which can be quantified by a spectrophotometer. The 
magnitude of the colour change is proportional to the amount of protein present. 
 
Biuret solution formulation: 0.75g Copper(II) sulfate pentahydrate (Sigma) 
                3g Potassium sodium tartrate tetrahydrate (Sigma) 
                16.66g Sodium Hydroxide 
                500ml distilled water 
 
In order to prepare a standard curve, 20% human albumin solution (Zenalb) was serially 
diluted two fold to produce 8 standards ranging from 200mg/ml down to 1.56mg/ml. 15μl 
of standard or liver homogenate sample was then added in duplicate to individual cuvettes, 
following which 1ml of biuret solution was added to every tube. Samples/standards were 
left at room temperature for 1 hour to allow colour change which was then quantified on a 
spectrophotometer. 69 
 
Chapter 5 Materials and Methods 
2.20 Determination of phenotypic subsets within global CD8 T cells 
PBMC were surface stained with the following antibodies for 30 minutes at 4
oC; anti-
CD27-FITC, anti-CD8-PE, anti-CD3-PerCPCy5.5 and anti-CD45RA APC. Cells were then 
washed twice in PBS containing 1% FBS, and resuspended in a solution of PBS, 0.1% 
formaldehyde and 10% FBS ready for acquisition on a Becton Dickinson Facs Calibur 
using Cell Quest Software. To determine CD3ζ expression within the different subsets, a 
slightly modified protocol was used whereby cells were instead surface stained with anti-
CD27-FITC, anti-CD45RA APC and anti-CD8PerCP, then intracellularly stained with 
TCRζ PE as described above. 
2.21 Quantification of telomere length in CD8 T cells with fluorescence in situ 
hybridisation (Flow FISH) 
Telomeres cap the ends of chromosomes and in humans are made of repeating hexameric 
TTAGGG sequences. Flow FISH incorporates a technique whereby a fluorescently 
labelled protein nucleic acid telomeric probe is hybridised onto the telomeric repeats. The 
flouresence intensity can then be measured on a per cell basis and is a quantitative measure 
of the length of the telomeres. By co-staining for markers CD8 and CD27, telomere length 
can be compared between subsets in any individual, or between different individuals. 
2 x 10
6 PBMC were washed in RPMI, then stained for the following surface markers: 
•  1
o layer : anti-CD8 biotin (20 minutes at room temperature), x1 wash in PBS 
•  2
o layer: anti-streptavadin Cy3 (20 minutes at room temperature), x1 wash in PBS 
•  anti-CD27 FITC mAb (20 minutes at room temperature) x 1 wash in PBS 
Cells were then fixed for 30 minutes at 4
oC with 1mM BS3 (Perbio Science) following 
which the reaction was quenched with 1ml of 50mM TRIS in PBS (pH7.2) for 20 minutes 
in the dark at room temperature. After a further two washes, cells were resuspended in 
hybridisation buffer and this suspension was equally redistributed to 3 new FACS tubes so 
that triplicate tubes for each individual could be run to minimise error. 0.75μg/ml protein 
nucleic acid telomeric probe (C3TA2)3
 conjugated to Cy5 was added, and cells were heated 
to 82
oC in a waterbath for 10 minutes to allow denaturation of telomeric DNA. Cells were 70 
 
then rapidly snap cooled and left at room temperature for 2 hours in the dark to allow 
hybridisation to occur.  
Samples were finally washed twice in post-hybridisation buffer, and twice in PBS to 
remove excess probe and analysed on the flow cytometer. In addition to running triplicate 
samples, an internal control was run for every experiment; PBMC from a healthy donor 
whose telomere length had been predetermined both by southern blotting for TRF length 
and by flow FISH. 
Mean fluorescence intensity values were averaged from triplicate samples and used as a 
quantitative measure of telomere length. In addition, these values were plotted against a 
standard curve to obtain absolute values of TRF length. 
 
Hybridisation buffer: 7ml formamide 
      0.2ml 1M stock Tris HCL 
      2.5ml 4% Bovine Serum Albumin 
   0.3ml  5M  NaCl 
 
 
Post Hybridisation buffer: 7ml formamide 
             0.1ml 1M Tris HCL 
             0.25ml 4% Bovine Serum Albumin 
             0.1ml 10% Tween 20 
             0.3ml 5M NaCl 
             2.25ml distilled water 71 
 
2.22 Telomere length measurement in virus-specific CD8 T cells 
Determination of telomere length in virus-specific populations used the above protocol, 
however, with the following exceptions; 
1.  PBMC were first stimulated with HLA-A2 restricted viral peptides representing the 
immunodominant epitopes to CMV/EBV or HBV for either 12 hours at a 10μM 
concentration (ex vivo), or for 10 days at 37
oC at a 1μM concentration.  
2.  PBMC were not surface stained with anti-CD27 FITC 
3.  Cells were permeabilised with cytoperm/cytofix instead of BS3 
4.  Following permeabilisation, PBMC were additionally intracellularly stained with 
anti-IFNγ FITC in PBS containing saponin to allow detection of virus-specific CD8 
T cells. This incubation step was for 30 minutes at 4
oC, following which cells were 
washed twice and then resuspended in hybridisation buffer. 
 
2.23 Measurement of telomerase activity 
2.23.1 Purification of CD8 T cells  
CD8 T cells were isolated by negative selection using the human-CD8 T cell isolation kit 
II (Miltenyi Biotech) as per the manufacturer’s instructions. Briefly, PBMC were 
incubated with a cocktail of biotin conjugated antibodies against markers of non-CD8 T 
cells, including CD19, CD4, CD123, CD56, Glycophorin A and TCR gamma/delta. Cells 
were then subsequently stained with anti-biotin microbeads which bind to the antibody-
tagged cells. Within the magnetic field of the MACS separator, these magnetically tagged 
non-CD8 T cells were attracted to stick to the column through which they passed, and 
untouched CD8 T cells were free to pass through and be collected. 72 
 
2.23.2 Stimulation of CD8 T cells and Ki67/Trucount analysis 
Collected CD8 T cells were then either snap frozen (0.1x10
6) for ex vivo analysis of 
telomerase activity, or stimulated for 3 or 5 days with anti-CD3 (1ug/ml) in combination 
with irradiated PBMC (40 Grays gamma radiation) at 37
oC in a humidified 5% CO2 
incubator to induce telomerase activity. Since telomerase activity is predominantly induced 
in cycling lymphocytes and is low in resting cells, two additional wells of CD8 T cells 
were seeded to allow for co-staining of CD8 with Ki67, a marker of cell cycling, and 
enumeration of the absolute number of CD8 T cells with Trucount beads (BD biosciences). 
Thus, upon the PCR stage of telomerase detection, samples were adjusted according to 500 
Ki67+ CD8 T cells per reaction.  
2.23.3 Detection of telomerase activity 
Telomerase activity was determined by a gel based TRAPeze system (Chemicon), 
modified from the PCR based telomeric repeat amplification protocol, or alternatively with 
the Roche PCR ELISA Plus TRAPeze Kit as per the manufacturer’s instructions. Snap 
frozen samples were first thawed on ice and incubated with CHAPS lysis buffer. Samples 
were then centrifuged at 12,000rpm for 20 minutes to precipitate cell debris, and cell 
extracts were collected for determination of telomerase activity which involved a two step 
process.  
1)  Telomerase present within the sample cell extract added telomeric repeats onto the 
3’ end of a substrate oligonucleotide (TS) 
2)  The product was then amplified by PCR  
 
This generated a ladder of products with 6 base increments starting at 50 nucleotides. Total 
Product Generated (TPG) was then used as a quantitative measure of telomerase activity. 
The positive control used an extract from a telomerase positive tumour cell line. The 
negative control involved adding lysis buffer to the PCR mix in place of cell extract. 
For quantitative detection of the amplified product, the TS primer was initially end labelled 
with radioactive γ-
33P-ATP. Radioactively labelled TS primer was then added to reaction 
buffer, dNTP mix, TRAP primer mix, Taq Polymerase and distilled water to make up a 
master mix, to which sample extract was added. After the PCR amplification step, loading 73 
 
buffer was added to the PCR reaction tube, and 25μl of mixture was loaded onto a 12% 
polyacrylamide gel in 0.5X TBE buffer. This was run at 400V for approximately 1 hour 40 
minutes. After electrophoresis, gels were removed and dried, and placed onto X-ray film in 
cassettes overnight. Telomerase activity was determined using a GS-800 Bio-rad 
densitometer using the Quantity one software. 
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Chapter 6 Materials and Methods 
2.24 Quantification of IL-10 in serum and supernatant 
2.24.1 Serum 
IL-10 levels in serum were quantified with the Human IL-10 High Sensitivity Elisa Kit 
(Diaclone) as per the manufacturer’s instructions. The range of detection for this kit was 
between 1.56pg/ml – 50pg/ml. 
2.24.2 Supernatant 
PBMC from patients and controls were stimulated for 5 hours with PMA and ionomycin, 
following which supernatants were collected and stored at -80
oC. IL-10 content in batch 
collected supernatant samples was then quantified with the Human IL-10 Elisa Kit 
(Diaclone). 
2.25 Stimulation and phenotypic analysis of B cells 
PBMC were stimulated with CpG oligonucleotide type B (InVivoGen), a human TLR9 
ligand, for 96 hours at 37
oC. For the last four hours of stimulation, PMA and ionomycin 
were added to restimulate the cells, in addition to Brefeldin A to prevent export of 
cytokines out of the cell. Cells were then surface stained for markers CD19, CD24 and 
CD38, fixed and permeabilised, then intracellularly stained with anti-IL-10 APC for 50 
minutes at room temperature. After two further washes, cells were fixed in PBS containing 
FBS (1%) and formaldehyde and immediately acquired on the flow cytometer. (In addition 
to stimulation with CpG, in some cases PBMC were stimulated with HBcAg (10μg/ml) 
with or without irradiated Chinese Hamster Ovary (CHO) cells expressing CD40L which 
has been shown to induce IL-10 production in B cells by binding to CD40 on their surface. 
In these preliminary experiments, PBMC were additionally intracellularly co-stained with 
anti-TNF PE, to investigate the differential induction of this cytokine in patients vs. 
healthy donors.  
On analysis with Flojo software, dependent on expression of surface markers CD24 and 
CD38, CD19+ B cells were categorised into 3 phenotypic subsets; mature, memory and 
transitional (CD19+CD24
highCD38
high). IL-10 production could then be analysed within 
total B cells (CD19+) or within each of these subsets. 75 
 
In some patients, serially stored PBMC were available at multiple timepoints before, 
during and after flares of liver disease. In these individuals, PBMC were stained ex vivo 
for phenotypic markers, and the frequency of the different peripheral B cell subsets was 
analysed longitudinally. In addition, PBMC were stimulated with CpG as described above 
for 96 hours, following which longitudinal fluctuations of IL-10 producing CD19+ B cells 
and phenotypic subsets could be analysed.  
2.26 Positive selection of B cells with magnetic beads 
CD19+ cells were depleted from PBMC by positive selection within a magnetic field. The 
magnitude of virus-specific CD8 T cell responses, expanded for 10 days with viral peptides 
was then compared between PBMC with or without B cells present. 
2.27 Depletion of transitional CD24
high CD38
high B cells by flow based cell sorting 
PBMC were surface stained with anti-CD38 FITC (BD Pharmingen), anti-CD24 PE (BD 
Pharmingen) and anti-CD19 Pe-Cy7 (eBioscience) for 20 minutes at room temperature in 
the dark. After a wash in MACS buffer containing BSA (0.5%) and EDTA, samples were 
resuspended in buffer in polypropylene tubes suitable for use on the BD FACSAria Cell-
Sorting System. Manual gates were drawn to allow selective depletion of the 
CD24
highCD38
highCD19+ transitional B cells. These highly pure transitional cells were then 
collected in separate tubes to the PBMC depleted fraction. Additionally, whole PBMC 
stained with antibodies were passed through the machine untouched as a control. In later 
experiments, magnitude of virus-specific CD8 T cell responses could then be compared 
between whole PBMC, and those depleted of transitional cells. 
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Figure 2c: Diagram to show the stimulation protocol for sorted and unsorted cells. 
 
2.28 Short term virus-specific stimulation with IL-10/IL-10R blockade 
PBMC from HLA-A2+ individuals were seeded in duplicate into a 96 well plate 
(0.25x10
6/well) in the presence of 1μM viral peptide (see table 2.1) and 50 U/ml IL-2, with 
or without the addition of either a) anti-IL-10 (ebioscience) 5μg/ml b) anti-IL-10R 
(eBioscience) 10μg/ml or both together. Medium was refreshed on day 4 with further 
addition of exogenous IL-2 (50U/ml) and anti IL-10 (2.5μg/ml) or its receptor (5μg/ml). 
On day 10, PBMC were pulsed for a further 5 hours with 1μM peptide in the presence of 
Brefeldin A (10μg/ml) and then stained with anti-CD8 APC, anti-CD3 PerCPCy5.5 and 
intracellularly stained with anti-IFNγ-FITC as described above. 
 77 
 
2.29 Co-culture of PBMC with transitional cells 
To investigate whether transitional cells could suppress virus-specific CD8 T cell 
responses in vitro, transitional cells were either depleted or added back with PBMC at a 1:4 
ratio, and the effect on the magnitude of virus-specific CD8 T cell responses was 
determined. In addition, to test whether suppression of virus-specific CD8 T cell responses 
by transitional B cells could be mediated by immunosuppressive IL-10, in some conditions 
anti-IL-10 and anti-IL-10R were added in addition to transitional cells to block the effect 
of IL-10 (Figure 2c.) 
PBMC were stimulated with a pool of 7 HLA-A2 restricted HBV peptides, or a control 
CMV peptide. 
The magnitude of virus-specific CD8 T cell responses was then compared between these 
various conditions. For each condition, 0.25x10
6 cells were plated with 1uM control 
peptide/ pool of 7 HBV peptides for 10 days with the addition of IL-2 on day 0 and day 4 
to aid survival of cells. Cells were restimulated on day 10 with 1μM peptide for 5 hours in 
the presence of Brefeldin A, and virus-specific CD8 T cell populations were detected by 
staining with anti-CD8-PerCP and intracellular anti-IFN-γ-APC. 
2.30 Statistical analysis 
Statistical significance was calculated in all cases by the non-parametric Mann-Whitney U 
test. A p value of <0.05 was deemed significant. 
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3 Functional skewing of the global CD8 T cell population in chronic HBV infection. 
 Background 
Chronic Hepatitis B virus (CHB) infection remains a major global health threat today 
affecting over 400 million individuals worldwide (Ocama et al. 2005). Immune clearance 
is mediated primarily through a strong virus-specific CD8 T cell response, however 
through production of pro-inflammatory cytokines TNF/IFN-γ and lysis of infected 
hepatocytes, these cells also contribute to liver damage. CD8 T cells therefore play a dual 
role within the HBV infected liver (Bertoletti & Maini 2000). 
In patients with uncontrolled CHB infection, but not in those who resolve, a large non-
antigen specific lymphocytic infiltrate is recruited into the liver (Maini et al. 2000), which 
comprises a high proportion of CD8 T cells (Doherty & O'Farrelly 2000). What role these 
cells serve in the HBV inflamed liver is as yet unknown. Within the virus-specific CD8 T 
cell population, marked qualitative (Reignat et al. 2002) and quantitative defects (Boni et 
al. 2007;Maini et al. 2000;Webster et al. 2004) have been described, however there is little 
known about the characteristics of the global CD8 T cell population and their role in viral 
control and or liver immunopathogenesis. Previous reports have shown that T cells isolated 
from patients with CHB displayed an impaired response to mitogens and recall antigens, 
and that responses could be recovered on reduction of viral load with lamivudine (Boni et 
al. 1998;Livingston et al. 1999). This non-antigen specific global T cell defect is thought to 
be particularly evident within the immunotolerant liver environment, where CD8 T cells 
have been shown to proliferate very poorly and are prone to activation induced cell death 
(Crispe 2003). Here we define the functional profile of non-antigen specific CD8 T cells in 
patients with CHB, and in further chapters, investigate mechanisms for the defects seen. 
Selective defects in virus-specific CD8 T cell function have been described in a number of 
chronic viral infections and observed to be progressively lost in a predictable hierarchy 
according to the duration and strength of antigenic stimulation and availability of CD4 help 
(Kaech et al. 2002;Wherry et al. 2003a). Loss of CD8 T cell-derived IL-2 is an early defect 
that has recently been found to result in poor viral control and disease outcome in HIV 
infection (Trimble et al. 2000;Zimmerli et al. 2005). Functional defects affecting non-
antigen-specific CD8 T cells would need to invoke factors other than excessive antigenic 
drive through MHC/peptide interactions. Bystander activation and effects of the large 79 
 
quantities of circulating HBV antigens are possible candidates. In addition, the liver 
microenvironment, where the non-antigen-specific CD8 T cells accumulate in HBV 
infection, has long been recognised to be immunotolerant (Calne et al. 1969). In active 
HBV infection, intrahepatic T cells would be exposed to a high production of HBV 
antigens and recurrent hepatic inflammation. Putative factors affecting non-antigen-
specific T cells include high levels of pro-inflammatory cytokines, hepatocyte expression 
of tolerising ligands (Crispe 2003), depletion of essential nutrients (Bronte & Zanovello 
2005) or accumulation of toxic metabolites (Fallarino et al. 2006;Frumento et al. 2002). 
Through studying the characteristics of non-antigen specific CD8 T cell dysfunction, we 
may gain a better insight into mechanisms of dysfunction within virus specific CD8 T 
cells, study of which is hampered by extremely low circulating frequencies in patients and 
difficulty in isolating cells from liver samples. In addition, it may also provide a valuable 
insight into the role of non-antigen specific CD8 T cells within the HBV inflamed liver. 
In patients with CHB, we found a skewing of effector function in all CD8 T cells, 
regardless of their specificity. Compared to healthy donors, CHB patients had circulating 
and intrahepatic CD8 T cells with poor IL-2 production and proliferative potential, 
however maintained their capacity to produce IFNγ and TNF. Our findings point to a dual 
pathogenic role for non-antigen specific CD8 T cells within the liver, contributing to both 
liver inflammation and poor viral control.  80 
 
Results 
3.1 Global CD8 T cells in CHB are impaired in their ability to produce IL-2 upon T 
cell receptor stimulation 
In patients with high viral load and liver inflammation, there is a large influx of non-virus 
specific CD8 T cells into the liver, not seen in the absence of liver inflammation (Maini et 
al. 2000). Although these cells account for a significant proportion of the infiltrating 
lymphocytes, little is known about what role these cells might play in viral control and/or 
disease immunopathology in the setting of chronic HBV infection. In order to better 
understand their role, we first set out to characterise the functional properties of the global 
CD8 T cell subset in healthy donors and patients with chronic HBV infection. 
PBMC were isolated from peripheral blood from patients or controls, and then stimulated 
with either TCR dependent mitogens (anti-CD3/anti-CD28) or TCR bypassing mitogens 
(PMA/ionomycin). Ability to produce a panel of cytokines was then assessed by 
intracellular cytokine staining. One of the cytokines measured was IL-2, which is required 
for proliferation of virus-specific CD8 T cells upon antigen encounter. Loss of CD8-
derived IL-2 is an early defect that has recently been found to result in poor viral control 
and disease outcome in HIV infection (Trimble et al. 2000;Zimmerli et al. 2005).  
Representative data for CD8 T cell IL-2 production is shown in figure 3.1(a) for a healthy 
donor, patient with low viral load (<10
6 IU/ml HBV DNA) and a patient with high viral 
load (>10
6 IU/ml HBV DNA). Cross-sectional data is summarised in figure 3.1(b), where 
patients have been subdivided according to their viral load, ALT (surrogate marker of liver 
inflammation) or HBeAg status (marker of active viral replication). Upon a TCR 
dependent stimulus (anti-CD3 and anti-CD28), there was a significant impairment in CD8 
T cell IL-2 production in CHB, with a mean 3 fold decrease in patients with high viral load 
compared to the controls (p<0.001, Mann Whitney test). There was a trend to progressive 
impairment with high viral load (>10
6 IU/ml) and raised alanine transaminase (ALT >50 
IU/L) (3.1(b)). In contrast, upon a TCR independent stimulus with ionomycin and PMA, 
no significant difference in IL-2 production was detected between groups, raising the 
possibility that this defect may be selectively associated with dysfunction in the T cell 
receptor or its signalling pathway (fig 3.1(c)). 
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Table 3.1 Clinical Characteristics of patients and controls used for Chapters 3 and 4. BLQ, 
DNA positive but below limit of quantification, i.e. <50 IU/ml. 
 
   Overall CHB  Low viral load  High Viral Load  Healthy Donor 
N  58 35  23 28 
Median age (range)  35 (23-69)  35 (23-69)  36 (23-63)  28 (22-44) 
Sex (M:F ratio)%M          (41:17) 70%  (25:10) 71%  (16:7) 70%  (14:14) 50% 
Median serum HBVDNA  
(IU/ml) (range) 
250000  
(BLQ*-340x10
6)
1400  
(BLQ-945700) 
78x10
6
(1.1x10
6-340x10
6) 
- 
Median ALT (IU/l) (range)  50 (21-498)  36 (21-498)  73 (24-363)  - 
HBeAg status (% positive)  11%  10%  87%  - 82 
 
 
Figure 3.1: Global CD8 T cell dysfunction in IL-2 production upon T cell receptor 
stimulation. PBMC were stimulated with mitogens OKT3 (anti-CD3, 1ug/ml) and anti-
CD28 (5ug/ml) and IL-2 production was determined by intracellular cytokine staining. a) 
Representative dot plots show IL-2 staining by CD8 T cells in a representative healthy 
control, patient with low viral load (<10
6 IU/ml) and a patient with high viral load (>10
6 
IU/ml).  Cross-sectional data is shown in (b), where subjects have been categorised 
depending on their HBV DNA levels, ALT (marker of liver inflammation) or HBeAg 
status (marker for active viral replication). %CD8+IL-2+ on the Y axis= ‘percent CD8+IL-
2+/total CD8+. c) Levels of CD8 T cell IL-2 in the different groups following TCR 
independent stimulation with PMA and ionomycin. (*=p<0.05, **=p<0.01, ***=p<0.001, 
non-parametric Mann-Whitney U test). 83 
 
3.2 Impaired CD8 T cell IL-2 production is associated with poor proliferative 
capacity 
The impairment of CD8 T cell IL-2 production would be expected to limit T cell clonal 
expansion potential, particularly within the liver, where CD4 help is restricted (Norris et al. 
1998). To test this, we measured the proliferative capacity of CD8 T cells upon mitogenic 
stimulation by CFSE dilution. PBMC stained with CFSE dye, were stimulated with a TCR 
dependent stimulus (anti-CD3/anti-CD28) for 6 days, after which they were harvested and 
the proportion of CFSE low cells (those that have divided) were detected by flow 
cytometry. Consistent with their impaired IL-2 production and/or a direct block of cell 
cycle progression, fewer CD8 T cells from patients with CHB divided, and those that did 
underwent fewer divisions, than those from controls (representative examples fig. 3.2(a)). 
The proportion of CD8 T cells able to undergo at least one division was significantly 
reduced in CHB patients with high viral load and expression of HBeAg, and showed a 
negative correlation with liver inflammation within the patient group (r
2=0.59, p=0.043), 
(data not shown). Impaired CD8 T cell division was seen upon stimulation of whole 
PBMC, indicating that the available CD4 T cell help could not compensate for the CD8 T 
cell defect in these patients. Compatible with this, reduced IL-2 production by CD4 T cells 
was also noted in patients with HBV infection compared to healthy controls (data not 
shown). Interestingly, only patients with high viral load showed a significant reduction in 
proliferating CD8 T cells compared to controls, despite both patients with low and high 
viral load having significant impairment in CD8+ IL-2 compared to controls (fig 3.2.b). In 
these patients, it is likely that additional factors such as differentiation status (see chapter 
5), propensity to exhaustion (Wherry et al. 2003a), replicative senescence, and growth 
cycle arrest through L-arginine depletion (Rodriguez et al. 2007), in addition to IL-2 loss, 
could tip the scales towards proliferative dysfunction.    
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Figure 3.2: Impaired CD8 T cell IL-2 production is associated with impaired proliferation. 
a) Representative histograms to show proliferation of CD8 T cells (as measured by 
proportion of CFSE low cells) upon a TCR dependent stimulus in a control, and in patients 
with low and high viral load.  (blue histogram = anti-CD3/anti-CD28 stimulus 6 days; solid 
black line = unstimulated).  b) Cross-sectional summary of data, stratified by disease 
variables HBV DNA, ALT and HBeAg status. (*=p<0.05, non-parametric Mann-Whitney 
U test).  85 
 
3.3 CD8 T cells from patients with high viral load maintain their capacity to produce 
proinflammatory cytokines and lyse cells 
By contrast to IL-2 production, CD8 T cell production of IFN-γ was maintained in patients 
with high HBV load, liver inflammation and expression of HBeAg compared to healthy 
carriers or healthy donors (Figure 3.3 top panel). Similarly, TNF-α production and 
cytolytic potential (measured by surface expression of CD107) were maintained in CHB, 
and tended to be higher in patients with active disease (Figure 3.3 middle and bottom 
panels). Using PMA and ionomycin as a TCR bypassing signal, no differences in CD8 T 
cell effector function could be detected between CHB patients and controls (data not 
shown). This pointed to the skewed CD8 T cell effector function resulting from aberrations 
within the T cell receptor associated signalling machinery. This was supported by the fact 
that cytokine skewing was maintained upon substituting anti-CD3/CD28 stimulation with 
plate-bound anti-CD3 alone or anti-CD3 in combination with irradiated APC.  
CD8 T cells with this altered IFN-γ:IL-2 ratio have recently been noted in other chronic 
viral infections such as HIV and LCMV and found to correlate with poor viral control and 
disease progression (Wherry et al. 2003a;Zimmerli et al. 2005). 86 
 
 
Figure 3.3: CD8 T cells from patients with high viral load maintain capacity to produce proinflammatory cytokines and lyse cells. 
Left panel: Dot plots to show production of IFN-γ, TNF-α and CD107 (marker of cytolysis) in CD8+ T cells from different patient 
groups upon anti-CD3/anti-CD28 stimulation.  Summary data for each cytokine is shown on the right hand panel. %CD8+IFNγ+ on 
the Y axis= ‘percent CD8+IFNγ+/total CD8+.  (*=p<0.05, **=p<0.01, non-parametric Mann-Whitney U test). 87 
 
3.4 Skewed IFN-γ:IL-2 ratio in CHB is regardless of virus specificity 
HBV-specific CD8 T cells are markedly depleted in patients with CHB (Maini et al. 
2000;Webster et al. 2004), such that circulating responses are barely detectable, even when 
overlapping peptides covering the whole genome are applied (Boni et al. 2007). Based on 
this finding, it is logical to assume that the majority of the CD8 T cells we are studying in 
the periphery of these patients are non-HBV specific. In order to confirm that the 
qualitative dysfunction we observed was not restricted to the HBV-specific CD8 T cells 
but also extended to other virus specificities, PBMC from HLA-A2 positive donors were 
stimulated directly ex vivo with peptides representing immunodominant HLA-A2-
restricted viral epitopes from CMV, EBV and influenza A in addition to HBV (figure 
3.4(a)). Virus-specific CD8 T cells from healthy donors produced predominantly IFN-γ but 
had a clear population of dual IFN-γ:IL-2-responding cells, whereas those from CHB 
patients only produced IFN-γ (Figure 3.4(a). The percent of IFN-γ positive to dual IFN-
γ:IL-2 positive peptide-specific CD8 T cells was plotted as a ratio, following subtraction of 
background readings from controls without peptide. As shown in figure 3.4(b), regardless 
of the virus specificity, there was a significantly higher IFN-γ:IL-2 ratio in patients with 
active HBV infection compared to healthy donors (p<0.01). Since CMV infection has also 
been reported to skew the repertoire of T cell responses (Almanzar et al. 2005) and was 
therefore a potential confounding factor, we also compared exclusively CMV-specific 
responses in a subset of CHB patients and controls who were known to be CMV 
seropositive. The proportion of CD8 T cells able to produce IL-2 in response to the 
immunodominant HLA-A2 restricted NLV epitope from pp65 showed a stepwise reduction 
from healthy donors to low and high level CHB patients (Figure 3.4(c)). These data further 
confirm that functional impairment is present in the generalised T cell population in 
patients with CHB, regardless of antigen specificity. 88 
 
 
          
Figure 3.4: Skewed IFN-γ:IL-2 ratio in CHB is regardless of virus specificity. 
Determination of IL-2 and IFNγ production by CD8 T cells following stimulation with 
HLA-A2 restricted viral peptides. a) Representative flow cytometric dot plots to show 
distribution of IFN-γ and IL-2 positive responder cells following ex vivo stimulation with 
peptides (for INF-A, CMV, HBV envelope pool) in a healthy donor and in a high level 
carrier. All ex vivo responses were in the range of 0.1-4% following subtraction of 
background readings. A response was determined as any reading>mean+ 2SD of 
background. b) Cumulative data to show mean IFN-γ:IL-2 ratio following stimulation with 
peptides for controls, and patients with low (<10
6IU/ml) and high (>10
6IU/ml) viral load. 
c) Histogram to show proportion double positive (IFNγ+IL2+/IFNγ+) CD8 Tcells in 
controls and patients following stimulation with the NLV peptide of CMV ex vivo. Mean 
and standard error are shown. (*=p<0.05, **=p<0.01, non-parametric Mann-Whitney U 
test). 89 
 
3.5 Intrahepatic CD8 T cells in CHB have impaired IL-2 production compared to 
those from patients with non-viral liver disease 
CD8 T cells are enriched in the liver compared to the periphery (Norris et al. 1998), with 
CD8 T cells constituting 60-90% of intrahepatic T cells. In order to better understand what 
role this population may play in HBV-associated inflammation and/or viral control, 
intrahepatic CD8 T cells were isolated and studied. Liver tissue was obtained from routine 
diagnostic biopsies or resected tissue from six patients with HBV-related liver disease and 
six controls without HBV infection. Control liver samples included liver tissue with 
normal architecture and uninflammed histology taken distal to a metastasis, and tissue 
from patients with other inflammatory liver diseases (see Table 3.2). Following isolation, 
intrahepatic PBMC were stimulated directly ex vivo with T cell receptor dependent 
mitogens, and IFN-γ and IL-2 production was determined by intracellular staining 
(representative examples, Figure 3.5(a)). In non-HBV infected patients, three populations 
of responder cells could be seen; IFN-γ single positive, IFN-γ:IL-2 double positive and IL-
2 single positive. In each of the 6 CHB infected donors however, intrahepatic CD8 T cells 
almost exclusively produced IFN-γ, resulting in a significantly raised mean IFN-γ:IL-2 
ratio compared to the non-HBV infected group (p<0.01) (Figure 3.5(b)). Indeed this is 
further shown in figure 3.5(c), where it is apparent that there is a selective loss of CD8+ 
IL-2 producing cells within lymphocytes isolated from HBV livers, however these cells 
maintain their ability to produce IFN-γ. These data revealed a dysfunction in global 
intrahepatic CD8 T cell IL-2 production in CHB.  90 
 
 
Figure 3.5: Intrahepatic CD8 T cells in CHB have impaired IL-2 production compared to 
those from patients with non-viral liver disease. a) Intrahepatic CD8 T cells were isolated 
from liver biopsies and cytokine production was determined by intracellular staining 
following  αCD3/αCD28 stimulation. Representative dot plots show IL-2 and IFN-γ 
production by CD8 T cells for a typical patient with chronic HBV and a patient with non-
viral liver pathology. b) Following mitogenic stimulation, the ratio of IFN-γ:IL-2 
production by intrahepatic CD8 T cells was determined for 6 patients with chronic HBV, 
and 6 patients without chronic HBV infection. Ratios are plotted in the figure (b) and mean 
IL-2 and IFN-γ production for the two groups are shown separately in (c). CD8+IL-2+ on 
the Y axis= ‘percent CD8+IL-2+/total CD8+.  (**=p<0.01, non-parametric Mann-Whitney 
U test). 
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Subject Pathology ALT 
(IU/L)
HBeAg Sex Age 
H1   CHB mild fibrosis  45  NEG  Male  31 
H2   CHB mild fibrosis  100  POS  Male  23 
H3   CHB moderate fibrosis 246  POS  Male  42 
H4   CHB cirrhosis  498  NEG  Male  34 
H5   CHB no fibrosis   48  NEG  Male  43 
H6   CHB mild fibrosis  63  NEG  Male  43 
C1   Non Primary
Liver Carcinoma
* 
140 N/A  Female  34 
C2   Non Primary
Liver Carcinoma
* 
26 N/A  Female  56 
C3   Cholangiocarcinoma  41  N/A  Female  34 
C4   Non Primary
Liver Carcinoma
* 
34 N/A  Male  60 
C5   Non Primary
Liver Carcinoma
* 
17 N/A  Female  67 
C6   Non Primary
Liver Carcinoma
* 
209 N/A  Male  66 
 
 
Table 3.2 Clinical characteristics of patients and controls for liver samples. *  resection 
specimens adjacent to non-primary liver carcinoma; all tissue was of normal architecture. 
 92 
 
Discussion 
Chronic hepatitis B virus infection is characterised by an intrahepatic influx of non-antigen 
specific CD8 T cells that fail to suppress viral replication and may instead amplify liver 
damage initiated by HBV-specific CD8 T cells (Ando et al. 1993;Bertoletti & Maini 
2000;Maini et al. 2000). To better understand their role in the liver, we characterised the 
functional properties of global CD8 T cells isolated from both the periphery and liver of 
patients with CHB infection. We found that the global CD8 T cell population (including 
CD8 T cells specific for HBV and for other chronic viruses) were skewed towards 
IFNγ/TNF production and were impaired in their ability to produce IL-2 and proliferate. 
This functional bias could contribute to both the failure of viral control and the 
pathogenesis of resultant liver inflammation, suggesting a dual role for non-antigen 
specific CD8 T cells. 
In patients with high viral load who fail to control HBV infection, the circulating 
frequencies of virus-specific CD8 T cells ex vivo are barely detectable, thus restricting the 
study of these cells. By scrutinising the global CD8 T cell population instead, we have 
identified a functional bias within these cells which may contribute to the failure of virus-
specific CD8 T cells to survive and proliferate sufficiently to control HBV replication. 
Previous reports have demonstrated that HBV-specific CD8 T cells have impaired capacity 
for clonal expansion (Boni et al. 2007;Maini et al. 2000;Webster et al. 2004) and a greater 
susceptibility to Bim-mediated apoptosis (Lopes et al. 2008). In this study we showed that 
global CD8 T cells were impaired in their capacity to produce IL-2. Autologous IL-2 
production has been reported to drive replication of CD8 T cells in settings of impaired 
CD4 help, such as in the liver environment where CD4 are depleted relative to the 
peripheral blood (Lopes et al. 2008;Norris et al. 1998), and during HIV infection where 
there is a CD4 lymphopenia (Lopes et al. 2008;Zimmerli et al. 2005). Thus, an intrahepatic 
T cell deficiency in IL-2 could both hamper HBV-specific CD8 T cell proliferation, and 
simultaneously confer a greater propensity for these cells to undergo apoptosis through the 
IL-2 dependent Bcl-2 pathway (Lopes et al. 2008). A generalised defect in the ability to 
mount efficient T cell responses in patients with CHB is supported by the long-standing 
clinical observation that these patients are significantly less likely to reject a liver 
transplant than patients with other chronic liver diseases (Adams et al. 1991;Farges et al. 
1996). Although this global dysfunction in IL-2 might also be expected to compromise the 93 
 
ability of CD8 T cells to control concurrent intrahepatic infections with other persistent 
non-cytopathic viruses, we suggest that the HBV-specific response may be most affected 
by this global CD8 T cell impairment, due to their additional attrition by mechanisms 
including PD-1 induced anergy (Boni et al. 2007) and Bim mediated apoptosis (Lopes et 
al. 2008).  
We observed that global CD8 T cells capable of IFNγ and TNF release were maintained in 
CHB patients with high viral load and liver inflammation. These cytokines may have a 
dual role in the HBV inflamed liver. In the transgenic mouse model, IFNγ and TNF have 
been shown to mediate non-cytolytic clearance of HBV, and are therefore required for viral 
control (Guidotti et al. 1996). On the other hand, both these cytokines are pro-
inflammatory and may additionally cause immunopathology (Bertoletti & Maini 2000). 
Constitutive expression of IFNγ in the liver of transgenic mice induces chronic hepatitis 
(Toyonaga et al. 1994). Liver damage in this setting is partially attributable to IFN-γ 
mediated induction of chemokine release (CXCL9 and CXCL10) from hepatocytes, which 
attract a non-antigen specific cellular infiltrate into the liver (Kakimi et al. 2001b), 
including NK cells which have been shown recently to induce TRAIL-mediated apoptosis 
of hepatocytes during CHB (Dunn et al. 2007). Blockade of chemokine signalling reduces 
the severity of liver disease. In addition, IFNγ may also increase the susceptibility of the 
liver to TNF mediated damage (Morita et al. 1995). TNF has been demonstrated to mediate 
potent hepatocyte destruction, particularly when expressed in a cell-bound form (Maeda et 
al. 2003) and its effects may be heightened through the capacity of the HBx protein of 
HBV to sensitize hepatocytes to TNF-mediated apoptosis (Su & Schneider 1997). Thus 
bystander CD8 T cell production of pro-inflammatory cytokines may further drive the non-
antigen specific lymphocytic infiltrate and propagate liver inflammation.  
Functional biasing of CD8 T cells towards IFNγ and TNF production, with a failure to 
produce IL-2, has previously been reported in terminally differentiated CD8 T cells 
isolated from healthy donors, and in ‘exhausted’ virus specific CD8 T cells from patients 
with chronic viral infections. Hamann et al. characterised the functional and phenotypic 
profile of global CD8 T cells, and showed that terminally differentiated revertant cells, 
phenotypically defined as CD27-CD45RA+CD8+, were IL-2 negative but still capable of 
producing IFNγ and TNFα on PMA/ionomycin stimulation (Hamann et al. 1997). An 
accumulation of terminally differentiated virus specific CD8 T cells have been reported 94 
 
during human chronic viral infections, and associated with failure of virus control. Wherry 
et al showed in a mouse model of LCMV, that CD8 T cells could be driven by persistent 
high dose antigen towards functional exhaustion. This loss of function was progressive; 
capacity to produce IL-2 and to proliferate was lost first, but ability to produce TNF and 
IFNγ were not compromised until later stages of exhaustion (Wherry et al. 2003a). CD8 T 
cells from patients with HBV in our study had the functional profile of CD8 T cells in the 
‘partial exhaustion 1’ phase, characterised by loss of IL-2 production and proliferative 
capacity, but maintenance of IFNγ and TNF production (Shin & Wherry 2007). A similar 
functional profile has been attributed to virus specific CD8 T cells in other chronic viral 
infections including, Mouse Hepatitis Virus (MHV) (Bergmann et al. 1999), HIV (Trimble 
& Lieberman 1998) and HCV (Radziewicz et al. 2007;Urbani et al. 2006). Thus, 
accumulation of functionally exhausted virus-specific CD8 T cells secondary to persistent 
HBV load could potentially explain the skewed functional profile of CD8 T cells in 
patients with CHB. However, since HBV-specific CD8 T cell populations are scanty in the 
periphery, a global biasing of CD8 T cell phenotype and function would require the 
additional influence of bystander factors. Possible contributors include cytokines IFNα and 
TNF, which are known to induce CD28 loss on global CD8 T cells (Chiu et al. 
2006;Fletcher et al. 2005;Lewis et al. 2004) and are elevated in patients with CHB (Dunn 
et al. 2007;Sheron et al. 1991), high quantities of circulating HBeAg which is thought to 
have immunoregulatory properties (Milich et al. 1990), and ligation by tolerizing ligands 
expressed on hepatocytes (Crispe 2003). 
From our data, we have found that upon stimulation with PMA and ionomycin, there was 
no difference in the proportion of IL-2/IFNγ positive CD8 T cells in healthy donors and 
patients with low and high viral load. Therefore, although an enrichment of highly 
differentiated CD8 T cells (which have been shown to be IL-2 low on PMA/ionomycin 
stimulation (Hamann et al. 1997)) could partially explain the functional bias, clearly other 
factors are at work. Notably, we have observed that in patients with high viral load, in 
whom there was the lowest IL-2 production by CD8 T cells, this defect was mediated 
through T cell receptor dependent stimulation. Therefore, in chapter 4, we have 
investigated the role of T cell signalling machinery dysfunction in CD8 T cells, as another 
potential mechanism for the defects in effector function and proliferation described.  95 
 
Through study of the non-antigen specific CD8 T cells in patients with CHB, we were able 
to identify a functional biasing in patients with high viral load. This provides an insight 
into possible mechanisms of dysfunction within virus-specific CD8 T cells, direct study of 
which is hampered by extremely low circulating ex vivo frequencies. We have 
demonstrated that CD8 T cells from patients with CHB have impaired IL-2 and 
proliferative capacity, regardless of their specificity. Such functional skewing could impair 
their survival and anti-viral potential, particularly for persistent non-cytopathic viruses in 
the CD4 depleted liver environment. Their capacity for IFNγ/TNFα production could 
contribute to the pro-inflammatory milieu, thereby exacerbating mechanisms underlying 
their dysfunction. Our data suggest that chronic exposure to the microenvironment of an 
inflamed liver could impair T cell effector functions critical to the control of this virus. A 
major limitation to the success of therapeutic vaccination in the setting of persistent virus 
infection such as HBV is thought to be the impaired T cell proliferative capacity. 
Approaches to remedy these T cell defects in patients with CHB could therefore form an 
important adjunct to future immunotherapeutic strategies. 
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4 Global CD8 T cell downregulation of proximal TCR-associated signalling 
molecules, CD28 and CD3ζ, associated with depletion of amino acid L-arginine in 
CHB. 
Background 
A global CD8 T cell defect in IL–2 production and proliferation upon a T cell receptor 
(TCR) dependent, but not TCR-bypassing stimulus, pointed towards dysfunction within the 
T cell receptor signalling machinery. In this chapter, we examine aberrant expression of 
proximal TCR associated signalling molecules CD3ζ and CD28, as putative mechanisms 
for impaired CD8 T cell effector function.  
In other diseases of chronic inflammation and high load antigenic persistence analogous to 
the situation in CHB, selective defects in global CD8 T cell function have been associated 
with downregulation of CD3ζ, in some cases with a superimposed CD28 downregulation. 
These include autoimmune disorders (Krishnan et al. 2005;Tsuzaka et al. 2003), 
malignancy (Nakagomi et al. 1993) and chronic viral (Trimble et al. 2000;Trimble & 
Lieberman 1998), and bacterial (Bronstein-Sitton et al. 2003) infections. The CD3ζ chain 
exists as a disulphide linked homodimer and is a proximal T cell receptor associated 
signalling molecule (Baniyash 2004). Upon T cell receptor ligation, SRC family kinases 
phosphorylate ITAM residues on the intracytoplasmic domain of the CD3ζ and these then 
serve as docking sites for adaptor proteins such as ZAP-70 which potentiate further 
downstream signalling events. CD3ζ is structurally and evolutionarily distinct from other 
CD3 components as it has 3 ITAM residues on its intracytoplasmic tail (as opposed to 1 on 
other components) therefore it can most efficiently amplify and propagate a signal into the 
cell rendering it a rate limiting step in T cell activation (Pitcher et al. 2003;Sussman et al. 
1988).  
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Figure 4a: Signalling through CD28 and the T cell receptor. (Modified from Baniyash 
Nature Reviews Immunology 2004 and Alegre Nature Reviews Immunology 2001). (Left) 
Ligation of the co-receptor CD28 induces phosphorylation of tyrosine on the 
intracytoplasmic chain, recruitment of PI3K and GRB2, and resultant cascades which lead 
to activation of factors including AKT. The biological result is release of IL-2 and 
upregulation of anti-apoptotic BCL-XL. (Right) Ligation of the T cell receptor results in 
phosphorylation of ITAM residues on CD3ζ, recruitment of ZAP-70 and phosphorylation 
of additional adaptor proteins including LAT (linker for activation of T cells) and SLP-76 
(SRC homology 2 (SH2)-domain-containing leukocyte protein of 76kDa). A cascade of 
further downstream signalling events results in gene transcription within the nucleus. 
Cross-talk between pathways may be mediated by CD28 activation of LCK (Holdorf et al. 
1999) or recruitment of CD28 signalling elements to LAT and subsequent enhancement of 
TCR mediated signalling (Acuto & Michel 2003).  
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Along with CD3ζ, downregulation of CD28, a proximal co-stimulatory molecule required 
for efficient signalling, has also been described in viral infections (Maki et al. 
2004;Trimble et al. 2000) and associated with T cell anergy.CD28 is a 44kDa glycoprotein 
which binds CD80 and CD86 on antigen presenting cells and provides a second 
costimulatory signal which reduces the threshold for TCR activation (Alegre et al. 2001). 
Similar to TCR triggering, ligation of CD28 results in phosphorylation of tyrosine residues 
on its intracytoplasmic tail by SRC family kinases LCK and FYN. However, these tyrosine 
residues are not incorporated within ITAM residues (as they are for CD3ζ) and there is no 
subsequent recruitment of ZAP-70 and activation of the LAT-SLP76 complex. Instead 
CD28 signalling leads to downstream activation of proteins including PI3K, ITK, VAV1, 
AKT and the TEC protein tyrosine kinases which are all involved in the TCR signalling 
pathway. Based on this observation and microarray studies which showed that CD28 co-
ligation with TCR signalling up/downregulated thousands of genes, but CD28 agonists 
alone elicited few changes in gene expression (Diehn et al. 2002), Acuto et al. suggested 
that CD28 may have primarily a quantitative role in amplifying TCR signalling. The 
convergence of CD28 and TCR pathways in this case was hypothesized to be mediated 
through LAT, which could provide a scaffold onto which CD28 signalling elements could 
bind and enhance further TCR mediated downstream signalling cascades (Acuto & Michel 
2003). The biological consequences of CD28 co-stimulation include potent stimulation of 
IL-2 production (Lucas et al. 1995), promotion of cell cycle progression (Bonnevier & 
Mueller 2002) and upregulation of anti-apoptotic BCL-XL (Boise et al. 1995), which are all 
beneficial for CD8 T cell expansion and survival. Loss of CD3ζ, with or without CD28 
downregulation, could therefore impair IL-2 production and proliferation, and 
subsequently hamper viral control.  
Both these proximal molecules are upstream elements which are required to initiate 
signalling, and thus play a rate-limiting role in controlling the efficiency of TCR signal 
transduction and consequent generation of effector function. In this chapter, we show that 
both CD3ζ and CD28 are downregulated in CD8 T cells from patients with CHB, and that 
upon reconstituting their expression by transfection of CD8 T cells with chimeric 
receptors, the defect in IL-2 production can be reversed. In addition, we provide evidence 
that CD3ζ downregulation is further exacerbated within intrahepatic CD8 T cells, and this 
may partially be due to local depletion of the non-essential amino-acid L-arginine, which is 99 
 
required for the production of CD3ζ. L-arginine levels were found to be significantly lower 
in the serum of patients with liver inflammation, and we suggest could be even more 
depleted within the HBV inflamed liver, where we have shown that the enzyme arginase-1, 
which catabolises L-arginine, is more highly expressed than in livers with non-viral liver 
disease.  
Exposure to inflammatory cytokines, viral particles and a nutrient depleted environment 
within the HBV inflamed liver could potentiate downregulation of CD3ζ and CD28. 
Aberrant T cell signalling could thus provide a partial mechanism for the non-antigen 
specific CD8 T cell defect in IL-2 production and proliferation. This in turn could hamper 
the capacity for HBV-specific CD8 T cells to expand and survive, and attenuate viral 
control.  
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Results 
4.1 CD3ζ downregulation in CD8 T cells from patients with chronic HBV infection 
Based on our observation that CD8 T cells from patients with chronic HBV display an IL-2 
and proliferative defect selectively upon TCR-mediated stimuli but not TCR-bypassing 
stimuli, we hypothesized that this impaired effector function could be associated with 
dysfunction within the T cell signalling pathway. In other chronic infectious diseases such 
as HIV, a CD8 T cell defect in IL-2 has been partially attributed to selective 
downregulation of CD3ζ, a proximal TCR associated signalling molecule (Boise et al. 
1995;Trimble et al. 2000). This molecule can be downregulated independently of other 
CD3 signalling molecules, which maintain their expression on the cell surface. In order to 
investigate whether CD3ζ downregulation could be occurring in CD8 T cells from patients 
with chronic HBV, we isolated PBMC from subjects (control n=16, patients with low level 
HBV (viral load<10
6) n=20; patients with high level HBV (viral load >10
6) n=12) and 
CD3ζ expression was determined by intracellular cytokine staining. CD3ζ expression was 
determined after gating on CD3ε+CD8+ T cells, to confirm that downregulation of CD3ζ 
was an isolated defect, and not secondary to downregulation of the entire CD3 complex 
(anti-CD3ε binds an extracellular domain on the CD3ε chain, therefore does not interfere 
with binding of CD3ζ to its intracellular determinant). CD3ζ expression after gating on 
CD3ε+CD8+ cells is shown for a representative patient with CHB and healthy donor in fig. 
4.1a. 
  101 
 
Subject Pathology  ALT 
(IU/L) 
HBeAg Sex  Age 
H1 
a CHB  mild  fibrosis  45  NEG Male  31 
H2 
a CHB  mild  fibrosis  100  POS Male  23 
H3 
a CHB  moderate  fibrosis  246  POS Male  42 
H4 
a,b CHB  cirrhosis  498  NEG  Male  34 
H5 
a CHB  no  fibrosis    48  NEG Male  43 
H6 
a CHB  mild  fibrosis  63  NEG Male  43 
H7 
b CHB
d 40  -  Male  60 
H8 
b CHB
d 56  -  Male  66 
H9 
b CHB
d 110  -  Male  56 
H10 
b CHB
d 79  -  Male  44 
H11 
b CHB
d 45  -  Female  48 
H12 
c CHB  cirrhosis  31  -  Male  54 
H13 
c CHB  fibrosis  67  NEG  Male  49 
H14 
c CHB  cirrhosis  54  NEG  Male  53 
H15 
c CHB  cirrhosis  47  NEG  Male  50 
H16 
c  CHB + Hepatocellular Carcinoma  19  NEG  Male  61 
C1 
a,b  Non Primary Liver Carcinoma
e 140  N/A Female 34 
C2 
a  Non Primary Liver Carcinoma
e 26  N/A Female 56 
C3 
a,b Cholangiocarcinoma  41  N/A  Female  34 
C4 
a  Non Primary Liver Carcinoma
e 34  N/A Male  60 
C5 
a,b  Non Primary Liver Carcinoma
e 17  N/A Female 67 
C6 
a  Non Primary Liver Carcinoma
e 209  N/A Male  66 
C7 
b  Hepatitis C virus infection  54  N/A  Female  41 
C8 
b  Non Primary Liver Carcinoma
e 30  N/A Female 60 
C9 
b  Non Primary Liver Carcinoma
e 30  N/A Male  54 
C10 
b Nonalcoholic  steatohepatitis  108  N/A  Female  32 
C11 
c  Healthy transplant donor  -  N/A  Male  56 
C12 
c Alcoholic  cirrhosis  19  N/A  Male  63 
C13 
c  Primary sclerosing cholangitis  138  N/A  Female  29 
C14 
c  Primary sclerosing cholangitis  69  N/A  Female  60 
C15 
c  Primary sclerosing cholangitis  -  -  Female  - 
 
a Used for functional ICS (Chapter 3) 
b Used for CD3ζ staining (Figure 4.2) 
c  Used for arginase activity (Figure 4.11) 
d CHB, histology unavailable 
e resection specimens adjacent to non-primary liver carcinoma; all tissue was of normal architecture 
 
 
Table 4.1 Clinical characteristics of patients and controls for liver sample (extended table). 102 
 
              
Figure 4.1: Global CD8 T cells from patients with chronic HBV have downregulated 
CD3ζ. PBMC were surface stained for CD3ε and CD8, fixed and permeabilised, then 
stained for intracellular CD3ζ or its isotype. A tight lymphocyte gate and secondary gate 
over CD3ε+CD8+ cells has been applied. A marker was applied at the edge of the isotype 
control (solid black line) and proportion CD8 T cells to the right of this line represented the 
CD3ζ+ fraction. a) Representative flow cytometric histogram illustrating CD3 expression 
(as a percentage and as mean fluorescence intensity:MFI) for a chronic HBV infected 
patients with high viral load (>10
6 IU/ml) (dashed line) and low viral load (<10
6 IU/ml) 
(grey). b) CD3ζ levels, shown as both MFI and percentage of CD3ζ+ in the total CD8 are 
shown against viral load (above), and percentage values are further broken down by 
HBeAg status and ALT (below). CD8+CD3ζ+ on the Y axis= ‘percent CD8+CD3ζ+/total 
CD8+. (*=p<0.05, ***=p<0.001, non-parametric Mann-Whitney U test). 103 
 
To determine whether CD3ζ downregulation correlated with disease status, patients were 
categorised by their viral load (<10
6 or >10
6 IU/ml), HBeAg status or by their alanine 
aminotransferase level (raised >50 IU/l). Patients were classed as ALT high if their ALT 
was raised at time of sampling, or had been raised in the previous 6 months. This allowed 
more accurate categorisation, as it is common for patients to have cyclical changes of ALT 
over time. As shown in figures 4.1b, we observed that CD3ζ expression in CD8 T cells 
correlated inversely with each of the three parameters. With increasing viral load, we 
observed a progressive decrease in CD8+CD3ζ+ expression. Patients with the highest viral 
load had the lowest CD3ζ expression in their CD8 T cells, with a mean reduction of 40% 
compared to controls. Expression of CD3ζ was also reduced in CD4 T cells from these 
patients, but to a lesser degree than the CD8 T cells (data not shown), as noted previously 
in HIV infection (Trimble & Lieberman 1998). 
Interestingly, we observed a degree of inter-patient variability in CD3ζ expression even 
within the control group. This heterogeneity may have been partially attributable to 
whether or not individuals had intercurrent infections at the time of sampling, 
predetermined variation of zeta secondary to genetic polymorphisms of the CD3ζ gene 
(Gorman et al. 2008), and the differentiation status of CD8 T cells (discussed further in 
chapter 5). 
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4.2 CD3ζ downregulation is greatest in intrahepatic CD8 T cells  
CD3ζ downregulation has been attributed to sustained exposure to inflammatory cytokines 
and antigenic stimulation; we therefore hypothesised that it would be more pronounced in 
the intrahepatic compartment, the site of HBV replication and associated pathology. 
Intrahepatic lymphocytes were isolated from biopsy tissue obtained from 6 patients with 
CHB and 7 patients with non-viral liver disease (Table 4.1). CD3ζ expression was then 
compared between intrahepatic and peripheral T cells for each individual (representative 
example in Figure 4.2a). CD3ζ expression was lower in intrahepatic compared to 
peripheral CD8 T cells for all HBV infected patients with a mean of 24% fewer CD3ζ+ 
cells in the liver compared to the periphery (fig 4.2b). In the 7 patients with non-viral liver 
disease, the difference in CD3ζ expression between peripheral and intrahepatic CD8 T 
cells was significantly less. These data suggest therefore that the inflamed liver in patients 
with CHB, may further potentiate CD3ζ downregulation.  
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Figure 4.2: CD3ζ downregulation is more marked within intrahepatic CD8+ T cells. 
Peripheral blood and intrahepatic lymphocytes (isolated from biopsy tissue) were obtained 
from 6 patients with chronic HBV and 7 patients with non-viral liver disease. CD3ζ 
expression was determined by intracellular cytokine staining. a) Histogram to illustrate 
differential expression of CD3ζ by peripheral (dark grey) and intrahepatic (light grey) CD8 
T cells from a CHB donor (dotted line=isotype). b) The difference in CD3ζ expression 
between intrahepatic and peripheral CD8 T cells is plotted for each patient with HBV/non-
HBV related liver disease. (**=p<0.01, non-parametric Mann-Whitney U test). 106 
 
4.3 CD28 is also downregulated in CHB patients 
CD28 is a co-stimulatory molecule on the cell surface which facilitates efficient T cell 
signalling. Previous studies have suggested that CD28 and CD3 signalling pathways when 
activated synchronously, converge together and have a synergistic effect in inducing IL-2 
production in T cells (Acuto & Michel 2003;Hombach et al. 2001). Like CD3ζ, CD28 
downregulation has been described in chronic viral infections such as HIV and CMV and 
has been associated with cell anergy and dysfunction in IL-2 production (Almanzar et al. 
2005;Trimble et al. 2000). In order to investigate whether CD28 downregulation could be 
playing a role in chronic HBV, we compared surface expression of CD28 on CD8 T cells 
in patients and controls. Co-staining of CD28 with CD3ζ revealed that CD8 T cells that 
were CD28 negative in CHB were more likely to have downregulated CD3ζ than their 
CD28 positive counterparts, but these two proximal signalling molecules were not always 
down-regulated together (fig 4.3a). The percentage of CD28 positive CD8 T cells was 
lower in patients with CHB compared to controls (representative examples are shown in 
fig. 4.3b). CD28 expression was significantly lower in HBeAg patients with high viral load 
and elevated ALT compared to those with low viral load or healthy donors (4.3c). As 
CD28 expression is known to be affected by CMV status and age (Almanzar et al. 2005), 
data was reanalysed with only age matched CMV seropositive individuals and the same 
trend was seen (data not shown).  
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Figure 4.3: CD28 is downregulated in CD8 T cells from patients with high viral load. 
Representative dot plot to show the co-expression of CD28 and CD3ζ in CD8 T cells in a 
patient with high viral load. b) Flow cytometric histogram to show the proportion of CD8 
T cells which are CD28+ in a patient with high viral load (grey) and a healthy donor 
(dotted line). c) Cumulative data for CD28 expression is shown against viral load, HBeAg 
status and ALT level. %CD8+CD28+ on the Y axis= ‘percent CD8+CD28+/total CD8+. 
(*=p<0.05, **=p<0.01, non-parametric Mann-Whitney U test). 108 
 
4.4 Transfection of peripheral blood leucocytes with a dual CD3ζ/CD28 chimeric 
receptor replenishes signal molecule expression and IL-2 production 
We observed that CD8 T cells from HBeAg positive patients with high viral load and liver 
inflammation had the lowest expression of CD3ζ and CD28 and were unable to produce 
IL-2. To test whether a direct link existed between aberrant signalling and functional 
skewing within these cells, we sought to reconstitute expression of CD3ζ and CD28 
signalling molecules and measure the functional consequences. To achieve this, we 
transfected PBMC from patients with CHB with plasmid DNA encoding a chimeric 
receptor with intracellular CD3ζ and CD28 domains. Following transfection, we observed 
that within 4 hours, uptake of the receptor was in the region of 60% for most patients (fig 
4.4). Following an overnight rest, transfected PBMC were then stimulated with three types 
of stimuli; anti-CD3 and anti-CD28 (TCR-dependent stimulus); CD33Ag which could only 
bind to the extracellular domain of the chimeric receptor, therefore acting like an antigen 
specific stimulus, or both stimuli together. The same experiments were repeated on 
untransfected cells which had also been passed through the AMAXA transfection system, 
however PBS was added in place of the DNA. When PBMC were stimulated through the 
TCR or via CD33Ag we saw similar levels of IL-2 production. Addition of both stimuli 
together, further increased IL-2 production. Interestingly, production of IL-2 by the dual 
stimulus exceeded the combined additive effect of adding either the TCR dependent or 
antigen specific stimuli separately (fig 4.4). This may suggest that the newly introduced 
CD3ζ and CD28 may not only function following the antigen specific stimulus, but may 
also be recruited to T cell receptor signalling following CD3/CD28 stimuli.  Previous 
reports have suggested that activation of Lck by CD28 could enhance tyrosine 
phosphorylation events induced by TCR engagement (Holdorf et al. 1999). Furthermore, 
Acuto et al have proposed a model whereby proteins activated through CD28 signalling 
could be recruited to the adaptor protein LAT which is activated during signalling through 
the T cell receptor, and thus amplify signal transduction through the TCR. This ‘kinase 
promiscuity’ could therefore enhance TCR mediated signalling (Acuto & Michel 2003).  
No effect was seen by adding CD33Ag alone with the untransfected cells, however they 
were able to produce IL-2 following CD3/CD28 stimulation suggesting that they were not 
anergic following the transfection process. 
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Figure 4.4: Transfection of peripheral blood leucocytes with a dual CD3ζ/CD28 chimeric 
receptor replenishes signal molecule expression.  a) Histogram shows transfection 
efficiency in a representative patient following transfection of a chimeric receptor with an 
extracellular CD33-binding domain, and intracellular CD3ζ and CD28 domains. b) 
Following antigen-specific stimulation through the chimeric receptor, T cell receptor (anti-
CD3/anti-CD28) or both together, IL-2 production was determined by ELISA. Mean and 
SEM of IL-2 production is shown for 3 individuals following the different stimuli.    
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4.5 Functional reconstitution of CD3ζ in CD8 T cells from CHB patients is partially 
dependent on L-arginine 
We observed that upon resting of PBMC overnight in complete medium, there was 
significant upregulation of CD3ζ to levels observed in healthy donors (p<0.001), but not 
CD28 expression (p=ns), compared to CD8 T cells ex vivo (fig 4.5.1 a+b). This was 
accompanied by a functional reconstitution in IL-2 production, as shown for a 
representative patient (fig 4.5.1c). The fact that functional reconstitution accompanied a 
selective upregulation of CD3ζ but not CD28 within CD8 T cells from patients with CHB, 
suggested that CD3ζ dysfunction may be more important in the setting of CHB infection.  
Furthermore, we hypothesized that constituents of the culture medium may have 
contributed to the substantial upregulation of CD3ζ we observed over a relatively short 
culture time. One potential candidate was the non-essential amino acid L-arginine, 
depletion of which is associated with CD3ζ downregulation in both mouse and human 
studies (Rodriguez et al. 2003;Zea et al. 2004). To investigate whether L-arginine levels 
modulate CD3ζ expression in T cells of patients with CHB in vitro, PBMC were cultured 
overnight in medium with or without L-arginine (0.2g/L) and CD3ζ expression was 
subsequently determined. We observed that after culture in L-arginine reconstituted 
medium, there was significant upregulation of CD3ζ (MFI 94.3) compared to directly ex 
vivo (MFI 28.8). However, when L-arginine was depleted from the medium, there was less 
upregulation of CD3ζ (MFI 71.7) (fig.4.5.2). In addition to measuring CD3ζ expression, 
proliferative capacity of CD8 T cells was determined after 6 days of culture with a TCR-
dependent stimulus in medium with or without L-arginine. We observed that proliferation 
of CD8 T cells in L-arginine free medium was lower than for CD8 T cells cultured in 
medium with L-arginine and that in the presence of L-arginine, CD8 T cells both 
proliferated more and also underwent a further mean division (fig 4.5.3). Therefore, these 
data suggest that CD8 T cells from patients with CHB are unable to reconstitute CD3ζ 
fully without replenishment of L-arginine. In addition to loss of proliferative function due 
to CD3ζ downregulation, L-arginine deprivation has also been directly linked to growth 
arrest at the G0-G1 phase of the cell cycle (Rodriguez et al. 2007), compatible with the 
striking loss of CD8 T cell proliferation we observed. Once these cells were removed from 111 
 
factors present in the HBV-infected patient, they were susceptible to functional 
reconstitution. 
 
              
Figure 4.5.1: Reconstitution of CD3ζ but not CD28 upon incubation in medium is 
associated with recovery of IL-2 production. a) Histogram illustrates effect of overnight 
culture in medium on CD3ζ levels (dark grey histogram) compared to when measured 
directly ex vivo (light grey histogram). Isotype control is shown as the dotted line. b) 
Cumulative data to show change in CD28 (p=non-significant) and CD3ζ expression 
(p<0.0001, non-parametric Mann-Whitney U test) following in vitro culture compared to 
ex vivo in 5 and 9 patients respectively. c) IL-2 production was determined in parallel 
before and after culture and representative dot plots are shown. 112 
 
          
 
Figure 4.5.2: L-arginine amino acid is partially responsible for selective upregulation of 
CD3ζ. CD3ζ expression in CD8 T cells was determined directly ex vivo, and then again 
after overnight culture in medium with or without L-arginine (0.2g/l). 
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Figure 4.5.3: Depletion of L-arginine in vitro abrogates proliferation of global CD8 T cells 
upon T cell receptor stimulation. To investigate whether the presence of L-arginine affects 
CD8 T cell proliferation, PBMC were preincubated with medium with or without L-
arginine for 24 hours, stained with CFSE, and then resuspended in their respective 
mediums in the presence of a TCR-dependent stimulus for 6 days. A gate has been applied 
on CD8 T cells.  114 
 
4.6 HBV specific CD8 T cells are unable to proliferate/expand when L-arginine is 
depleted during short term in vitro culture 
To determine what effect L-arginine depletion would have on HBV-specific CD8 T cells 
which are critical for viral control, PBMC were isolated from HLA-A2 positive patients 
who had resolved infection, and were stimulated with HBV core18-27 peptide to initiate 
clonal expansion of HBV-specific cells for 7 days in medium with or without L-arginine 
present. The expanded population was detected with a core18-27 specific tetramer on day 
7, and proliferative capacity of these cells was also determined by their dilution of CFSE 
dye, which was added at the beginning of culture. As shown in figure 4.6a, in the presence 
of L-arginine (0.2g/L, which represents the  normal amount found in complete medium), a 
large core18-27 tetramer+ CD8 T cell population was detectable, and 80% of those cells 
had undergone at least one division as determined by CFSE. In contrast, only a minority of 
HBV-specific CD8 T cells had divided by one week in arginine-depleted medium and in 
every case there was inhibition of proliferation compared to responses in the presence of 
arginine (fig 4.6b). Upon supplementation of L-arginine back into L-arginine depleted 
medium, we observed a dose dependent recovery in the magnitude of core18-27 specific 
CD8 T cell responses (fig 4.6c).  115 
 
                 
Figure 4.6: HBV specific CD8 T cells are unable to proliferate when L-arginine is depleted 
during short term in vitro culture. a) To determine the effect of L-arginine on proliferation 
of HBV-specific CD8 T cells, PBMC from HLA-A2+ patients who had resolved HBV 
infection were stimulated with core 18-27 peptide for 7 days and detected with an HLA-
A2/c18-28-specific tetramer. Representative dot plots depict the HBV-specific CD8 T cell 
population expanded at one week, along with the number of divisions these populations 
have undergone, determined by CFSE dilution, in the presence (upper panel) or absence 
(bottom panel) of L-arginine. b) Cumulative data illustrate the effect of depleting L-
arginine on the percent of tetramer positive populations dividing by one week in 5 patients 
(**=p<0.01, non-parametric Mann-Whitney U test). c) HLA-A2/core 18-27 tetramer 
positive CD8 T cells were compared following 7 days peptide stimulation of PBMC 
incubated in a range of L-arginine concentrations (0μM, 5μM, 25μM, 50μM, 150μM, 
1mM).  116 
 
4.7 In vivo depletion of serum L-arginine in patients with CHB 
To gauge whether L-arginine depletion could potentially impact CD8 T cell signalling and 
function in vivo, we initially compared serum L-arginine levels in healthy donors and 
patients with CHB. A significant reduction in circulating L-arginine was observed in 
patients with high liver inflammation (ALT>100 IU/L), compared to those with normal or 
mildly elevated ALT and healthy donors (Figure 4.7).  Furthermore, the dose range of L-
arginine concentrations detected in the serum of patients was equivalent to that we had 
shown to be sufficient to impair expansion of HBV-specific CD8 T cell responses from 
resolved individuals in vitro. The concentration of extracellular L-arginine is likely to be 
lower in the liver. To investigate this, we determined L-arginine concentrations from liver 
homogenates from patients with CHB vs. non-viral liver disease. Although the 
homogenisation process is known to release high quantities of arginase-1 from hepatocytes 
which can rapidly deplete L-arginine levels, we still managed to detect a significantly 
lower L-arginine concentration within liver homogenates from patients with CHB 
compared to patients with non-viral liver disease (data not shown). 
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Figure 4.7: Circulating L-arginine is reduced in patients with ALT.  Serum L-arginine 
levels were compared in healthy donors (n=21), patients with low-moderate liver 
inflammation (ALT<100 IU/L, n=13) and patients with high liver inflammation (ALT>100 
IU/L, n=11). (control vs. high ALT p<0.01; low ALT vs. high ALT p<0.05). 118 
 
4.8 Arginase activity correlates with flares of liver disease and is elevated in the HBV 
inflamed liver 
Depletion of L-arginine within patients with CHB could suggest an increased rate of 
metabolism of this amino-acid during CHB. Arginase-1 is an enzyme which can catabolise 
L-arginine to urea and ornithine. It is expressed almost exclusively in the liver making it a 
candidate for L-arginine breakdown within the inflamed intrahepatic environment, 
however it can be induced in other cell types also following exposure to cytokines and 
agents such as LPS (Morris, Jr. 2002). Within the HBV infected liver, myeloid suppressor 
cells (Bronte & Zanovello 2005) and macrophages exposed to Th2 cytokines such as IL-10 
(Modolell et al. 1995), which we have shown is raised during HBeAg negative flares of 
HBV (Chapter 6), may additionally contribute to arginase activity. 
To determine whether HBV related inflammation resulted in upregulation of arginase 
activity which could account for L-arginine depletion and resultant CD8 T cell 
dysfunction, we measured arginase activity in both serum and liver homogenates from 
patients with CHB. Arginase activity was determined by incubating serum/liver 
homogenate samples with a saturating concentration of substrate L-arginine, and 
measuring the amount of urea output over a fixed period of time. For liver samples, 
arginase activity was normalised to the protein content of liver tissue. Ex vivo serum 
arginase levels showed a non-significant trend to be higher in CHB patients with active 
liver inflammation but showed considerable variability within patient groups and controls 
(data not shown). To remove the confounder of inter-patient variability, arginase activity 
was measured longitudinally in three patients undergoing eAg negative flares of liver 
disease, characterised by rapid fluctuations of disease activity over a condensed timeframe 
(fig 4.8). In these individuals, we observed large fluctuations of arginase activity, with 
peaks correlating with flares of disease activity as measure by ALT or viral load. Since 
arginase-1 is mainly expressed in the liver, these fluctuations could reflect increased 
release from the relevant tissue source, as is the case in pregnancy (arginase release from 
placenta) (Kropf et al. 2007) and during orthoptic liver transplantation (Roth et al. 1994). 
On measurement of arginase activity from liver homogenates ex vivo, we observed 
significantly elevated activity in liver extracts derived from patients with CHB (n=5) 
compared to those taken from patients with non-viral liver disease (n=5) (fig 4.9).  
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Figure 4.8: Serum liver type arginase-1 activity is elevated during chronic flares of liver 
disease. Graphs depict longitudinal fluctuations in serum arginase activity (dashed line, 
IU/L) in association with viral load (solid green line, HBV DNA IU/ml) and ALT 
(turquoise shaded histogram, IU/L) for 3 patients with flares of CHB. 
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Figure 4.9 Arginase-1 activity in the liver is higher in patients with CHB compared to 
those with non-viral liver disease. The arginase activity of liver homogenates is shown for 
5 individuals with CHB, and 5 individuals with non-viral liver pathology. (*=p<0.05, non-
parametric Mann-Whitney U test). 121 
 
Discussion 
We observed a defect in IL-2 production by CD8 T cells in patients with CHB upon a T 
cell receptor dependent stimulus, however not upon a TCR bypassing stimulus. This led us 
to hypothesize that aberrant signalling through the TCR complex, may in part be 
responsible of this selective defect. In other settings of chronic inflammation and persistent 
antigenic stimulation, analogous to CHB, downregulation of CD3ζ with or without CD28 
has been associated with a CD8 T cell dysfunction in IL-2 production. These proximal 
TCR associated molecules are upstream initiators of signalling cascades, and play a rate-
limiting role in efficient T cell signal transduction. In this chapter, we showed that both 
CD3ζ and CD28 were downregulated in CD8 T cells from patients with CHB compared to 
healthy donors and that this was greatest within CD8 T cells isolated from HBeAg positive 
patients with high viral load and liver inflammation. Transfection of PBMC with chimeric 
receptors with intracellular CD3ζ and CD28 domains was able to restore IL-2 production. 
Moreover, CD3ζ expression was found to be even lower within intrahepatic CD8 T cells, 
suggesting that factors within the HBV inflamed liver may further potentiate CD3ζ 
downregulation and exacerbate the global functional defects. From our in vitro 
experiments, we showed that depletion of the non-essential amino acid L-arginine, both 
attenuated upregulation of CD3ζ and impaired expansion of global and HBV-specific CD8 
T cells in a dose dependent manner. In support of this, we noted that L-arginine was 
depleted within the  serum of patients with CHB (with liver inflammation), and that 
arginase-1, which is almost exclusively expressed in the liver and catabolises L-arginine, 
was upregulated selectively in liver extracts from patients with CHB. 
Mechanisms for CD3ζ downregulation have been described previously at both the protein 
level (caspase 3 mediated degradation (Krishnan et al. 2005)) and at the mRNA level 
(mutations in the gene encoding CD3ζ (Tsuzaka et al. 2003)). Within the HBV infected 
liver, multiple mechanisms could apply. One hypothesis is that the inflammatory cytokine 
environment may play a role. Transgenic mouse models of HBV have shown high levels of 
IFN-γ within the liver (Guidotti et al. 1996). In situations of chronic bacterial stimulation 
in mice, IFN-γ has been shown to indirectly induce CD3ζ downregulation within T cells, 
through induction of reactive oxygen intermediate production (Bronstein-Sitton et al. 
2003). Therefore, IFN-γ mediated CD3ζ downregulation may be one potential mechanism. 122 
 
Similarly, Isomaki et al. showed that chronic exposure to TNF-α suppressed peptide 
specific IL-2 production and this was associated with TNF mediated downregulation of 
CD3ζ. Withdrawal of TNF resulted in a reconstitution of both CD3ζ expression and cell 
function (Isomaki et al. 2001). In this system however, downregulation of CD3ζ was in 
combination with the entire CD3/TCR complex, and not a selective defect as we and others 
have observed. Nevertheless, high levels of TNF have been reported in the plasma of 
patients with CHB (Sheron et al. 1991), and we have shown that global CD8 T cells in 
patients with high viral load maintain their TNF production, thus by selectively studying 
CD3ζ downregulation on CD3ε gated CD8 T cells, we may have underestimated the total 
loss of CD3ζ. 
Alternatively, global downregulation of CD3ζ may also be related to depletion of amino 
acids within the micro-environment such as L-arginine (Fallarino et al. 2006;Rodriguez et 
al. 2003). Previous reports have shown that L-arginine is required for post-transcriptional 
mechanisms in stabilisation of CD3ζ mRNA, and depletion of extracellular levels results 
in CD3ζ downregulation in human T cells (Zea et al. 2004). Depletion of other non-
essential amino acids such as L-glutamine did not have this effect (Rodriguez et al. 2002). 
In our study, we showed that CD8 T cells from chronic HBV infected patients depleted of 
L-arginine in vitro had reduced CD3ζ expression and proliferated poorly compared to CD8 
T cells cultured in the presence of L-arginine. Deficiency of L-arginine was also shown to 
impair the expansion of HBV-specific CD8 T cell responses from resolved individuals in a 
dose dependent manner. Notably however, CD8 T cells from CHB patients showed some 
reconstitution of CD3ζ once they were removed from the source of antigenic stimulation 
and inflammation, even in the absence of arginine. This suggests that other factors within 
the inflamed liver may also contribute to this defect including exposure to reactive oxygen 
intermediates (Otsuji et al. 1996) or inflammatory cytokines or depletion of other amino 
acids. In particular, depletion of tryptophan and accumulation of tryptophan catabolites has 
also been shown to inhibit T cell proliferation via CD3ζ down-regulation (Fallarino et al. 
2006;Frumento et al. 2002). 
We found that circulating concentrations of L-arginine were significantly lower in patients 
with CHB compared to healthy donors. This deficiency could be either due to reduced 
supply, or increased demand. Since we are not aware of any change in dietary intake of 
amino acids used to synthesize L-arginine, or defects in L-arginine synthesis in patients 123 
 
with CHB, it is likely that lower levels of L-arginine in the periphery are secondary to 
increased breakdown. L-arginine is catabolised in the body by either arginase or nitric 
oxide synthase. Arginase-1 is found predominantly in the cytosol of hepatocytes and is 
therefore a prime candidate for L-arginine depletion in HBV (Bronte & Zanovello 2005). 
We showed that arginase activity was elevated in liver homogenates from patients with 
CHB, and longitudinal serum arginase activity correlated temporally with flares of HBV 
DNA and ALT in 2 patients undergoing chronic flares of liver disease.  
Elevated arginase activity during HBV infection may have several potential sources. 
Although arginase is exclusively expressed in the cytosol of hepatocytes (Morris, Jr. 2002), 
and these cells have been shown to reduce L-arginine levels by arginase-1 release 
following orthoptic liver transplantation (Roth et al. 1994), arginase may also be induced 
in other cell types. Macrophages and myeloid suppressor cells recruited to the liver by 
IFNγ induced chemokine release may further contribute to arginase release and local L-
arginine depletion (Kakimi et al. 2001b). Macrophages exposed to Th2 cytokines IL4 and 
IL13 (Rodriguez et al. 2003) or IL-10 (Modolell et al. 1995;Munder et al. 1999) or 
bacterial lipopolysaccharide, with which the liver is enriched (Morris, Jr. 2002), upregulate 
arginase-1 and can downregulate CD3ζ in T cells indirectly by consumption of 
extracellular L-arginine. We have shown that serum IL-10 levels, like arginase, correlate 
temporally with flares of HBV DNA and ALT during HBeAg negative flares of HBV and 
may therefore be a potential inducer of arginase (see chapter six). 
 In addition to macrophages, arginase-1 released by myeloid-derived suppressor cells can 
deplete local L-arginine levels (Rodriguez et al. 2005) and this has been associated with 
CD3ζ downregulation and impaired T cell function (Ezernitchi et al. 2006). They are 
enriched in settings of chronic inflammation (Bronte & Zanovello 2005;Haile et al. 2008), 
however what their role is during chronic HBV infection is not yet clear.  
Apart from immune cells, certain parasites or bacteria have been shown to produce their 
own arginase or manipulate the host’s own arginase as a mechanism to suppress T cell 
function and evade immune control. Helicobacter pylori for example has been shown to 
produce arginase-1 which results in L-arginine depletion dependent CD3ζ downregulation 
within the gut (Zabaleta et al. 2004). It is not known whether HBV can directly release or 124 
 
modulate host arginase, and thus potentially contribute to subversion of the immune 
response through arginase-L-arginine mediated impairment of T cell responses. 
Although impairment of proliferation may be partially related to CD3ζ downregulation, 
there is also evidence that L-arginine depletion can attenuate proliferation of T cells 
directly. L-arginine deprivation has been linked to growth arrest at the G0-G1 phase of the 
cell cycle (Rodriguez et al. 2007), compatible with the striking loss of CD8 T cell 
proliferation we observed. This may partially be due to the fact that one of its breakdown 
products, L-ornithine, is a precursor for synthesis of polyamines by the ornithine 
decarboxylase pathway, required for cell growth and differentiation (Bronte & Zanovello 
2005). 
 
 
 
Figure 4b. Schematic diagram to show potential pathways of L-arginine depletion with the 
HBV inflamed liver. MSC: myeloid suppressor cell, Mac.: macrophage, LSEC: liver 
sinusoidal endothelial cell. 125 
 
In addition to CD3ζ downregulation, we found marked CD28 downregulation also in CD8 
T cells from patients with high viral load. Loss of CD28 has been related to chronic 
antigen persistence (Effros et al. 1996), and this could drive HBV-specific CD8 T cells 
towards a CD28 null phenotype. However, a global loss of CD28 expression would require 
the influence of bystander stimulation, either through inflammatory cytokines or viral 
antigens. Notably, both TNF (elevated in the plasma of patients with CHB (Sheron et al. 
1991)) and IFN-α (elevated during flares of eAg negative HBV (Dunn et al. 2007)), have 
been shown to induce CD28 loss (Fletcher et al. 2005;Lewis et al. 2004), and thus could 
exacerbate signalling dysfunction and T cell hyporesponsiveness in CD8 T cells already 
dysfunctional through CD3ζ loss. 
In summary, we show that non-antigen specific CD8 T cell dysfunction in IL-2 and 
proliferation may in part be due to aberrant TCR signalling in CHB. Reconstitution of 
signalling molecule expression is able to partially reverse the IL-2 defect. Furthermore, we 
show that both downregulation of CD3ζ and impaired proliferative function of CD8 T cells 
within the inflamed liver, may be exacerbated by local depletion of the nutrient L-arginine, 
which is lower in the serum of patients with liver inflammation, and may be further 
depleted in the HBV-infected liver where we have shown arginase-1 to be upregulated. 
These data provide a novel mechanism for loss of CD8 T cell function and impairment of 
viral control in CHB.  
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5 Premature senescence of CD8 T cells in patients with chronic HBV infection. 
Background 
During chronic viral infection, a high dose of antigen can often persist over many years in 
the host. In this setting, we hypothesize that chronic activation of CD8 T cells may drive 
them prematurely towards a terminally differentiated phenotype and replicative 
senescence: an end stage state associated with functional exhaustion and loss of 
proliferative capacity. In this chapter, we investigate whether the qualitative and 
quantitative defects within virus specific and non-antigen specific CD8 T cells described in 
CHB, could partially be due to accelerated ageing of this compartment associated with 
chronic activation by the virus itself, or cytokines induced in the surrounding environment.  
As a background to this, I will first review the normal differentiation pathway of CD8 T 
cells during an acute anti-viral response, and then examine how this pathway may be 
altered if antigen instead is not cleared and persists indefinitely. 
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5.0.1 CD8 T cell differentiation 
There are three phases to an anti-viral CD8 T cell response during acute infection. 1) 
Antigen specific CD8 T cells undergo clonal expansion to give rise to a population of 
effector cells.  2) this large number of effector cells is then diminished during the 
contraction phase, at which point 85-90% of them undergo activation induced cell death. 3) 
From the remaining cells, a population of memory CD8 T cells are generated which are 
required for long-term immunity (Zimmerman et al. 1996). 
Therefore, antigen encounter can result in the formation of either an ‘effector’ or ‘memory’ 
CD8 T cell. These two populations have phenotypically and functionally distinct 
characteristics. Hamann et al showed that effector cells were characterised by expression 
of CD45RA, but not CD27 or CD62L and that these cells contained granzyme B, had 
immediate cytolytic capacity and could produce IFNγ and TNF upon mitogenic 
stimulation, which has been associated with control of virus replication. These cells could 
not produce IL-2 however and had lost their ability for autocrine proliferation. Memory 
cells on the other hand, defined as CD45RA-CD45RO+, were able to produce a wide range 
of cytokines including IL-2, IL-4, TNF and IFNγ, however were not cytotoxic without 
prior in vitro stimulation. Naïve cells, which expressed both CD45RA and CD27 were the 
main producers of IL-2, however, unlike primed cells, produced relatively low quantities 
of IFNγ and TNF as determined by intracellular staining and ELISA (Hamann et al. 1997). 
Therefore the distinct functional characteristics of these cells may hint towards 
independent roles in the immune response against the virus.  
Although the above model suggests a linear differentiation pathway for CD8 T cells from 
naïveÆeffectorÆmemory, whether or not the memory subset actually arise from the 
effector population is still under debate. A number of alternative models have been put 
forward. 
Model 1: This supports the notion of a divergent pathway whereby upon antigenic 
stimulation of naïve T cells, either a memory or effector cell can be generated. 
Lanzavecchia et al proposed a model in which they suggested that the duration and 
strength of TCR stimulation could induce hierarchical levels of CD8 T cell differentiation 
characterised by distinct survival, homing and functional capacity (Lanzavecchia & 
Sallusto 2000). In this model, fit cells which had received optimal stimulation were 128 
 
arrested at intermediate stages of differentiation and survived as effector memory (Tem) or 
central memory (Tcm) T cells. Too much stimulation initiated activation induced cell death 
whereas too little stimulation resulted in death by neglect. Therefore, in this model, naive T 
cells reached hierarchical thresholds of differentiation depending on the ‘instructions’ 
provided by dendritic cells and cytokines which they themselves ‘decoded’ into a cell fate 
decision. If a sufficient threshold of stimulation was reached, naïve T cells could become 
memory T cells and bypass the effector stage altogether (Kaech et al. 2002). In support of 
this instructional hypothesis, Yang et al. showed that different costimulatory pathways 
could induce differential phenotypes in CD8 T cells. For example, HSA/B7 costimulation 
was required to induce a memory phenotype, whereas B7 not HSA was required for 
generation of effector CD8 T cells. Therefore, in this model effector cells were not a 
mandatory intermediary for memory cell induction (Liu et al. 1997). 
 
Figure 5a. Divergent model of CD8 T cell differentiation. Adapted from (Kaech et al. 
2002) 
Model 2: In contrast to model 1, longitudinal studies in mice with LCMV infection favour 
a linear differentiation pathway (NaïveÆeffector Æmemory) whereby memory cells arise 
from the effector population.  Expression of CD127 and responsiveness to homeostatic 
cytokines are characteristic of memory cells. Sarkar et al showed that, during an acute 
response to LCMV, all the antigen specific effector CD8 T cells were CD127 low. These 
cells could be subdivided into killer cell lectin-like receptor subfamily G, member 1 
(KLRG-1) intermediate or high expressers, which functionally were similar in their 
cytotoxic ability, granzyme B expression, and cytokine profiles. However, only the 
intermediate KLRG-1 expressing cells could produce IL-2 and upon resolution of 
infection, had the capacity to upregulate CD127 expression. Therefore, they showed with 129 
 
KLRG-1 expression that memory precursors were present within the effector population 
(Sarkar et al. 2008).  
 
 
Figure 5b Linear model of CD8 T cell differentiation. Adapted from (Kaech et al. 2002) 
In another study, Opferman showed that only B6.2.16 CD8 T cells (transgenic T cells 
specific for male H-Y antigen) which underwent at least 5 rounds of stimulation (as 
determined by CFSE) on stimulation with H-Y male antigen were able to give rise to H-Y 
specific CD8 memory T cells upon adoptive transfer into mice, whereas transfer of 
undivided pre-effector B6.2.16 CD8 T cells did not. This suggested that memory cells 
could arise from effector populations, but not the pre-effector, which is against the 
divergent hypothesis (Opferman et al. 1999). 
In acute HBV and HCV infection, Urbani showed that the majority of HBV and HCV 
tetramer positive CD8 T cells belonged to the effector memory subset (CCR7-CD5RA-).  
Therefore it is likely that these cells are the precursors for memory cells which are 
detectable on resolution of these infections (Urbani et al. 2002). 
Model 3: This has been termed the ‘decreasing potential hypothesis’ and suggests that the 
distinguishing factor between death and survival for an effector T cells is the duration and 
dose of antigenic stimulation it is exposed to. Therefore, with persistent long-term 
antigenic stimulation, analogous to a situation of chronic viral infection, effector cells 
would progressively lose function, and thus be progressively less capable of generating 
memory populations. Late stage effector cells are unfit both metabolically and functionally 
to generate memory populations and undergo apoptosis instead. It has been suggested, that 
an accumulation of these late stage effectors during persistent viral infections may be a 
potential mechanism for impaired memory cell production (Kaech et al. 2002).  
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Figure 5c A model of the decreasing potential hypothesis. Adapted from (Kaech et al. 
2002) 
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5.0.2 Subsets of memory CD8 T cells 
Memory CD8 T cells facilitate a rapid immune response upon secondary encounter with a 
specific antigen. In humans, they can be subdivided into either central memory (Tcm) or 
effector memory T cells (Tem) dependent on expression of molecules, CCR7 and CD62L 
involved in homing to lymph nodes (Sallusto et al. 1999). CCR7 is a chemokine receptor 
required for migration through high endothelial venules in lymph nodes into T cell areas 
(Lanzavecchia & Sallusto 2000).  
Central memory CD8 T cells home to lymph nodes and can proliferate and produce IL-2 
but have limited cytolytic function. Effector memory CD8 T cells on the other hand, home 
to tissues and can rapidly produce IFNγ on antigen encounter. They also have cytolytic 
capacity as they contain prestored perforin, however unlike Tcm, have a low proliferative 
capacity. Based on their immediate effector capabilities and homing capabilities, it was 
suggested that Tem were required to rapidly contain pathogens at tissue sites, whereas Tcm 
were more important for long-term protection by sustaining the effector pool 
(Lanzavecchia & Sallusto 2005). Tcm may also have additional regulatory functions as 
these cells have been shown to help B cell proliferation, modulate the function of antigen 
carrying dendritic cells and IL-10 producing cells are found in this compartment (Wherry 
& Ahmed 2004).  
The relationship between Tcm and Tem is not clear cut. I have discussed briefly the model 
put forward by Lanzavecchia and colleagues, who suggested that the threshold of 
activation of naive T cells could determine which cell fate decision was reached 
(Lanzavecchia & Sallusto 2000). However, other studies suggest a more intimate 
connection between Tem and Tcm and that CD8 T cells may even interchange between the 
two compartments. Wherry et al. showed that following antigen clearance in a mouse 
model of LCMV, effector memory CD8 T cells developed into central memory CD8 T 
cells over time (Wherry et al. 2003b). Sallusto et al however, have shown that in vitro 
stimulation of central memory CD8 T cells resulted in loss of CCR7 expression and 
differentiation to effector memory (Sallusto et al. 1999). The close association between 
these subsets was analysed further by Romero et al, who characterised effector CCR7-
CD45RA-CD8+ T cells by expression of CD27 and CD28, and discovered a population of 
EM1 cells(CD8+CD27+CD28+CD45RA-CD127
hiperforin
logranzymeB
loCCR7-) which 
were phenotypically and functionally similar to central memory cells bar the expression of 132 
 
CCR7. These CCR7- EM1 cells were suggested therefore to be a distinct memory 
population of similar lineage to the central memory, which could potentially mediate the 
same function within the tissues rather than the lymph nodes (Romero et al. 2007).  
A further population of memory cells which re-express CD45RA have also been described. 
These ‘revertant’ CD8 T cells have low proliferative capacity and are relatively resistant to 
apoptosis (Dunne et al. 2002). Additionally, they have been shown to have immediate 
cytolytic activity and can produce cytokines IFNγ and TNF similar to effector memory 
CD8 T cells, however are unable to produce IL-2 (Hamann et al. 1997). Faint et al. showed 
using HLA class I restricted tetramers that a significant fraction of herpes-virus specific 
CD8 T cells reverted from CD45RO to CD45RA after priming, and were CCR7
lowLFA1
high 
in phenotype. These cells furthermore had shorter telomere lengths, and potently produced 
IFN-γ on stimulation suggesting that they were memory and not naïve CD8 T cells (Faint 
et al. 2001). Recent studies have shown that revertant populations originate from central 
memory CD8 T cells exposed to IL-15, in an antigen-independent manner (Dunne et al. 
2005;Geginat et al. 2003). In support of this, Geginat et al. showed that sorted Tcm 
cultured with homeostatic cytokines IL-7 and IL-15 could differentiate into revertant cells, 
however upon antigenic stimulation through the TCR, Tcm instead differentiated almost 
exclusively into CD45RA-CCR7- effector memory cells (Geginat et al. 2003). 
 
Figure 5d T cell differentiation. Modified from (Akbar & Fletcher 2005). 133 
 
Although there is still some debate on the lineage of central and effector memory CD8 T 
cells, it is clear nonetheless that they have distinct phenotypic and functional profiles 
which may allow them to mount synergistic control of pathogen in the lymph nodes and 
within tissues. 
5.0.3 Homeostatic maintenance of memory populations 
The fact that thymic involution occurs at a young age suggests that survival of memory 
cells over many decades involves proliferation and periodic turnover (Akbar & 
Vukmanovic-Stejic 2007). This ‘homeostatic proliferation’ requires cytokines IL-15 and 
IL-7, which signal through the common gamma chain of the IL-2 receptor, however does 
not require self/MHC and antigenic stimulation. Cytokine responsiveness and IL15 
receptor expression was low in naïve T cells for example, however progressively increased 
in Tcm, Tem and revertant CD8 T cells  (Geginat et al. 2003). Experiments by Tan et al. 
have shown in cytokine knockout mice that either IL-7 or IL-15 were sufficient for CD8 T 
cell homeostatic proliferation, however in the absence of both cytokines, this process was 
arrested. Interestingly, in CD4 T cells, homeostatic proliferation was independent of both 
IL-7 and IL-15 production (Tan et al. 2002). Additionally, Tough et al. showed that 
bystander production of type I IFN could induce TCR independent proliferation and could 
further contribute to maintenance of memory (Tough et al. 1996). Therefore, these 
cytokines allow for memory populations to be maintained over a lifetime without altering 
the total size of the memory T cell pool.  
Unlike memory cells, naïve CD8 T cells require constant low affinity interaction or 
‘tickling’ with self MHC and antigen as well as IL-7 for their survival (Lanzavecchia & 
Sallusto 2000;Tan et al. 2002). This is illustrated by a high expression of CD127 (IL-7Rα) 
on their surface. Interestingly however, Alves et al identified a new population of naïve 
CD8 T cells which were CD127 low both at the mRNA and protein level and exhibited a 
low proliferative response to IL-7 but not anti CD3/anti CD28 stimulation. These cells 
were enriched in circumstances where a relative paucity of classical naïve CD8 T cells was 
expected, for example in the elderly, early after heamopoeitic stem cell transplantation or 
in HIV. The authors suggested therefore that these cells may be a population of naïve T 
cells which had recently received homeostatic signals, which are known to induce short-
term rapid downregulation of CD127 expression (Alves et al. 2007). 134 
 
5.0.4 Altered CD8 T cell differentiation during chronic viral infection 
5.0.4a Virus-specific CD8 T cells 
If antigen is not cleared and instead persists, the above paradigm of effector and memory 
cell differentiation may be altered. Wherry et al. showed that during chronic LCMV 
infection of mice, persistent antigenic stimulation in the absence of CD4 T cell help 
accelerated differentiation of CD8 T cells towards an end stage phenotype. This 
progressive ‘exhaustion’ was associated with a hierarchical loss of effector function; IL-2 
production and cytolytic capacity were lost first, followed by ability to produce TNF-α, 
whereas IFN-γ production was most resistant to loss. Fully exhausted CD8 T cells were 
further rendered incapable of IFN-γ production and were susceptible to deletion (Wherry et 
al. 2003a). Therefore, in this model, antigen load itself could drive exhaustion of the CD8 
T cell response. 
This may not necessarily occur with all chronic viral infections however, as the ability to 
influence CD8 T cell responses depends on the type of virus, its tissue distribution, 
differential responses to viral epitopes and availability of CD4 help. For instance, viruses 
may establish either latent infection with periods of reactivation (e.g. EBV) or chronic 
infection with life-long low level viral persistence (e.g. CMV) or high level viral 
persistence (HBV/HIV/HCV). The important difference between the latter two varieties is 
low level ‘smoldering’ infections provide intermittent antigen exposure with rest periods, 
whereas during chronic infection with high levels of viraemia, there is constant barrage of 
antigen and CD8 T cell activation in the absence of critical rest periods. This may make 
CD8 T cells in these infections more susceptible to functional exhaustion (Wherry & 
Ahmed 2004).  
In this study, we investigated whether the virus-specific and global CD8 T cell defects in 
IL-2 production and proliferation could partially be attributable to functional exhaustion of 
CD8 T cells in CHB. Similar to chronic LCMV infection, CHB is characterised by high 
level viral persistence over many decades. Additionally, as a unique phenomenon, HBV 
infection is also associated with production of high levels of sub-viral particles which have 
no known role in viral replication, however instead have been implicated as having 
‘immunomodulatory’ function (Milich et al. 1990). Furthermore, the virus has a selective 
tropism to hepatocytes, making the liver environment the site of highest viral replication 135 
 
and inflammation. At this site, there has also been reported to be a relative lack of CD4 T 
cells compared to the periphery (Norris et al. 1998). Under these circumstances it is 
feasible that local chronic activation of CD8 T cells by high viral load in the absence of 
rest periods and CD4 help, may be conducive to a loss of CD8 T cell function and 
premature exhaustion of virus-specific CD8 T cells. This could provide a partial 
mechanism for the failure of viral control in this setting.  
5.0.4b Global CD8 T cells 
Persistent TCR-mediated antigenic stimulation may drive progressive exhaustion of HBV-
specific CD8 T cells, however would not be expected to do the same for the non-antigen 
specific CD8 T cell population. Based on our observations that these cells are IL-2 and 
proliferation impaired and CD28 low in patients with high level CHB, we hypothesize that 
they may also be driven to functional exhaustion. Putative factors that may drive these 
global CD8 T cells towards dysfunction may include the inflammatory cytokine milieu in 
the HBV inflamed liver, or exposure to high levels of sub-viral particles, which may be 
tolerogenic (Milich et al. 1990). As discussed in chapter 4, high levels of TNF and IFNα 
have been observed in the plasma and serum respectively in patients with CHB (Dunn et 
al. 2007;Sheron et al. 1991), and have been shown to induce loss of CD28 (Fletcher et al. 
2005;Lewis et al. 2004). In addition, homeostatic cytokines such as IL-15 can drive 
differentiation of central memory CD8 T cells into CD45RA re-expressing memory cells 
without the requirement for antigen (Dunne et al. 2005;Geginat et al. 2003). Longitudinal 
fluctuations of IL-15 mRNA have been observed within serial liver biopsies from 
woodchucks infected with chronic WHV, although they did not correlate with the weak 
changes in viraemia (Schildgen et al. 2006). One may speculate therefore, that 
dysregulated production or responsiveness to homeostatic cytokines may alter both the 
survival capacity of memory cells and possibly the differentiation status of CD8 T cells 
within the liver. In addition to cytokines, large quantities of viral antigens including the 
HBeAg of HBV, may have an immunotolerant role (Milich et al. 1990).  
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5.0.5 Telomeres, Telomerase and Replicative Senescence 
Hayflick et al first showed in 1965 that somatic cells had a finite replicative capacity, 
demonstrated by their observations that fibroblasts cultured in vitro divided only a limited 
number of times (Hayflick 1965). This ‘mitotic clock’ is attributable to telomere length in 
cells.  
In mammalian cells, telomeres are made up of hexanucleotide TTAGGG repeats that cap 
the ends of chromosomes and protect from DNA damage. With each cell division, 50-200 
bases of terminal DNA is lost due to the inability of DNA polymerase to replicate the 
terminal portion (Hodes et al. 2002). In accordance with this, telomere length was found to 
be shorter in memory compared to naïve CD8 T cells (Weng et al. 1995). Shortening of 
telomeres continues with divisions until a critical length is reached, (<4kbases) at which 
point the cell reaches an end stage phenotype known as replicative senescence associated 
with poor functional capacity and impaired proliferation analogous to functionally 
exhausted cells described by Wherry et al. Indeed, studies have shown that telomere length 
is shortest in highly differentiated cells and is associated with an inability of these cells to 
divide (Akbar & Fletcher 2005;Plunkett et al. 2007). 
However, progression to replicative senescence can be postponed by the enzyme 
telomerase which has the capability to add back telomeric repeats onto the chromosome 
ends. Telomerase is a ribonucleoprotein enzyme made up of a catalytic reverse 
transcriptase subunit and an RNA template which it uses to synthesize telomeric repeats 
(Akbar & Vukmanovic-Stejic 2007). Resting lymphocytes have a low baseline telomerase 
activity (Satra et al. 2005), however this can be upregulated on stimulation. This capability 
to upregulate telomerase expression may be crucial during an acute anti-viral response. For 
instance, during the expansion phase of acute infectious mononucleosis, there are a series 
of multiple large clonal expansions of antigen specific CD8 T cells (Callan et al. 1996), 
with up to 28 population doublings. This rapid number of divisions over a condensed 
timeframe would normally be expected to result in telomere shortening and predispose to 
replicative senescence. However, in this setting, Maini et al. showed that despite exhibiting 
a CD45RO+CD28- memory phenotype, there was a preservation of telomere length (TRF 
length) associated with a compensatory increase in telomerase activity in CD8 T cells but 
not CD4 T cells. Preservation of telomere length in this case may be required to generate a 
population of long lived memory cells. Interestingly however, in five controls and five 137 
 
patients with resolved infection, there was no significant difference in TRF length between 
CD8 and CD4 T cells. Furthermore on follow up 1-3 months post AIM infection, there was 
rapid telomere shortening within CD8 T cells to the extent that no difference in TRF length 
between CD8 and CD4 T cells were observed (Maini et al. 1999b). These findings 
collectively suggested attenuation of telomerase activity over time in chronic infection. 
This was supported by in vitro studies by Valenzuela et al. who demonstrated significant 
upregulation of telomerase activity in CD4 and CD8 T cells upon primary stimulation with 
antigen, however on repetitive stimulation, the ability of CD8 T cells to upregulate 
telomerase was lost. These data have also been shown in vivo in X-linked 
lymphoproliferative disease (XLP) and during HIV infection. Young children with XLP 
displayed short CD8 T cell telomere lengths comparable to those observed in the elderly 
population. This premature shortening of telomere length was driven by excessive 
stimulation of these cells (Plunkett et al. 2005). In HIV infection, in which there is 
persistent infection of high viraemia, Effros et al. showed that there was an expanded 
CD28-CD8+ population associated with reduced proliferative capacity which had TRF 
lengths 5-7kb shorter than CD28+CD8+ T cells from the same patient. These TRF lengths 
were analogous to those in PBMC from uninfected centenarians (Effros et al. 1996). 
Similarly Palmer et al. showed that TRF length was shorter in CD8 T cells from HIV 
infected patients compared to uninfected individuals (Palmer et al. 1997) and Franzese et al 
showed reduced telomerase activity in CD4 T cells infected with HIV-1 (Franzese et al. 
2007). Upon transduction of HIV-specific CD8 T cells with hTERT, the catalytic subunit 
of telomerase, there was prolonged secretion of IFNγ and TNF by these cells, a delay in the 
loss of CD28, delayed accumulation of cell cycle inhibitors and increased longevity of 
these cells (Dagarag et al. 2004). In addition, Herpesviruses EBV and CMV, which 
develop latent and smoldering infections respectively, have also been shown to drive 
immunosenescence, and in elderly individuals, a large accumulation of effector CMV 
specific cells have been associated with an immune risk phenotype (Akbar & Fletcher 
2005).  138 
 
 
Figure 5e. Progressive loss of telomeres leads to end stage replicative senescence. The 
enzyme telomerase can ‘rescue’ telomeres by addition of telomeric repeats onto 
chromosome ends. 
These data collectively suggest that upon acute infection, short term exposure to antigen 
allows for clonal expansion of antigen-specific cells, associated with telomerase 
upregulation and maintenance of telomere lengths (in the case of AIM infection), and 
formation of a memory population upon disease resolution. However, on persistent 
stimulation, CD8 T cells may be driven prematurely towards a terminally differentiated 
phenotype associated with shortened telomeres and inability to upregulate telomerase. This 
‘end stage’ phenotype associated with replicative exhaustion and functional impairment 
could hinder the virus-specific response. 
5.0.6 Aims 
In this study we investigate whether chronic infection with HBV could result in premature 
immunosenescence of CD8 T cells, and partially account for the functional defects 
observed within this compartment.  139 
 
Results 
5.1 Enrichment of CD27 negative effector memory and revertant CD8 T cells in 
patients with CHB 
To determine whether functional impairment of CD8 T cells could partially be attributable 
to premature ageing within this compartment, PBMC were isolated from patients and 
healthy donors and CD8 T cells were phenotyped ex vivo. In confirmation of previous 
work, we observed that CD8 T cells could be subdivided into four phenotypically distinct 
subsets dependent on expression of CD27 and CD45RA (Hamann et al. 1997), figure 5.1.1. 
The proportions of these CD8 T cell subsets were then compared between 20 healthy 
donors, 19 patients with low viral load and 17 patients with high viral load (table 5.1) and 
representative dot plots are shown for each group in figure 5.1.2a. On cross-sectional 
analysis, there was a trend towards a progressive decline in naïve CD8 T cells with 
increasing viral load. Patients with high viral load had the lowest proportion of this subset 
(35±20.1) compared to those with low viral load (51±14.5) (p<0.05) and healthy donors 
(60.8±19.5) (p<0.001). No significant difference in the proportion of central memory CD8 
T cells were observed between any group. Conversely, effector memory and revertant CD8 
T cells were both enriched in patients with high viral load compared to controls (p<0.01, 
p<0.001) (fig. 5.1.2b). Interestingly, revertant but not effector memory CD8 T cells were 
enriched in patients with low viral load compared to controls. Based on this observation 
one could speculate that at a lower threshold of viral load, naïve CD8 T cells may 
preferentially be induced to become revertant over effector cells. Indeed, previous studies 
have shown that central memory CD8 T cells in the presence of IL-15 could differentiate 
directly into revertant CD8 T cells in the absence of antigen (Geginat et al. 2003). 
However, an alternative scenario is that this discrepancy may partially be attributable to 
other variables known to influence the phenotypic repertoire of CD8 T cells, such as age 
and CMV/EBV seropositivity of the patients, or viral factors such as HBeAg status and 
liver inflammation. 
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Subject HBV 
DNA 
(IU/ml) 
ALT 
(IU/L) 
HBeAg AGE SEX CMV  Zeta  MFI 
done 
HD 1  N/A  Normal  N/A  34 M  neg   
HD 2  N/A Normal  N/A 34 M  neg  yes 
HD 3  N/A  Normal  N/A  34 F  neg  yes 
HD 4  N/A Normal  N/A 23 M  pos  yes 
HD 5  N/A  Normal  N/A  24 F  pos   
HD 6  N/A Normal  N/A 34 M  pos  yes 
HD 7  N/A  Normal  N/A  34 F  pos   
HD 8  N/A Normal  N/A 22 F  not  tested  yes 
HD 9  N/A  Normal  N/A  22 F  not tested   
HD 10  N/A Normal  N/A 22 M  not  tested   
HD 11  N/A  normal  N/A  23 M  not tested   
HD 12  N/A normal  N/A 24 M  not  tested  yes 
HD 13  N/A  normal  N/A  24 M  not tested   
HD 14  N/A normal  N/A 24 M  not  tested  yes 
HD 15  N/A  normal  N/A  24 F  not tested   
HD 16  N/A normal  N/A 32 F  not  tested  yes 
HD 17  N/A  normal  N/A  32 F  not tested   
HD 18  N/A normal  N/A 33 F  not  tested  yes 
HD 19  N/A  normal  N/A  33 ?  not tested  yes 
HD 20  N/A normal  N/A 36 ?  not  tested  yes 
CHB 7  1400  30  neg  21 M  not tested   
CHB 9  4100 42  neg 45 ?  not  tested   
CHB 13  72172  405  neg  46 M  not tested   
CHB 61  ? ?  ? 54 ?  not  tested  yes 
CHB 62  ?  ?  ?  64 ?  not tested  yes 
CHB 63  420000 270  pos 25 M  pos  yes 
CHB 4 '  440  23  meg  29 M  pos   
CHB 59  blq 32  neg 33 F  pos   
CHB 2  blq  57  neg  38 M  pos  yes 
CHB 64  blq 25  neg 43 M  pos   
CHB 14  170000  56  neg  48 F  pos  yes 
CHB 65  570 23  neg 49 M  pos   
CHB 5  850  22  neg  25 F  not tested   
CHB 66  140000 31  pos 27 M  not  tested   
CHB 12  40000  24  Neg  31 F  not tested   
CHB 8  1400 56  Neg 32 M  not  tested   
CHB 53  blq  18  Neg  35 M  not tested   
CHB 67  510 17  Neg 40 F  not  tested   
CHB 68  1300  29  Neg  50 F  not tested   
CHB 69  15000000 88  Pos 25 M  not  tested   
CHB 70  high *  Pos  25 F  not tested  yes 
CHB 71  60000000 35  Pos 34 M  not  tested   141 
 
CHB 57  330000000  39  Pos  34 M  not tested   
CHB 20  1127317 189  Neg 42 F  not  tested   
CHB 72  high *  high*  Pos  45 F  not tested  yes 
CHB 30 '  260000000 196  Neg 51 F  not  tested  yes 
CHB 21  1400000  58  Pos  62 M  not tested   
CHB 33 '  11000000 62  Pos 24 F  pos  yes 
CHB 26 '  23000000  322  Pos  26 F  pos   
CHB 28  110000000 24  Pos 31 F  pos   
CHB 34 '  290000000  418  Pos  36 M  pos  yes 
CHB 32 '  120000000 76  Pos 40 M  pos  yes 
CHB 27  67000000  96  Pos  40 M  pos  yes 
CHB 19  1100000 151  Neg 47 F  pos   
CHB 22  2000000  69  Pos  60 M  pos  yes 
CHB 73  1548076 112  Pos 62 F  pos   
 
Table 5.1 Characteristics of patients and controls used for study of CD8 T cell 
differentiation. Blq: below quantification. (*) denotes that HBV DNA/ALT levels were not 
available at the time of sampling, and instead values from the previous clinic visit are 
shown. A dash (‘) next to the patient code denotes that this patient has been used in more 
than one assay, and the sampling timepoint studied, may vary between different 
experiments. HD = healthy donor.    142 
 
 
Figure 5.1.1: CD8 T cells can be subgrouped by expression of CD27 and CD45RA. PBMC 
were isolated from patients and healthy donors and stained for surface markers CD8, CD27 
and CD45RA ex vivo. Representative dot plot from a patient with high viral load shows 
the distribution of CD8 T cells into four distinct groups; naïve (CD27+CD45RA+), central 
memory (Tcm, CD27+CD45RA-), effector memory (Tem, CD27-CD45RA-) and revertant 
(Temra, CD27-CD45RA+). 
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Figure 5.1.2: Effector memory and revertant CD8 T cells are enriched in patients with 
CHB. a) Representative dot plots from an age matched control, patient with low viral load 
(<10
6 IU/ml) and patient with high viral load (>10
6IU/ml) depict the subdivision of CD8 T 
cells into subsets dependent on expression of surface markers CD27 and CD45RA. Cross 
sectional data in (b) compares the proportions of each subset against viral load in 20 
healthy donors, 19 patients with low viral load and 17 patients with high viral load. 
(*=p<0.05, **=p<0.01, ***=p<0.001, non-parametric Mann-Whitney U test). 
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5.2 Enrichment of CD27 negative CD8 T cells in age and CMV matched individuals 
Increasing age and CMV status are known to drive CD8 T cell differentiation towards a 
terminally differentiated phenotype. To confirm that the accumulation of highly 
differentiated CD8 T cells in patients with high viral load was a consequence of HBV 
infection and not simply due to differences in age/CMV status between different patient 
groups, data were re-analysed in either young age-matched individuals (figure 5.2a) or 
only CMV seropositive individuals under the age of 50 years (figure 5.2b). From these 
data, we showed that even within young individuals, patients with highest viral load had 
the lowest proportion of naïve CD8 T cells, and an accumulation of both effector and 
revertant CD8 T cells. Similarly, in CMV positive individuals, there was an incremental 
increase in the proportion of revertant CD8 T cells with viral load and those individuals 
with highest viral load conversely had the lowest proportion of naïve CD8 T cells.  
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Figure 5.2: Enrichment of CD27- negative CD8 in age and CMV matched individuals. a) 
Graphs show the proportion of each CD8 T cell subset against viral load in age matched 
individuals (20-40years) and only CMV seropositive individuals under the age of 50 in (b). 
(*=p<0.05, **=p<0.01, ***=p<0.001, non-parametric Mann-Whitney U test). 146 
 
5.3 Progressive downregulation of CD3ζ with differentiation 
In the previous chapter we had observed that CD3ζ downregulation was greatest in 
patients with high viral load, in whom we have now shown to have an accumulation of 
highly differentiated CD8 T cells. Based on this correlative finding, we hypothesized that 
downregulation of CD3ζ could be a contributory mechanism for the functional exhaustion 
seen in these terminally differentiated cells. To test this hypothesis, PBMC were isolated 
from healthy donors and patients, surface stained for markers CD8, CD27 and CD45RA, 
then intracellularly stained for CD3ζ. As shown in figure 5.3a, following separation of 
CD8 T cell subsets by CD27 and CD45RA expression, the mean fluorescence intensity of 
CD3ζ expression was then compared between the 4 subsets. We observed in almost all 
patients, that MFI of CD3ζ expression was reduced in CD27 negative subsets, compared to 
CD27 positive CD8 T cell subsets from the same individual. In some cases, there was a 
progressive reduction in CD3ζ expression as cell progressed from naïveÆcentral 
memoryÆeffector memoryÆrevertant, especially in patients with low viral load (fig 5.3b). 
Progressive loss of CD3ζ MFI was not observed in healthy donor CD8 T cells, although a 
subtle decrease in CD3ζ MFI was observed in the Tem subset compared to naïve CD8 T 
cells in some patients. These data suggest therefore that highly differentiated CD27 
negative CD8 T cells from patients with CHB have lower CD3ζ. This may reduce their 
ability to respond to stimuli through the T cell receptor complex and partially explain why 
they are characteristically less able to produce IL-2 and proliferate than CD27 positive 
CD8 T cells. Furthermore, only revertant CD8 T cells from patients with CHB, but not 
healthy donors, downregulated CD3ζ, suggesting that accumulation of differentiated 
subsets is not in itself enough to account for the discrepancy in global CD8 T cell CD3ζ 
expression between patients and controls.  147 
 
 
     
Figure 5.3: Progressive downregulation of CD3ζ with differentiation in CD8 T cells from 
patients with CHB.  PBMC were surface stained for CD8, CD27 and CD45RA, and 
intracellularly stained for CD3ζ. a) Representative dot plot shows the distribution of CD8 
T cell subsets in a typical low level carrier (left) and the mean fluorescence intensity of 
CD3ζ expression for each subset is shown on a histogram (right). (red=CD45RA+CD27+, 
blue=CD45RA-CD27+, green=CD45RA-CD27-, orange=CD45RA+CD27-). b) Graphs 
depict the difference in CD3ζ MFI between CD8 T cell subsets in healthy donors, patients 
with low viral load (HBV DNA <10
6IU/ml) and patients with high viral load (HBV DNA 
>10
6IU/ml). 148 
 
5.4 Global CD8 T cells from patients with chronic HBV have shorter telomeres 
Telomere length is shortened in highly differentiated CD8 T cells, and is associated with 
reduced replicative ability. To determine whether global CD8 T cells from patients with 
CHB had shorter telomeres, PBMC were surface stained  for CD27, and telomere length 
was determined by a flow based fluorescence in situ hybridisation assay (flow FISH). 
Briefly, telomere specific FITC-labelled PNA probe was added to the cell suspension, and 
heated to 82
oC in order to allow denaturation of DNA and subsequent hybridisation of the 
fluorescent probe onto the telomeric ends. The level of fluorescence detected on the flow 
cytometer could therefore be used as a quantitative measure of the telomere length on a per 
cell basis. As shown in figure 5.4a, telomere length was determined both within global 
CD8 T cells, as well as separately within CD27 negative and CD27 positive fractions. 
From the cross-sectional analysis, we observed a trend towards a decrease in telomere 
length in the global CD8 T cells with increasing viral load, with shortest telomere length in 
CD8 T cells from patients with high viral load (p<0.05) (patient details; table 5.2). 
Previous data from the group of Professor Akbar have determined telomere length by flow 
fish in CD8 T cells obtained from young, middle aged and elderly individuals (unpublished 
data). In their study, the range of telomere MFI ranged from 176 in cord blood CD8 T 
cells, to 82 in CD8 T cells from an elderly individual (age 63).  We observed a mean drop 
in telomere MFI from 150 (controls) to 135 (high viral load), corresponding to shortening 
of TRF lengths from 9.1 to 8 kilobases (TRF length was previously determined by 
southern blotting and plotted on a standard curve against MFI values obtained by flow 
FISH). This was a biologically significant reduction and roughly equated to premature 
ageing of the immune system by up to 10 years. Furthermore, in the one individual who 
showed a telomere MFI less than 100 (98.25), HBV DNA was in excess of 1 x10
8 IU/ml at 
this timepoint.  This trend was maintained in the CD27 negative fraction, however, there 
was no significant alteration of telomere length within the CD27 positive fraction. For all 
individuals, telomere length was shorter by at least an MFI of 20 in the CD27 negative 
fraction compared to the CD27 positive fraction with a mean difference of 31.27. 
Therefore, not only was there an accumulation of CD27 negative CD8 T cells in chronic 
HBV infection, but these CD8 T cells also had shorter telomeres than the equivalent subset 
in healthy donors.  149 
 
These initial data suggest that premature senescence of CD8 T cells may be secondary to 
chronic HBV infection, however are still preliminary in nature due to the limited sample 
sizes. In order to confirm these preliminary findings and also dissect out the relationship 
between telomere length and viral load/liver inflammation, it would be important in future 
experiments to:  
1.  Increase the sample size within the healthy donor and patient cohorts 
2.  Determine telomere length longitudinally in patients in whom viral load and liver 
inflammation are fluctuating temporally. 
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Name HBVDNA 
(IU/ml) 
HBeAG  ALT 
(IU/L) 
age Sex 
HD 12  N/A  N/A  Normal  23  M 
HD 6  N/A  N/A Normal  32  M 
HD 2  N/A  N/A  Normal  28  F 
HD 1  N/A  N/A Normal  32  M 
HD 3  N/A  N/A  Normal  32  F 
HD 16  N/A  N/A Normal  32  F 
HD 21  N/A  N/A  Normal  28  M 
HD 7  N/A  N/A Normal  32  F 
HD 18  N/A  N/A  Normal  33  F 
CHB 59              blq   Neg 32  27  F 
CHB 58  160  Neg  39  36  M 
CHB 74  380  Neg 29  34  F 
CHB 75  460  Neg  58  33  M 
CHB 5  850  Neg 22  25  F 
CHB 7  1400  Neg  30  23  M 
CHB 8  1400  Neg 56  32  M 
CHB 12  40000  Neg  24  30  F 
CHB 66  140000  Pos 31  27  M 
CHB 63  420000  Pos  270  24  M 
CHB 19 ‘  1400000  Neg 62  47  F 
CHB 31 ‘  20000000  Pos  83  23  M 
CHB 71  60000000  Pos 35  34  M 
CHB 33 ‘  78000000  Pos  103  24  F 
CHB 28  110000000  Pos 24  30  F 
CHB 27 ‘  150000000  Pos  63  40  M 
CHB 57  330000000  Pos 39  35  M 
CHB 32 ‘   Not done  Pos  73  40  M 
 
Table 5.2 Clinical characteristics of patients and healthy donors used for determination of 
telomere length by Flow FISH. HD = healthy donor.    151 
 
      
 
Figure 5.4 Global CD8 T cells from patients with CHB have shorter telomeres. Telomere 
length in PBMC was determined ex vivo by flow FISH. a) flow cytometric plots depict the 
gates used to analyse telomere MFI on either global CD8 T cells, or within either 
CD8+CD27+ or CD8+CD27- T cells. b) Cross-sectional data shows telomere MFI vs. viral 
load for global CD8 T cells, and CD8+CD27+ and CD8+CD27- cells. (*=p<0.05, non-
parametric Mann-Whitney U test). 
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5.5 HBV-specific CD8 T cells have the shortest telomeres 
To determine whether HBV-specific CD8 T cells were more susceptible to telomere loss 
than CD8 T cells of other viral specificities, PBMC from HLA-A2 positive donors were 
stimulated with viral peptides representing immunodominant epitopes of CMV, EBV and 
HBV for 10 days, following which telomere length was determined by flow FISH. Dot 
plots in figure 5.5.1 illustrate the magnitude of virus-specific CD8 T cell responses as 
determined by IFN-γ production in two patients with low viral load. After gating on the 
virus specific populations, the telomere MFI was then compared between different CD8 T 
cell specificities in the same individual. As shown in the right hand histograms, telomere 
MFI was significantly lower in HBV-specific CD8 T cells compared to EBV-specific CD8 
T cells in patient 1 and CMV-specific CD8 T cells in patient 2. In both cases, telomere 
length in HBV-specific CD8 T cells was subtly also shorter compared to the global CD8 T 
cell population (Patient 1 global=154, C18=149), (Patient 2 global=158, C18=153).  One 
caveat to this finding, however, was that MFI of telomere length in these experiments was 
at a higher range than that seen ex vivo. For example, CMV specific CD8 T cells in patient 
1 had an MFI of 175, which is similar to that seen in cord blood T cells.  
Therefore, to rule out artefacts associated with tissue culture, these experiments were 
repeated ex vivo in a patient with high viral load. As shown in figure 5.5.2, we observed 
that the telomere MFI was significantly shorter in HBV-specific CD8 T cells compared to 
EBV or CMV-specific CD8 T cells from the same individual (5.5.2 middle panel). Since 
there was slight variation in the global CD8 MFI between individual tubes, samples were 
run in triplicate to reduce variability and a mean of the triplicates was taken (figure 5.5.2 
lower panel). On this analysis, we observed that the telomere MFI in global CD8 T cells 
was highly consistent between samples. The MFI of EBV and CMV-specific cells was 
similar to the global population or slightly elevated respectively. Only HBV-specific cells 
consistently had a lower telomere MFI compared to the global CD8 T cells, with a mean 
reduction of 13 (global MFI 115, HBV specific MFI 102). This again would equate to 
premature ageing of this compartment by 10 years and may partially explain the marked 
quantitative and qualitative defects observed in this compartment. These preliminary data 
suggest that HBV-specific CD8 T cells may have even shorter telomeres than global CD8 
T cells and those of other viral specificities, however further ex vivo experiments are 
required to explore this finding.  153 
 
One finding of note in this study is that it is extremely unusual to detect HBV-specific CD8 
T cells ex vivo, especially from patients with high viral load in whom there are barely 
detectable circulating frequencies. Despite this, we were able to detect an ex vivo response 
towards the HBV c18-27 epitope in one high level carrier (patient CHB 34). In support of 
this data, Boni et al have shown that following stimulation with a pool of overlapping 
peptides covering the whole HBV genome, mainly responses to core and polymerase but 
not to envelope were detected (Boni et al. 2007). This suggested that CD8 T cells specific 
to different epitopes may have differential susceptibility to a hierarchical loss of T cell 
effector function and exhaustion. Envelope specific CD8 T cells may have undergone 
deeper exhaustion due to exposure to large frequencies of circulating HBeAg. It is feasible 
therefore, that comparison of telomere length between CD8 T cells specific for different 
HBV epitopes may further reveal differential telomere erosion; this is a subject of future 
study. 
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Figure 5.5.1 HBV-specific CD8 T cells have the shortest telomeres.  PBMC from two 
patients with CHB were stimulated with HLA-A2 restricted viral peptides representing 
immunodominant epitopes on HBV, CMV and EBV and virus-specific responses were 
allowed to expand for 10 days. Telomere length within virus-specific CD8 T cells was 
subsequently determined by flow FISH.  
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Figure 5.5.2 HBV-specific CD8 T cells ex vivo display shortest telomere length.  156 
 
5.6 Determination of telomerase activity in CD8 T cells in patients and controls 
Telomerase is a ribonucleoprotein enzyme that can compensate for progressive telomere 
loss, and can delay progression to replicative senescence. CD8 T cells can upregulate 
telomerase activity upon activation, and a compensatory increase has been associated with 
preservation of telomere length in EBV-specific CD8 T cells during acute infectious 
mononucleosis (Maini et al. 1999b). To determine whether loss of telomere length during 
CHB is secondary to aberrations in telomerase activity, CD8 T cells were negatively 
selected, pelleted and lysed, and cell extract was obtained to determine telomerase activity. 
This was done by a gel based TRAPeze system, a modification of the PCR based TRAP 
(telomeric repeat amplification protocol) assay, and involved a two step process in which 
telomerase added telomeric repeats onto the 3’ end of a substrate oligonucleotide (TS), 
following which the TS-telomerase product was amplified by PCR. This generated a ladder 
of products with 6 base increments as shown in 5.6b. Total product generated (TPG) was 
then used as a quantitative measure of telomerase activity. A representative dot plot in 5.6a 
shows the purity of CD8 T cells upon negative selection (91%) in a patient with high viral 
load. Standardisation of this assay required the absolute number of CD8 T cells, which was 
enumerated using Trucount beads, and information on the stage of cell cycle for each cell, 
which was determined by Ki67 staining (which identifies cells in all phases of the cell 
cycle). Telomerase activity could be corrected per 500 cycling cells- and thus direct 
comparison of telomerase activity within cycling cells could be done between CD8 T cell 
extracts isolated from patients and healthy donors (Plunkett et al. 2007;Reed et al. 2004). 
As we detected virtually no telomerase activity in our ex vivo PBMC samples (fig 5.6), in 
this assay, CD8 T cells were additionally stimulated with anti-CD3 and irradiated APC for 
3 days to initiate proliferation and induce telomerase upregulation. Two separate gels 
depicting telomerase activity before and after stimulation in six patients with CHB, and 
one healthy donor are shown in 5.6b. Comparison of data between gels was difficult due to 
much higher background values in one gel compared to the other. However, comparison of 
TPG content between ex vivo (day 0) and stimulated (day 3) was possible, and revealed 
paradoxically that there was a downregulation of telomerase activity upon stimulation in 
all cases 5.6c. This may potentially have been an artefact of the assay however. The 
number of Ki67+ cells was used to calculate how much each sample should be diluted in 
CHAPS lysis buffer. This meant that stimulated samples, which had a large number of 157 
 
cycling cells, were much more diluted than unstimulated samples which had <1% Ki67+ 
cells (data not shown). However, because the volume of CHAPS lysis buffer was much 
lower for the unstimulated sample, the concentration of cells was higher. Although resting 
cells have been reported to have undetectable telomerase, in reality small baseline levels 
may be present (Dr. Franzese, personal communication). Therefore, the higher 
concentration of cells used for the ex vivo samples could partially explain the bias towards 
higher telomerase activity in this sample. In future experiments, direct comparison of 
telomerase activity between stimulated and unstimulated samples without correction for 
cycling may provide a more accurate comparison.  
 
Table 5.3. Characteristics of patients used for detection of telomerase by gel based 
TRAPeze assay. Blq: below level of quantification. 
Subject HBV  DNA 
(IU/ml) 
ALT 
(IU/L) 
HBeAg AGE SEX  CMV 
CHB 24 '  12000000  73  pos  38 M  Pos 
HD 11  N/A Normal  N/A 23 M  not  tested 
CHB 30 '  260000000  196  neg  51 F  not tested 
CHB 34 '  290000000 418  pos 36 M Pos 
CHB 27  67000000  96  pos  40 M  Pos 
CHB 28  110000000 24  pos 31 F  Pos 
CHB 54 '  Blq  46  neg  55 M  not tested 158 
 
 
Figure 5.6: Telomerase activity in patients and controls. PBMC were snap frozen ex vivo, 
or following stimulation with anti-CD3 and irradiated APC for 3 days. Extracts were then 
collected and telomerase activity was determined by the gel based TRAPeze assay. a) 
representative dot plots depict how the number of Trucount beads, total lymphocytes and 
the percentage of Ki67+ CD8 T cells was determined by flow cytometry. These values 
were then used to calculate volume of CHAPS lysis buffer (see table above). b) Gels 
illustrate ladders of telomeric products and summary data is shown in (c).  159 
 
5.7 Determination of telomerase activity by PCR ELISA plus kit 
A variety of assays are now available for the determination of telomerase activity and each 
have been reported to have different sensitivities. In addition to the Chemicon TRAPeze 
assay, we also tested a modified protocol by which the endpoint of telomerase activity 
could be determined by ELISA rather than with a gel. This assay was less labour intensive, 
allowed more samples to be run at once reducing inter-assay variability, and did not use 
radioactivity. Similar to the TRAPeze assay, 0.1 million negatively selected CD8 T cells 
were snap frozen, and upon thawing, were diluted in different amounts of CHAPS lysis 
buffer to correct for the number of Ki67+ cycling cells. Lysate was then collected and 
subjected to a similar PCR based amplification step after which product was detected by 
ELISA and expressed as relative telomerase activity. Preliminary data shown in fig. 5.7 
shows no significant difference between telomerase activity in 4 patients and 5 controls 
following 5 day in vitro stimulation with anti-CD3 and irradiated antigen presenting cells. 
Notably, we did not observe an increase in telomerase activity during CHB infection, 
which we might expect as a compensatory mechanism to counteract the accelerated 
telomere loss in CD8 T cells from these individuals.   
 
Subject HBV 
DNA 
(IU/ml) 
ALT (IU/L) HBeAg AGE SEX  CMV 
HD 15  N/A  normal  N/A  24 F  not tested 
HD 9  N/A normal  N/A  22 F  not  tested 
HD 6  N/A  normal  N/A  34 M  pos 
HD 5  N/A normal  N/A  24 F  pos 
CHB 2  blq  57  neg  38 M  pos 
CHB 53  blq 18  neg 35 M  not  tested 
CHB 68  1300  29  neg  50 F  not tested 
CHB 60  360  not done  neg 31 M  not  tested 
CHB 21  1400000  58  pos  62 M  not tested 
 
Table 5.4 Patients used for detection of telomerase by Roche PCR ELISA plus telomerase 
kit. 
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Figure 5.7: Telomerase activity determined by Roche PCR ELISA plus kit. 161 
 
Discussion 
In chapter one, we showed that global CD8 T cells in patients with CHB were impaired in 
their ability to produce IL-2 and to proliferate, but retained their capacity to produce 
proinflammatory cytokines. This skewed functional profile is reminiscent of that found in 
terminally differentiated CD8 T cells (upon PMA/ionomycin stimulation of healthy donor 
purified CD8 T cells) (Hamann et al. 1997), and CD8 T cells which had been driven to 
functional ‘exhaustion’ by persistent high level virus (Wherry et al. 2003a). In this chapter, 
we investigated the phenotypic properties of virus-specific and global CD8 T cells in 
patients with CHB in order to determine whether replicative senescence of these cells 
could partially account for their loss of effector function and proliferation. 
We found that in patients with high viral load, there was enrichment in the proportion of 
effector and revertant CD8 T cells, and a reduction in the proportion of naïve CD8 T cells 
compared to age-matched healthy donors. Global CD8 T cells from these patients also had 
the shortest telomeres, most pronounced within the CD27 negative fraction which was 
enriched in CHB, indicative of their highly differentiated status and susceptibility to end 
stage replicative senescence. Preliminary experiments showed no difference in the activity 
of telomerase between healthy donor and patient CD8 T cells. 
Chronic HBV infection is characterised by long-term high dose virus persistence. In this 
setting, persistent activation of HBV-specific CD8 T cells could drive them prematurely 
towards a terminally differentiated state associated with functional exhaustion. Urbani et 
al. showed that during acute HBV infection, the majority of virus specific CD8 T cells 
were of an effector memory phenotype (CCR7-CD45RA-) (Urbani et al. 2002). Whether 
this phenotype is altered during chronic HBV infection is as yet unclear. The phenotype of 
virus-specific CD8 T cells is known to vary depending on the virus in question. Appay et 
al showed that during chronic infection, EBV and HCV-specific CD8 T cells were mainly 
CD28+CD27+ double positive, whereas CMV-specific CD8 T cells were conversely 
mainly CD28-CD27- double negative. HIV-specific CD8 T cells had an intermediate 
phenotype (CD28-CD27+). Thus, depending on the viral infection, there were enrichments 
of distinct memory populations arrested at different stages along the differentiation 
pathway (Appay et al. 2002). Similarly, Fletcher et al. showed that after stimulation of 
CD4 T cells with different viral antigens, only CMV-specific CD4 T cells from young 
individuals had a significant enrichment of CD27-CD28- cells, however this was not the 162 
 
case for Varicella zoster virus (VZV), EBV or Herpes simplex virus (HSV) antigen-
specific CD4 T cells for which, in most cases, less than 25% of these cells occupied this 
compartment (Fletcher et al. 2005).  These data suggested that the type of viral infection 
did not necessarily correlate with the differentiation status of the virus-specific T cells. For 
example, one might expect that virus-specific CD8 T cells would be more differentiated if 
there was chronic infection with high level viraemia (HCV/HIV), and less differentiated 
during either latent (EBV) or low level ‘smoldering’ infection (CMV). Since this is not the 
case, we cannot use the type of chronic infection established to accurately predict what the 
phenotype of the majority of HBV-specific CD8 T cells is likely to be, and we can so far 
only speculate based on the trends observed in the global CD8 T cell population.  
The altered memory characteristics of virus-specific CD8 T cells in different infections 
suggested that factors other than virus load must additionally contribute to driving CD8 T 
cells towards a terminally differentiated phenotype. In CHB infection, the circulating 
frequencies of HBV-specific CD8 T cells are barely detectable ex vivo (after screening 
with overlapping peptides covering the HBV genome), thus the majority of these cells are 
non-HBV specific (Boni et al. 2007). Since we also see a shift in the phenotype of these 
global CD8 T cells in those patients with high virus load and liver inflammation, this 
supports the notion that other factors may be influencing CD8 T cell phenotype and 
function.  
One possibility is that CD8 T cells specific for other viruses, occupy a large amount of the 
‘immunological space’ and may skew the phenotypic profile of the global CD8 T cells 
(Akbar & Fletcher 2005). For example, large oligoclonal expansions of CMV-specific 
CD8 T cells accumulate in individuals with age, and are highly differentiated compared to 
EBV, HCV or HIV-specific CD8 T cells from the same subjects (Appay et al. 2002). We 
found that, in a sample of 25 patients in whom we tested CMV serology, over 80% of 
patients were CMV positive (16/19 CMV+), however the proportion of CMV positive 
healthy donors was much lower (1/6 CMV+). Although it is possible that this variable 
could skew global CD8 T cell phenotype, after re-analysing the data excluding CMV 
negative individuals, there was still a significant accumulation of both effector memory 
and revertant CD8 T cells in patients compared to healthy donors.  
As well as competing for immunological space, viruses may exert a pervasive influence on 
the phenotype of global CD8 T cells. After acute infectious mononucleosis, Sauce et al. 163 
 
showed that both EBV-specific and global CD8 T cells (as well as CD4 T and NK cells) 
lost expression of IL-15Rα, and this correlated with impaired responsiveness to IL-15 in 
vitro. Furthermore, loss of IL-15Rα was maintained for up to 14 years after AIM, however 
was not observed in healthy EBV carriers or EBV naïve individuals (Sauce et al. 2006). 
Whether or not HBV infection induces similar changes in global T cell IL-15Rα 
expression has not been tested. However, co-infection with EBV (in those who have 
recovered from AIM) could potentially skew the IL-15 responsiveness of global and HBV-
specific CD8 T cells. IL-15 is a homeostatic cytokine required for the proliferation and 
maintenance of memory CD8 T cells. Altered responsiveness to IL-15 could therefore 
impair the ability of global and HBV-specific CD8 T cells to survive and expand which 
may further exacerbate quantitative and qualitative defects observed. The dependence of 
HBV-specific CD8 T cells on IL-15 in vivo remains unclear however, and requires further 
attention.  
Hepatitis C virus has been described to have a pervasive influence on the phenotype of 
circulating CD8 T cells, as CMV-specific CD8 T cells from these individuals lost markers 
associated with maturity, and had increased expression of CCR7 (Lucas et al. 2004). 
Although, in this study, HCV infection paradoxically conferred a less differentiated 
phenotype onto CMV-specific CD8 T cells, in a study by Golden Mason et al., CMV 
specific CD8 T cells from patients with chronic HCV had upregulated expression of the 
inhibitory receptor PD-1, signalling through which is known to suppress CD8 T cell 
responses (Golden-Mason et al. 2007).  
In another study by Fletcher et al., it was shown that in elderly subjects, CD4 T cells of 
different virus specificities were more differentiated in CMV sero-positive individuals 
compared to CMV sero-negative individuals. This bystander effect on non-CMV specific 
CD4 T cells was mediated partially through IFN-α production by CMV stimulated 
plasmacytoid dendritic cells (pDC). PBMC stimulated with CMV lysate in which pDC had 
been depleted did not produce IFNα. Additionally, PPD specific CD4 T cells were cultured 
in vitro in the presence or absence of IFN-α to determine whether it could modulate the 
phenotype of these cells. By day 21, the proportion of cells with a highly differentiated 
CD28-CD27- phenotype was 25% compared to 3% in the absence of IFNα- suggesting 
that IFNα could induce loss of costimulatory receptors on non CMV positive cells 
(Fletcher et al. 2005).  164 
 
In patients with chronic HBV infection with high liver inflammation, there is elevated 
serum IFNα compared to those with low ALT or healthy controls. Furthermore, levels of 
IFNα correlated temporally with HBeAg negative flares of HBV (Dunn et al. 2007). Loss 
of CD28 and CD27 in global CD8 T cells observed in those patients with highest viral load 
and liver inflammation could therefore partially be mediated by IFNα. Another cytokine 
which has been associated with CD28 loss is TNF-α. In JTag cells (a subline of Jurkat 
cells which upregulate CD28 upon PMA stimulation), addition of exogenous TNF was 
able to inhibit PMA mediated upregulation of CD28 by inhibiting the formation of INR 
specific transcription complexes, and thus silenced CD28 transcription (Lewis et al. 2004). 
We showed that global CD8 T cells from patients maintained their production of TNF, and 
this cytokine was also shown to be elevated in the plasma of patients with HBeAg positive 
chronic HBV compared to healthy donors (Sheron et al. 1991). In addition, IL-15 has been 
shown to induce generation of CD28 null cells from freshly sorted CD8+CD28+ T cells, 
partially through induction of TNF. In these experiments, IL-15 induced proliferation 
resulted in stable downregulation of CD28 over a month, and this was partially 
reconstituted upon addition of neutralising anti-TNF antibody to block TNF in the culture 
medium (Chiu et al. 2006). These data may hint as to a possible role in dysregulation of 
homestatic cytokines in the altered phenotypic profile in CHB infection, however whether 
IL-15 levels are significantly altered in the intrahepatic cytokine milieu or circulation in 
these patients is as yet unclear. They do suggest however that TNFα and IFNα, which are 
both elevated in patients with high viral load and liver inflammation, may play a bystander 
role in driving antigen independent CD8 T cell differentiation towards a terminally 
differentiated phenotype in CHB. 
Another characteristic of exhausted CD8 T cells is the expression of molecules such as PD-
1; an inhibitory receptor of the CD28 family induced on T cells, B cells and myeloid cells 
upon activation (Greenwald et al. 2005). Its ligand PD-L1, is constitutively expressed on 
liver antigen presenting cells including LSEC’s, Kuppfer cells (Iwai et al. 2003) and 
Stellate Cells (Chen et al. 2006), and can be upregulated on hepatocytes stimulated with 
IFNα or IFNγ (Muhlbauer et al. 2006). Barber et al., in a gene profiling study, found PD-1 
to be selectively upregulated on functionally impaired-virus specific CD8 T cells from 
mice infected with chronic LCMV infection compared to functional memory CD8 T cells. 
Injection of mice with anti PD-1 or anti PD-L1 restored proliferation and cytotoxic 165 
 
function in exhausted LCMV specific CD8 T cells which were then able to kill infected 
cells and reduce viral load. This was not seen however when the CTLA-4 signalling 
pathway was blocked (Barber et al. 2006).  
In humans, PD-1 has been shown to be selectively upregulated on virus-specific CD8 T 
cells during CHB (Boni et al. 2007), HCV (Radziewicz et al. 2007;Urbani et al. 2006) and 
HIV infection (Day et al. 2006). PD-1 has also been reported to be upregulated on the 
global CD8 T cell subset in both chronic HCV (Golden-Mason et al. 2007) and HBV 
infections (Peng et al. 2008b), and thus could potentially mediate a pan CD8 T cell 
suppression in exhausted CD8 T cells. In order to investigate expression of PD-1 on HBV 
specific CD8 T cells, Boni et al. used pools of overlapping peptides covering the overall 
protein sequence of HBV genotype D, to detect HBV-specific CD8 T cell responses ex 
vivo over the course of chronic flares of HBeAg negative flares of HBV. The responses 
detected were mainly of core and polymerase specificity, and these cells hyperexpressed 
PD-1 compared to CMV/FLU virus specific CD8 T cells from the same individuals. 
Blockade of PD-1/PDL-1 signalling rescued HBV-specific CD8 T cell responses as 
detected by tetramers (Boni et al. 2007). These data suggest that hyperexpression of PD-1 
serves as a molecular signature for exhaustion of HBV-specific CD8 T cells at least, and 
blockade of PD-1 signalling is partially able to restore functional exhaustion. 
The fact that HBV-specific CD8 T cells are under the added pressure of high dose 
antigenic stimulation through the T cell receptor, which would induce repetitive mitotic 
cycling, could explain their further propensity to have shorter telomeres and telomerase 
loss compared to other virus specificities. We measured telomere length in both global and 
virus-specific CD8 T cells. Our initial preliminary studies showed that with increasing 
viral load, there was a trend towards a progressive reduction in global CD8 T cell telomere 
length. A similar global CD8, but not CD4 T cell, telomere erosion had been observed 
previously in HIV discordant monozygotic twins. In these twin pairs, CD8 T cells from 
HIV positive individuals consistently had shorter TRF lengths compared to their non HIV 
infected twins (Palmer et al. 1997).  Secondly, we further observed that HBV-specific CD8 
T cells (ex vivo (n=1), and after short term culture (n=2)) had shorter telomeres compared 
to CD8 T cells of other virus specifities from the same individuals. Although these findings 
are preliminary, one could speculate that further telomere attrition in HBV-specific CD8 T 
cells could be compatible with their added stimulation by antigen through the TCR. 166 
 
Telomeric shortening is counteracted by the enzyme telomerase, which can add back 
telomeric repeats onto chromosome ends and delay progression to replicative senescence. 
Inability to upregulate telomerase would therefore hasten telomere attrition. Telomerase 
activity may be influenced by a number of factors. Firstly, Reed et al showed that 
following purified protein derivative (PPD) injection into the skin, specific CD4 T cells 
isolated from the site of antigenic challenge at day 19 had significant telomere erosion 
(400bp-equivalent to 8 years ageing) compared to the CD4 T cells in the blood, and this 
was partially due to high quantities of IFNα in the tissue fluid which inhibited telomerase 
activity of PPD specific CD4 T cells both in vivo and in vitro (Reed et al. 2004). Therefore 
in patients with CHB infection, IFNα induced during HBeAg negative flares of HBV, 
could account for a non-antigen specific mechanism of telomerase inhibition, and 
accelerated telomere shortening. Other cytokines such as IL-15 are known to induce stable 
telomerase expression over long periods of time in memory cells, in this case by signalling 
through JAK3 and PI3K pathways (Li et al. 2005b), however whether this cytokine is 
altered during chronic HBV is unclear.   
Previous studies have shown that the ability to induce telomerase in CD8 T cells may 
require a signal from the costimulatory molecule CD28. Consistent with this is the finding 
that telomere length was shorter in CD28-CD8+ compared to CD28+CD8+ T cells 
(Monteiro et al. 1996). Plunkett et al. showed that telomere erosion in highly differentiated 
CD8+CD27-CD28- CD8 T cells was associated with defective AKT phosphorylation 
(Plunkett et al. 2007). hTERT, the catalytic subunit of telomerase, is a substrate for the 
AKT kinase, and itself requires phosphorylation at two sites for its activity. Highly 
differentiated CD8 T cells had a specific defect in phosphorylation of AKT at the Ser 473 
site, and were thus unable to upregulate telomerase. Since in patients with high viral load, 
we have shown that there is an accumulation of CD27 and CD28 negative CD8 T cell 
fractions in patients with high viral load, this mechanism could contribute to impaired 
telomerase upregulation in highly differentiated subsets. In support of this, we found that 
telomere length was shortest within CD27 negative CD8 T cells. Interestingly, PD-1 is 
known to limit AKT activation by inhibiting CD28 mediated activation of PI3K 
(Greenwald et al. 2005). Therefore elevated PD-1 on CD8 T cells in HBV may partially 
contribute also to inhibition of telomerase activity. 167 
 
Loss of telomere length may not always follow a linear progression, and at some points 
during the lifespan of a cell, it may occur sporadically as well. For example, telomeres are 
G-rich sequences, which are highly sensitive to oxidative damage. DNA damage, 
replication errors and failure to repair properly could provide additional stochastic events 
which could accelerate the linear loss of telomere length with ageing (Goronzy et al. 2006). 
Telomere loss has also been observed in other chronic inflammatory disorders including 
Rheumatoid Arthritis (Koetz et al. 2000), SLE (Honda et al. 2001), Psoriasis (Wu et al. 
2000) and Scleroderma. Although this telomere loss may be secondary to chronic antigenic 
stimulation, Artlett et al. showed that telomere erosion was found in patients with 
scleroderma, but also in their family members suggesting that telomere loss could be due 
to genetically imposed chromosome instability (Artlett et al. 1996). In patients with 
rheumatoid arthritis, telomere shortening was found both in naïve and memory T cells, 
indicating that chronic antigenic stimulation was not the only mechanism for telomere loss. 
Finally, Epel et al have provided evidence that chronic emotional stresses can accelerate 
telomere shortening (Epel et al. 2004). These data provide alternative mechanisms for 
global T cell telomere attrition, which could add to the heterogeneity of telomere loss 
within patients and controls. 
In this study we have shown that CD8 T cells from patients with chronic HBV infection 
and high viral load are more differentiated and may have significantly shortened telomeres. 
Although preliminary experiments have not shown any difference in telomerase activity 
between patients and controls, sample sizes were small and it will be worth undertaking 
future studies to determine telomerase activity over the course of HBeAg negative flares of 
HBV, during which we know factors such as IFNα fluctuate and may influence its activity. 
In conclusion, these data imply that CD8 T cells from patients with HBV may have a 
shorter residual lifespan and a greater propensity to replicative senescence, and this could 
partially contribute to their proliferative defects.  
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6 The role of IL-10 producing regulatory B cells in the pathogenesis of CHB 
Background 
In this chapter, we investigate the role of IL-10 in chronic HBV infection in the context of 
viral control and pathogenesis of disease. This cytokine is well known to be immuno-
suppressive and has been shown to modulate T cell responses during bacterial, viral and 
parasitic infection and autoimmune disease. In the setting of CHB, it is feasible that such a 
cytokine mediated suppression could contribute to both the virus specific and pan-CD8+ T 
cell defects we have seen. Thus we investigate the potential impact of IL-10 on the host 
virus interaction in HBV infection. 
6.0.1 Biology of IL-10 
IL-10 was first described as CSIF; a cytokine synthesis inhibitory factor produced by Th2 
clones upon conA/antigen stimulation, which was able to suppress cytokine production 
(IL-2, IL-3, TNF, IFN-γ, GM-CSF) by activated Th1 clones but not Th2 clones (Fiorentino 
et al. 1989). Thus, its reputation as an inhibitory cytokine was established. The mechanism 
by which it exerts its influence on T cells is thought to be twofold; either a) directly 
through binding to IL-10 receptor on T cells (de Waal et al. 1993) or b) indirectly through 
downmodulation of MHC II (de Waal et al. 1991), B7-1/B7-2 expression (Ding et al. 
1993) and chemokine and cytokine production (Berkman et al. 1995;Fiorentino et al. 1991) 
by monocytes, macrophages and dendritic cells leading to impaired antigen presentation to 
CD4 T cells. Either way, this leads to a profound suppression of primarily Th1 cytokine 
production. It should be noted however that IL-10 is pleiotropic in nature, and also serves 
other functions such as induction of proliferation and survival of B cells (Levy & Brouet 
1994;Rousset et al. 1992). 
The molecule itself is 178 amino acids long and binds to its receptor, which is a tetrameric 
structure composed of two IL-10R1 (alpha) chains and two IL-10R2 (beta) chains (Moore 
et al. 2001). IL-10R1 is expressed at very low levels on lymphocytes and is downregulated 
upon activation (Liu et al. 1994). It serves as the docking site for IL-10. IL-10R2 is not 
required for binding but is rather an accessory subunit for signalling. It is expressed 
constitutively on most cell/tissue types (Moore et al. 2001). On binding of IL-10 to its 
receptor, kinases JAK-1 and Tyk2 are activated and tyrosine residues on the intra-
cytoplasmic domain of Il-10R1 chain become phosphorylated. This serves as a docking 169 
 
site for STAT-3 which along with STAT-1 and STAT-5 are phosphorylated by the 
aforementioned JAK kinases. These STAT proteins subsequently form homo/heterodimer 
structures which translocate to the nucleus and drive transcription of STAT-3 responsive 
genes like SOCS-1 and SOCS-3 (Pestka et al. 2004). 
 
 
 
Figure 6a: IL-10 signalling pathway.  STAT-3, signal transducer and activator of 
transcription-3. SOCS-3, suppressor of cytokine signaling-3. Adapted from (Donnelly et al. 
1999). 
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6.0.2 IL-10 in disease 
IL-10 has a dual role in chronic infection. On the one hand, during certain bacterial 
(Kullberg et al. 1998), fungal, viral (Suvas et al. 2004) and parasitic infections (Couper et 
al. 2008;Gazzinelli et al. 1996;Hunter et al. 1997), IL-10 is required to suppress an over-
reactive Th1 response primarily mediated by IFNγ and TNFα. Ablation of IL-10 signaling 
in this setting results in severe immunopathology. On the other hand, mistimed or 
excessive IL-10 production has been shown to dampen both innate and adaptive host 
immune responses against pathogens, and thus promote persistence (Couper et al. 2008).  
Which of these effects is dominant in any particular chronic infection likely depends on the 
source and kinetics of IL-10 production in addition to the pathogen involved. 
To determine indeed whether the kinetics of IL-10 are important in manipulating the 
course of chronic infection, previous studies have tried to address whether IL-10 is the 
cause or consequence of high pathogen burden. However, the data which have been 
published provide convincing evidence for both sides of the argument, further eluding to 
the complex pleiotropic actions of IL-10.  On the one hand, there is evidence that viruses 
such as CMV and EBV produce their own viral homologues of IL-10 which have up to 
84% sequence homology (for EBV) and can bind the human IL-10 receptor (Kotenko et al. 
2000;Moore et al. 1990). In this case, IL-10 may be a viral escape mechanism to dampen 
the host immune response and promote long-term persistence. On the other hand, IL-10 
may be induced secondary to a pathogen insult, as a homeostatic mechanism designed to 
control an excessive inflammatory response against that pathogen. During infection with 
Leishmania major, high pathogenic load drives an excessive Th1 response characterised by 
production of IFNγ. This in turn has been shown to induce the production of IL-10 
producing adaptive T cells at the site, which act in a positive feedback loop to dampen Th1 
responses. Overactivation of IL-10 in this setting, can render Th1 responses ineffective and 
persistently dampen anti-microbial immune responses, resulting in maintenance of 
pathogen burden and prevention of lesion healing (Anderson et al. 2005). 
These studies therefore have attempted to dissect the functions of IL-10 production at 
various stages of disease, and have shown that IL-10 cannot only be assigned one function 
in any particular chronic infection, but rather is involved in striking a fine balance between 
ameliorating immunopathology and impeding pathogen clearance at the same time.  171 
 
6.0.3 IL-10 in chronic viral infection 
The most compelling evidence to show a role for IL-10 in chronic viral infection has been 
provided recently by two independent studies in LCMV infection, which have both shown 
that blockade of the IL-10 receptor is associated with resolution of infection. The mouse 
model of LCMV is a useful tool in the investigation of chronic infection, primarily because 
it is possible to reliably induce either chronic or acute infection depending on the strain of 
virus used, its dose and route of infection. Ejrnaes et al showed that mice infected with the 
Armstrong Clone strain 13 who developed chronic infection produced drastically higher 
amounts of IL-10 than those with acute infection. The source of this IL-10 was primarily 
from CD4 T cells which were thought to be IL-10 primed by CD8alpha negative dendritic 
cells. Blockade of IL-10R in vivo enhanced antiviral IFN-γ responses, reduced IL-10 
secretion and led to resolution of persistent infection with clearance of LCMV in the liver 
and kidneys by approximately 26 weeks (Ejrnaes et al. 2006). In similar experiments, 
Brooks et al. showed that therapeutic administration of an IL-10R blocking antibody 
restored T cell function and resolved established infection. However, as a slight 
contradiction, they suggested that the antigen presenting cells were the direct source of the 
elevated IL-10 seen (Brooks et al. 2006). Furthermore, these findings have been mirrored 
in human studies of HIV (Clerici et al. 1994) and HCV infection in which Rigopoulou et 
al. showed that blockade of IL-10 receptor in vitro enhanced CD4 proliferative responses 
to HCV antigens NS3, NS4 and Core (Rigopoulou et al. 2005).  
 
In support of these findings, genetic studies have also provided an insight into the 
importance of IL-10. In chronic HBV infection, Miyazoe et al. and Cheong et al. have 
independently shown in Japanese and Korean patient cohorts that polymorphisms of the 
IL-10 promoter associated with elevated IL-10 production increase disease severity and 
progression and are associated with viral persistence (Cheong et al. 2006;Miyazoe et al. 
2002). This association is not unique to HBV, and such polymorphism resulting in 
increased IL-10 have also been associated with a negative outcome of HCV infection 
(Knapp et al. 2003). 
The impact of these data provide mixed messages for the development of new therapeutic 
strategies against IL-10. On the one hand blockade of IL-10 in vivo in mice has shown a 
very promising effect on disease resolution. However, translation of this finding into the 172 
 
clinic may prove more difficult. Firstly, as we have learned, IL-10 likely mediates the 
critical balance between ameriolating immunopathology and impeding pathogen clearance. 
Blockade of IL-10 therefore may boost anti-viral immune responses, however tip the 
balance towards a pro-inflammatory state in an otherwise benign infection. Studies by 
Nelson et al. in chronic HCV infection have shown, for example, that long-term IL-10 
therapy reduced ALT and ultimately the incidence of fibrosis, however actually elevated 
the HCV RNA levels in the patients studied (Nelson et al. 2000;Nelson et al. 2003). 
Therefore for the success of IL-10 targeted therapies, it will be critical to choose the 
correct timepoint of drug administration as well as to identify the particular group of 
patients who would be most responsive to it. 
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6.0.4 Source of IL-10 in chronic HBV infection 
IL-10 is produced by mainly cellular sources including dendritic cells, monocytes, 
macrophages, T cells, B cells and NK cells (Couper et al. 2008). In this section, we discuss 
the potential sources of IL-10 in the HBV infected liver which could impact on the course 
of disease. 
6.0.4a Liver resident macrophages and endothelial cells 
The liver is an immunotolerant environment in which there is thought to be a constitutive 
suppression of immune response against gut derived bacterial antigens. In a recent study by 
Tu et al., it was shown that this suppression may be mediated by IL-10 produced by liver 
resident macrophages (Kupffer cells) in response to toll like receptor signals (Tu et al. 
2008a). In support of this theory, it has previously been shown that IL-10 deficient mice 
develop a spontaneous colitis in the absence of IL-10, suggesting that this may mediate a 
similar constitutive suppression against commensal gut bacteria (Kuhn et al. 1993). 
Furthermore, in patients undergoing orthoptic liver transplantation, le Moine et al 
suggested that IL-10 released by the graft could promote immune tolerance (Le Moine et 
al. 1994). Therefore, it is feasible that a single cytokine could alone maintain a strong 
tolerogenic influence on the liver. 
In the study by Tu et al, they showed that Kupffer cells isolated from liver mononuclear 
cells with magnetic beads produced IL-10 in a dose dependent manner in response to TLR 
ligands poly I:C, LTA and LPS. Interestingly, most of the IL-10 was produced following 
stimulation with bacterial products which signal through the MyD88 dependent TLR2 and 
TLR4 pathways, and less IL-10 was produced following signalling through the TRIF 
dependent TLR-3 pathway which is used more by viruses. These findings confirmed those 
previously supported by Knolle et al, who showed that Kupffer cells secreted IL-10 in 
response to LPS most optimally 12-24hours after challenge (Knolle et al. 1995). 
In a later study by Knolle et al, it was further shown that in a transgenic mouse model, 
Liver sinusoidal endothelial cells, but not macrovascular endothelial cells from the aorta, 
could prime naïve CD4+ T cells (with a transgenic receptor specific for influenza virus 
hemagglutinin) towards an IL10+IL4+ Th0 but not Th1 phenotype, which could further 
contribute to IL-10 production (Knolle et al. 1999). 174 
 
6.0.4b Virus specific/regulatory T cells 
Regulatory T cells (Tregs) have been implicated in the control of immune responses. They 
may be subdivided into natural CD4+CD25+FoxP3+ regulatory T cells which develop in 
the thymus, and adaptive regulatory T cells which are generated from naïve T cells in the 
periphery after encounter with antigen presented on dendritic cells with a distinct 
activation status and IL-10 (Mills 2004). Inducible regulatory subsets include CD4+ T 
regulatory 1 (Tr1) cells which predominantly mediate their suppressive function through 
secretion of IL-10 (Groux et al. 1997), and CD4+ T helper 3 (Th3) cells which secrete 
TGF-β (Miller et al. 1992). Another subset of CD8+ regulatory cells which have the 
capacity to release IL-10 and TGF-β have also been identified (Mills 2004). Natural and 
adaptive regulatory T cells differ by the way they mediate suppression of T cell responses. 
Natural regulatory T cells have the capacity to suppress via production of cytokines IL-10, 
soluble and surface bound TGF-β and IL-35 (Vignali et al. 2008), although there is debate 
as to the relative contribution of cytokine secretion in their suppressive action. This is 
highlighted by the fact that allergic inflammation and airway hypersensitivity can still be 
suppressed by transfer of IL-10 deficient natural regulatory T cells (Kearley et al. 2005), 
however in a different study, ablation of regulatory T cell IL-10 exacerbated lung allergic 
inflammation and hyper-reactivity (Rubtsov et al. 2008). The main mode of action for 
these cells is thought to be through contact dependent mechanisms. These include 1) 
engagement of cytotoxic T-lymphocyte antigen 4 (CTLA-4) on regulatory T cells with 
CD80/CD86 on dendritic cells which induces indoleamine 2,3-dioxygenase (IDO), an 
enzyme which catabolises tryptophan and has an immunosuppressive role (Fallarino et al. 
2003) 2) granzyme A/granzyme B/perforin dependent killing (Vignali et al. 2008) 3) direct 
transfer of suppressive cyclic AMP to effector T cells through membrane gap junctions 
(Bopp et al. 2007) 4) consumption of IL-2 by CD25 (high affinity IL-2Rα), resulting in IL-
2 dependent apoptosis (de la et al. 2004) and 5) elaboration of adenosine generated by 
ectoenzymes CD39 and CD73 (Deaglio et al. 2007). Tr1 cells secrete high amounts of IL-
10, no IL-4 and low IL-2 and IFN-γ (Roncarolo et al. 2006). IL-10 released by these cells 
inhibits cytokine production (TNF and IL-12) by dendritic cells and macrophages (Mills 
2004), and also downregulates expression of costimulatory molecules CD80 and CD86 
(Ding et al. 1993). IL-10 can also directly act on effector T cells by binding to IL-10R and 
suppress proliferation and IL-2 production. In the setting of the HBV inflamed liver, Tr1 175 
 
cells may be the more relevant source of IL-10, although natural and adaptive regulatory T 
cells may work together to amplify regulatory function.  
In chronic HBV infection, the frequency and functional characteristics of CD4+CD25+ 
regulatory T cells has been studied in both the periphery and liver of patients. In one 
report, Franzese et al. found no increase in the circulating frequencies of CD4+CD25+ 
regulatory T cells in HBeAg+ immunotolerant patients, as well as no fluctuations with 
treatment induced flares of chronic hepatitis, although they stress that this was a small 
exploratory study in which treatment induced flares may not necessarily represent those 
during disease flares. They did find however that on depletion of Treg populations, there 
was an increase in frequency and functional capability of HBV-specific CD8+ T cell 
responses (Franzese et al. 2005). More recently, Xu et al. performed a larger study in 
which they did find significantly elevated frequencies of CD4+CD25+ regulatory T cells in 
patients with severe HBV infection (>10
7 copies/ml HBV DNA)  compared to healthy 
donors. Furthermore, immunohistochemical staining of paraffin embedded tissue showed 
enrichment of CD4 and Foxp3 (transcription marker expressed on regulatory T cells) on 
liver sections from patients with severe HBV infection suggesting that these cells were also 
enriched within the liver. The frequency of circulating T regs correlated with serum HBV 
DNA levels and were able to suppress proliferation of PBMC following stimulation with 
HBV antigens (Xu et al. 2006). There are now a number of studies which have further 
reproduced the findings of Xu et al in patients with chronic HBV (Peng et al. 2008a;Stoop 
et al. 2005). 
Antigen-induced regulatory T cells can also be generated in the liver and produce IL-10 in 
chronic infection. In chronic HBV infection, Chang et al. showed that following 
stimulation with overlapping peptides spanning the whole HBV genome, there was a 
higher magnitude of intrahepatic CD8 T cells producing IL-10, especially in HBeAg+ 
patients, compared to peripheral CD8 T cells, which were instead skewed towards 
production of Th1 cytokines (Chang et al. 2007). Similarly, an enrichment of virus specific 
IL-10 producing CD8 T cells within the liver has also been observed in chronic HCV 
infection. Accapezzato showed, for instance, that an enriched HCV specific CCR7-CD8+ 
T cell population in the liver suppressed T cell responses via IL-10 production 
(Accapezzato et al. 2004). Indeed, HCV-specific CD8 T cells within the liver have been 
shown to have poor cytolytic ability and are unable to mediate viral control. Instead they 176 
 
may have a protective anti-fibrotic role, as they have been shown to cluster in areas of low 
liver fibrosis and low hepatcellular apoptosis where they might block inflammation by 
bystander T cells via IL-10 (Abel et al. 2006). 
Finally, antigen-induced CD4 T cells may also be induced in a similar way to the CD8 T 
cells. Indeed in both chronic HBV and HCV infections, stimulation of CD4 T cells, in 
HBV by HBcAg (Hyodo et al. 2004), and, in HCV by HCV core protein (MacDonald et al. 
2002), could induce IL-10 production. HBcAg is analogous to HBeAg, the secreted form 
of core protein, which has a short leader sequence cleaved from it. One feature unique to 
CHB is the production of vast amounts of circulating HBeAg, which has no known role in 
viral replication, but may instead have a tolerogenic effect on immune responses (Milich et 
al. 1990). Induction of immunosuppressive IL-10 production by CD4 T cells and other 
mononuclear cells could perhaps contribute to this tolerogenic effect.  
6.0.4c Regulatory B cells 
The antibody-independent function of B cells in regulating immune responses has become 
a recent topic of interest. In 2000, Harris et al. were the first to identify two subsets of B 
cells, B effector 1 (Be1) and B effector 2 (Be2), which produced different panels of 
cytokines, dependent on their initial interaction with antigen and T cells. Be1 cells 
primarily produced IFN-γ, whereas Be2 primarily produced IL-4. Both subsets were able 
to produce IL-10. Importantly, they showed that these cytokine-producing effector B cells 
could regulate the differentiation of naïve CD4 into either Th1 or Th2 helper cells, 
suggesting an important antibody-independent role of B cells in modulating the immune 
system (Harris et al. 2000). Indeed, it is thought that B cells are required for the Th1—Th2 
shift which is required to ameriolate disease pathology following an inflammatory cytokine 
response against Schistosoma mansoni infection. In B cell deficient uMT mice, there was a 
sustained Th1 response against the helminth egg compared to wildtype mice, which 
accelerated granuloma development (Hernandez et al. 1997). 
In addition to influencing the Th1-Th2 shift however, there is now strong evidence mainly 
in murine studies that a population of IL-10 producing B cells, termed ‘regulatory B cells’ 
by Mizoguchi, may regulate immune responses in chronic inflammatory autoimmune, 
infectious and tumor models (Mauri & Ehrenstein 2008;Mizoguchi & Bhan 2006). 177 
 
The most compelling evidence for the existence of regulatory B cells comes from three 
separate murine studies of collagen induced arthritis, EAE and a model of chronic 
intestinal inflammation in the Gut Associated Lymphoid Tissue (GALT).  
Immunisation of transgenic mice with type II collagen in Complete Freund’s adjuvant 
leads to a chronic collagen-induced arthritis, associated with a pathogenic Th1 response. In 
this model, Mauri et al showed that stimulation of B cells with antigen and agonistic CD40 
generated IL-10 producing B cells, which upon transfer into transgenic mice prevented 
arthritis development or ameriolated established disease. B cells isolated from IL-10 
knockout mice, however, had no protective function against arthritis, showing that this 
effect was IL-10 dependent (Mauri et al. 2003). In a followup study, these IL-10 producing 
regulatory B cells were shown to be phenotypically analogous to transitional 2 marginal 
zone precursor B cells (T2-MZP) found in the spleen of naïve mice. Transfer of T2-MZP, 
but not follicular or marginal zone B cells, into immunized DBA/1 mice, suppressed 
antigen-specific T cell responses and significantly prevented new disease and ameriolated 
established disease. T2-MZP from IL-10 knockout mice however could not mediate a 
protective effect (Evans et al. 2007). 
Akin to collagen induced arthritis, a similar protective role has been ascribed to regulatory 
B cells in Experimental Autoimmune Encephalomyelitis (EAE), a paralysing 
demyelinating model of multiple sclerosis. In this setting, antigen-specific IL-10-producing 
regulatory B cells were required for recovery of disease, and the absence of B cells (in 
uMT mice) resulted in severe type 1 autoimmunity. Furthermore, in a bone marrow 
chimeric system in which only B cells but not T cells were deficient in IL-10 production, 
the inflammatory response persisted and impeded recovery. Only transfer of IL-10-
producing regulatory B cells from B6 mice who had recovered EAE could result in 
resolution. Thus regulatory B cells control autoimmunity in this case by dampening pro-
inflammatory responses via IL-10 (Fillatreau et al. 2002). 
Finally, Mizoguchi et al. showed in a model of chronic intestinal inflammation that a 
subset of B cells expressing high CD1d could be induced in the inflammatory environment 
of the GALT and suppressed IL-1 mediated inflammation through IL-10 (Mizoguchi et al. 
2002). In confirmation of this, Yanaba et al have shown that a unique subset of 
CD1d
highCD5+ B cells, which were the main subset producing IL-10 in their CD19 178 
 
overexpressing transgenic mouse model,  normalised T cell mediated inflammation upon 
adoptive transfer into CD19 knockout mice (Yanaba et al. 2008).  
These studies therefore prove at least that B cells can mediate potent regulation of immune 
responses via IL-10 in different murine disease models. Less work has been done in human 
studies and this field is newly developing. However, studies by Duddy et al. have shown 
that IL-10 producing B cells exist in humans, and that they are phenotypically naïve (CD27 
negative), whereas those polarised towards TNF and IFNγ production have a memory 
phenotype (CD27+). This IL-10 production is context dependent though, and can be 
induced in vitro with CD40L stimulation alone, whereas CD40L and BCR dual ligation 
polarised B cells more towards lymphotoxin production (Duddy et al. 2004). Interestingly, 
they showed that in multiple sclerosis, stimulation of B cells with either stimulus produces 
less IL-10 in patients compared to healthy donors. IL-10 production could be recovered on 
mitoxontrone therapy (Duddy et al. 2007). These findings are analogous to the protective 
role attributed to B cells by Fillatreau et al. in EAE (Fillatreau et al. 2002). 
Whether regulatory B cells are protective as suggested by the above studies, or pathogenic 
in the context of chronic viral infection, is yet to be investigated. Studies in patients with 
cancer have shown that B cell depletion therapeutically enhanced anti-tumour immunity 
due to lack of B cell IL-10 (Inoue et al. 2006). In such cases, IL-10-producing regulatory B 
cells may be deleterious to the immune response against the tumour and hence be 
construed as pathogenic. 
6.0.5 Aims 
In this chapter we investigate the role of IL-10 in chronic HBV infection, including its 
ability to modulate anti-viral CD8 T cell responses. Furthermore, we study whether 
regulatory B cells could be a potential source of this cytokine, and thus play a role in 
regulating immune responses in chronic HBV infection. 
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Results 
6.1 IL-10 is raised in the serum of patients with chronic HBV infection 
IL-10 is a pleiotropic cytokine which both protects from immunopathology while at the 
same time can impede pathogen clearance in a number of chronic infectious diseases. To 
determine whether IL-10 plays a role in chronic HBV infection, we first investigated the 
circulating levels of this cytokine in the serum of patients and healthy donors by ELISA or 
with a cytometric bead array (CBA) inflammation kit. As shown in figure 6.1a, IL-10 
levels were significantly raised in patients compared to healthy donors by either assay.  
Furthermore, patients with high viral load and elevated ALT (surrogate marker of liver 
inflammation) had the highest circulating IL-10 levels compared to patients with low viral 
load (vs. DNA p<0.05, vs. ALT p<0.001) and healthy donors (vs. DNA p<0.001, vs. ALT 
p<0.001). IL-10 levels were also determined in 15 patients on anti-viral therapy (for 
varying periods of time), in whom viral load had been suppressed to below quantifiable 
levels. These patients had a significant reduction in serum IL-10 levels compared to those 
with high viral load not on treatment (p<0.01), down to levels seen in controls (fig 6.1b). 
Interestingly, we observed that the mean serum IL-10 level was higher in patients when 
measured by CBA (18.08pg/ml, n=16) compared to ELISA (3.32p/ml, n=34). Although 
this could be due to the CBA being a more sensitive assay, it is more likely this disparity is 
a result of different patient characteristics in the two cohorts. In the CBA cohort for 
instance, 10/16 patients had HBeAg negative chronic hepatitis with raised ALT (>60 IU/l) 
and/or intermediate to high viral load (HBVDNA >10
5 IU/ml) (table 6.1). In clinical terms, 
patients infected with viral variants incapable of expressing HBeAg have a unique course 
of disease, as they are more prone to spontaneous recurrent flares of hepatic inflammation 
associated with fluctuations in viral load (which is not typical of patients with HBeAg 
positive hepatitis). In these patients it is possible to monitor rapid changes in disease 
activity over a condensed timeframe. Out of the six patients with the highest IL-10 in the 
ELISA cohort, 4 had HBeAg negative hepatitis and their levels of IL-10 were comparable 
with those in patients in the CBA cohort. Therefore, the skewing towards higher IL-10 
levels in the CBA cohort may be a true effect dependent on patient characteristics, rather 
than an artefact of assay variability. 
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Figure 6.1: IL-10 is raised in the serum of patients with chronic HBV infection. Serum IL-
10 levels were determined by cytometric bead array (left) or by ELISA (right), and values 
for both healthy donors and patients are shown in (a). (b) Graph to compare serum IL-10 
levels in controls, patients with high viral load (>10
6 IU/ml), and patients with chronic 
HBV currently on treatment. In most cases, treated patients had suppression of virus to 
below quantifiable levels and had normalised their ALT. (*=p<0.05, **=p<0.01, 
***=p<0.001, non-parametric Mann-Whitney U test). 
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Patient DNA 
(IU/ml) 
ALT 
(IU/L) 
HBeAg IL-10 
(pg/ml) 
CHB 1  Blq  34  Neg  1.30 
CHB 2  Blq 57  Neg 0.00 
CHB 3  160  39  Neg  0.00 
CHB 4  440  23  Neg 3.01 
CHB 5  850  22  Neg  0.00 
CHB 6  870  28  Neg 1.06 
CHB 7  1400  30  Neg  3.02 
CHB 8  1400  56  Neg 0.73 
CHB 9  4100  42  Neg  0.20 
CHB 10  7100  50  Neg 1.01 
CHB 11  7800  73  Neg  17.19 
CHB 12  40000  24  Neg 0.70 
CHB 13  72172  405  Neg  2.65 
CHB 14  170000  56  Neg 0.58 
CHB 15  250000  48  Neg  1.08 
CHB 16  418571  116  Neg 6.96 
CHB 17  730000  102  Pos  2.68 
CHB 18  770000  33  Neg 0.00 
CHB 19 *  1100000  151  Neg  6.36 
CHB 20  1127317  189  Neg 2.81 
CHB 21  1400000  58  Pos  0.00 
CHB 22  2000000  69  Pos 3.29 
CHB 23 *  3800000  158  Neg  3.89 
CHB 24  12000000  73  Pos 1.16 
CHB 25  30000000  54  Pos  2.57 
CHB 26  35000000  89  Pos 2.29 
CHB 27  67000000  96  Pos  2.36 
CHB 28  110000000  24  Pos 3.00 
CHB 29  160000000  156  Pos  3.13 
CHB 30 *  160000000  125  neg 10.29 
CHB 31  160000000  54  pos  7.01 
CHB 32  166000000  64  pos 2.98 
CHB 33 *  320000000  77  pos  2.49 
CHB 34 *  510000000  206  pos 17.15 
T1  19  26  neg  0.88 
T2  37  50  pos 0.33 
T3  43  51  pos  0.03 
T4  1615  38  neg 1.67 
T5  2000  17  neg  0.00 
T6  26621  47  pos 1.50 
T7  Blq  16  neg  0.00 
T8  Blq 17  neg 0.00 
T9  Blq  42  neg  1.28 
T10  Blq 30  neg 0.00 
T11  Blq  25  neg  3.96 
T12  Blq 30  neg 6.23 
T13  Blq  37  neg  0.00 
T14  Blq 17  pos 0.00 
T15  Blq  24  pos  1.51 
        Serum IL-10 was determined in these patients by ELISA. 182 
 
Subject HBV  DNA 
(IU/ml) 
ALT 
(IU/L) 
HBeAg IL-10 
(pg/ml) 
CHB 35 *  13250  81  neg  14.8 
CHB 36 *  175000  403  neg 74.8 
CHB 37  397500  42  neg  10.5 
CHB 38 *  510000  472  neg 7.9 
CHB 39 *  552500  75  neg  5.3 
CHB 40  2105000  368  neg 12.4 
CHB 41  12875000  314  neg  53.7 
CHB 42 *  33750000  880  neg 26.9 
CHB 43 *  35250000  432  neg  9.1 
CHB 44  450000000  207  neg 7.2 
CHB 45  -  -  -  14.2 
CHB 46  - -  -  31.9 
CHB 47  -  -  -  3.6 
CHB 48  - -  -  2.4 
CHB 49  -  -  -  2.2 
CHB 50  - -  -  12.4 
    Serum IL-10 was determined in these patients by CBA. 
 
Table 6.1 Clinical characteristics of patients in whom IL-10 levels were measured in serum 
by ELISA (above table) and by cytometric bead array (bottom table). * = serum samples 
from these 11 individuals were collected at multiple timepoints, and longitudinal 
fluctuations in IL-10 are shown in fig 6.2. CHB = chronic HBV infection. T = on 
treatment. 
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6.2 Temporal correlation between serum IL-10 and flares of chronic liver disease 
In order to dissect further the relationship between IL-10 and viral load/ALT, serum 
samples were collected at multiple timepoints before, during and after chronic flares of 
HBeAg negative HBV in 9 patients and in 2 patients with HBeAg positive hepatitis 
(patients CHB 34 and CHB 33) and IL-10 was measured. Graphs in figure 6.2 show that in 
most cases, IL-10 peaked at a time point when both viral load and ALT were elevated; 
sampling was not frequent enough to distinguish with which it was more closely 
temporally correlated. However, in at least some cases, peaks in IL-10 clearly coincided 
with viral load and preceded liver inflammation (patients CHB 33 + CHB 43) or 
alternatively peaked with liver inflammation alone (patient CHB 36). Therefore these data 
imply that both ALT and viral load may be intimately associated with IL-10 levels. Only a 
study with more frequent sampling timepoints over the progression of a flare could perhaps 
detail any further subtle temporal correlations. 
In addition to these findings, we have also observed that in some cases, IL-10 was induced 
in response to increased inflammation (patients CHB 19, CHB35 and CHB 38) suggesting 
that in the context of HBV, it may be required as a physiological brake to attenuate an 
overactive immune response. However, this was not demonstrated in all individuals, as in 
other cases, IL-10 levels peaked before, and coincided with, the rise in ALT.  184 
 
 
Figure 6.2: Temporal correlation between serum IL-10 and chronic flares of liver disease. 
IL-10 levels were measured in serum samples collected before, during and after chronic 
flares of liver disease in 11 patients with chronic HBV. A graph for each patient shows the 
temporal longitudinal fluctuations in IL-10 (blue), in association with viral load (green) 
and ALT of the patient (pink). 185 
 
6.3 Elevated supernatant IL-10 from PBMC in patients with high viral load 
In order to investigate the capacity of peripheral blood mononuclear cells to produce IL-10 
in chronic HBV, PBMC were stimulated with mitogens PMA and ionomycin for 5 hours 
and supernatants were harvested for ELISA. As shown in figure 6.3, there was a trend 
towards a progressive increase in IL-10 production by PBMC taken from patients with 
increasing viral load. PBMC from patients with high viral load (>10
6IU/ml) produced 
significantly more IL-10 than those from healthy donors (p<0.05).  
 
Subject HBV  DNA 
(IU/ml) 
ALT 
(IU/L) 
HBeAg 
CHB 52  Blq  24  Neg 
CHB 53  Blq 18  Neg 
CHB 54  Blq  34  Neg 
CHB 1  Blq 34  Neg 
CHB 6  870  28  Neg 
CHB 12  40000  24  Neg 
CHB 14  170000  56  Neg 
CHB 11’  320000  96  Neg 
CHB 55  1000000  474  Neg 
CHB 33’  19000000  65  Pos 
CHB 56  20000000  83  Pos 
CHB 25  30000000  54  Pos 
CHB 26  35000000  89  Pos 
CHB 27  67000000  96  Pos 
CHB 28  110000000  24  Pos 
CHB 17  130000000  193  Pos 
CHB 30  160000000  125  Neg 
CHB 34’  310000000  249  Pos 
CHB 57  330000000  39  Pos 
 
Table 6.2 Clinical characteristics of patients used in graph 6.3. An (‘) beside a patient code 
denotes that a different sampling timepoint has been studied, compared to a previous assay.  
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Figure 6.3: Elevated supernatant IL-10 from PBMC in patients with high viral load. PBMC 
from patients and controls were stimulated for 5 hours with PMA and ionomycin, and 
supernatants were analysed for IL-10 content by ELISA.  Graphs show the mean IL-10 in 
supernatant in controls (n=9), patients with low viral load (<10
6 IU/ml) (n=8) and patients 
with high viral load (>10
6 IU/ml) (n=11). (*=p<0.05, non-parametric Mann-Whitney U 
test). 187 
 
6.4 IL-10 producing B cells are enriched in patients with CHB 
Recent studies have shown that IL-10 producing B cells can regulate immune responses in 
chronic inflammatory disorders. In order to identify whether such a population may exist in 
chronic HBV infection, PBMC were stimulated with either CpG type B or HBV surface 
and core antigens for 4 days. IL-10 producing B cells were then detected by intracellular 
cytokine staining after a further short incubation with PMA/ionomycin. A representative 
dot plot in figure 6.4a shows the frequency of IL-10 producing B cells following CpG 
stimulation in a typical HBV carrier. Upon this particular stimulation, the majority of IL-
10 produced was from CD19+ B cells. On cross-sectional analysis, there was a mean 5 fold 
increase in the frequency of IL-10 producing B cells in patients with low or high viral load 
compared to controls (p<0.001). No difference was observed however between patients 
with low and high viral load, in contrast to serum IL-10 levels and PBMC IL-10 
production which were both elevated in patients with high viral load. These data suggest 
therefore that the enriched fraction of IL-10 producing B cells may partially contribute to 
the regulatory framework in HBV infection, however it is likely that other cellular sources 
of IL-10 also contribute. 
During HBV infection, large quantities of HBsAg and HBeAg (the secreted form of HBV 
core antigen) are secreted, and are present in milligram concentrations in the serum. 
HBeAg has no discernible role in virus replication or binding, but instead, has been linked 
with tolerance of T cell responses (Milich et al. 1990), and has been shown to bind to 
lymphocytes including B cells (Cao et al. 2001). To determine whether antigen specific-B 
cells were a source of IL-10, PBMC were also stimulated with HBV core and surface 
antigens with a similar protocol. No IL-10 production was observed with surface antigen 
either by intracellular staining or by ELISA following positive magnetic bead separation of 
CD19+ B cells (data not shown). However, stimulation with core antigen alone or in 
combination with a co-stimulus CD40L was able to induce single positive IL-10 producing 
or TNF-α producing B cells (fig 6.4c). These data highlight the potential therefore for B 
cells in vivo to respond to circulating HBV antigens which could induce IL-10 production.  
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Subject HBV  DNA 
(IU/ml) 
ALT 
(IU/L) 
HBeAg  B cell IL-
10 
CHB 1  Blq  34  Neg  2.81 
CHB 54  Blq 34  Neg 1.19 
CHB 59  Blq  32  Neg  1.04 
CHB 58  160  39  Neg 2.39 
CHB 60  360  not done  Neg  5.87 
CHB 5  850  22  Neg 2.75 
CHB 6  870  28  Neg  2.97 
CHB 8  1400  56  Neg 0.94 
CHB 9  4100  42  Neg  2.27 
CHB 10  7100  50  Neg 3.95 
CHB 11  7800  73  Neg  3.45 
CHB 12  40000  24  Neg 3.97 
CHB 15  250000  48  Neg  3.11 
CHB 55  1000000  474  Neg 1.13 
CHB 22  2000000  69  Pos  3.26 
CHB 33*  19000000  65  Pos 0.91 
CHB 27*  24000000  61  Pos  7.282 
CHB 25  30000000  54  Pos 5.18 
CHB 28  110000000  24  Pos  2.46 
CHB 32*  120000000  76  Pos 3.67 
CHB 17*  130000000  193  Pos  1.96 
CHB 30  160000000  125  Neg 2.05 
CHB 34*  310000000  249  Pos  1.64 
CHB 24*  not done   76  Pos 1.49 
 
Table 6.3 Clinical characteristics of patients studied in figures 6.4 – 6.10.    189 
 
         
 
Figure 6.4: IL-10 producing B cells are enriched in patients with CHB. In order to analyse 
the frequency of IL-10 producing B cells, PBMC were stimulated for 4 days with CpG 
(PMA/ionomycin was added for the last 4 hours) and IL-10 production in CD19+ B cells 
was determined by flow cytometry a) representative dot plot to show the frequency of 
CD19+IL-10+ cells in a low level carrier (HBV DNA<10
6IU/ml). Cross-sectional data is 
summarised in (b) (***=p<0.001, non-parametric Mann-Whitney U test). c) Dot plots 
show IL-10 and TNF-α production in CD19+ gated B cells from a typical low level carrier, 
upon stimulation with HBV core antigen (HBcAg) alone or in combination with CD40L or 
CpG. 190 
 
6.5 IL-10 producing B cells are phenotypically naïve 
Dependent on expression of surface markers CD24 and CD38, peripheral B cells can be 
further subdivided into antigen naïve B cells (transitional and mature) and memory B cells 
(Carsetti et al. 2004). To investigate the phenotypic characteristics of IL-10 producing B 
cells, we next surface stained PBMC with the above markers prior to intracellular staining. 
As shown in figure 6.5, the majority of IL-10 producing CD19+ cells were transitional or 
mature, however only a small proportion were memory. This is consistent with 
observations by Duddy et al. who showed only CD27- human B cells produced IL-10, 
whereas CD27+ memory cells were skewed toward production of Th1 cytokines (Duddy et 
al. 2007). Furthermore, this data is supported by murine studies which have shown that 
transitional 2 marginal zone precursor B cells (phenotypically similar to human transitional 
B cells) but not follicular B cells were able to suppress collagen induced arthritis 
dependent on IL-10 production (Evans et al. 2007).  
As an alternative to markers CD24 and CD38, human transitional B cells also express 
CD21, CD23 and L-selectin and are CD10 negative (Carsetti et al. 2004). These additional 
phenotypic markers may further help to differentiate this population from the other B cell 
subsets. 
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Figure 6.5: IL-10 producing B cells are phenotypically naive (mature and transitional). 
CD19+ B cells can be subdivided into three phenotypic groups dependent on their 
expression of surface markers CD24 and CD38; transitional (CD24
high, CD38
high), mature 
(CD24
dull, CD38
dull) and memory (CD24
high, CD38
dull). Transitional and mature 
populations are the naïve subsets. A representative dot plot for a high level carrier gated on 
CD19+ B cells shows the phenotypic distribution of IL-10 positive B cells (black dots) 
overlayed over IL-10 negative B cells (red dots) upon overnight stimulation (16hours) with 
CpG.  
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6.6 Transitional B cells are enriched in the periphery of patients with CHB and 
correlate with disease flares 
Having characterised IL-10 producing B cells as naïve, we next determined whether the 
proportions of naïve and memory subsets were altered in patients with HBV (n=22) 
compared to healthy donors (n=14). As shown in figure 6.6a, on average twice as many 
transitional cells, but not mature or memory, were significantly enriched in patients 
compared to controls (p<0.001), and a similar trend was observed ex vivo (data not 
shown). This is despite the fact that CpG has previously been shown to drive transitional 
cells towards a memory phenotype (Capolunghi et al. 2008). To confirm that enrichment of 
transitional cells was specific to chronic HBV infection, we analysed the ex vivo frequency 
of these cells making use of serially stored PBMC samples collected over the course of 
flares of chronic HBV (fig. 6.6b).  In two out of three patients, the proportion of 
transitional B cells correlated temporally with liver inflammation (patient CHB 33) and 
both liver inflammation and viral load (patient CHB 30). No fluctuation was observed in 
patient CHB 34, an HBeAg positive patient with persistently high viral load and ALT 
sustained at levels greater than 4 times the upper limit of normal (ie.>200IU/l). However, 
in this patient, the proportion of transitional B cells consistently accounted for 5-8% of the 
total B cells, which was almost double the normal range reported in human studies (3-4%) 
and found in patients CHB 33 and CHB 30. Therefore, this maintained elevated 
transitional cell proportion could also be a reflection of disease. No temporal correlations 
with viral load or liver inflammation were observed with memory, mature or total B cell 
populations.  193 
 
       
 
Figure 6.6a: Transitional B cells are enriched in the periphery of patients with CHB. 
Graphs show the proportions of the different peripheral B cell subsets in patients with CHB 
vs. healthy donors. A representative example dot plot from a patient illustrates the 
distribution of CD19+ cells into 3 phenotypic groups dependent on surface expression of 
markers CD24 and CD38. (***=p<0.001, non-parametric Mann-Whitney U test). 194 
 
 
 
Figure 6.6b: Ex vivo frequencies of transitional cells correlate with disease flares. Graphs 
show the longitudinal fluctuations in the proportions of the different B cell subsets over the 
course of HBeAg negative flares in patients CHB 33 and CHB 30, and over the timecourse 
of disease in a patient with HBeAg positive disease (patient CHB 34). 
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6.7 IL-10 producing B cells display a CD24
highCD38
high transitional phenotype during 
peak of disease flares 
We observed that transitional cells are enriched during chronic flares of disease. Whether 
these new transitional cells are able to produce IL-10 or not however was unclear. To 
confirm this, we analysed the frequency of IL-10+ transitional cells longitudinally in 
flaring patients both ex vivo and following overnight stimulation with CpG. In fig 6.7a, 
representative dot plots illustrate the phenotype of IL-10 producing cells (black dots) 
overlayed over IL-10 negative B cells (grey dots) at various timepoints over the course of a 
flare in 1 patient with HBeAg negative chronic hepatitis. In this patient, during the peak of 
viral load, all IL-10 producing B cells clustered together in the transitional cell gate or at 
the margin between mature and transitional cells. At all other timepoints, this population 
was heterogenous in terms of its phenotype. Furthermore on stimulation with CpG, not 
only was there an enrichment of transitional cells during the peak of viral load, but there 
was also an enrichment of IL-10 production within these cells. Indeed, although the 
transitional cells represented only 12.4% of the total B cells, they accounted for 21.8% of 
the total IL-10 producing cells at this timepoint (fig 6.7b). Interestingly, no correlation in 
mature B cell IL-10 production was observed during disease, and indeed during the peak of 
viral load the production of mature cell IL-10 was lowest. These data suggest that the 
transitional subset which fluctuates with disease may be the putative regulatory subset in 
chronic HBV infection, although it is important to note that not all transitional cells 
produce IL-10, therefore other as yet unknown markers may be required to further 
differentiate the true regulatory B cell subset. 196 
 
                      
Figure 6.7: IL-10 producing B cells display a CD24
highCD38
high phenotype during disease 
flares. Dot plots show the phenotypic characteristics of IL-10 producing B cells over 
multiple timepoints during an HBeAg negative flare of disease in a representative patient 
either a) ex vivo or b) following overnight (16hour) stimulation with CpG. The gate 
applied in (a) encompasses both the CD24
highCD38
high transitional cells, as well as a subset 
of B cells at the mature/transitional border. IL-10 producing B cells (black dots) are 
overlayed on top of IL-10 negative B cells (grey dots). In (b), gates have been drawn to 
show the different phenotypic B cell subsets subdivided by CD24 and CD38 expression. 
Numeric values corresponding to each gate represent the proportion of CD19+IL-10+ cells 
which are of that subset. Red dots = IL-10 negative B cells; Blue dots = IL-10 positive B 
cells. 197 
 
 
6.8 Transitional B cells are present in an HBV liver 
Impairment in CD8+ T cell responses are most pronounced within the liver environment, 
the site of HBV replication. To investigate the potential of B cells to regulate immune 
responses in this setting, paired samples of peripheral blood and intrahepatic lymphocytes 
were obtained from two patients with CHB and the proportion of total and transitional B 
cells was quantified. As shown in a representative patient in 6.8, the proportion of 
transitional B cells was similar in the blood (6.37% of B cells) and liver (5.23% of B cells), 
although the total B cell proportion was lower in the liver (8.76% of lymphocytes) 
compared to blood (14.7% of lymphocytes). This is in concordance with data by Norris et 
al, who showed that the mean percentage of B lymphocytes in 10 healthy livers studied 
was 6.1% (Norris et al. 1998). These data therefore show that transitional B cells are 
present in the liver and have the potential to exert regulatory function. As a limitation to 
this study, we have only so far analysed the intrahepatic B cell compartment in livers 
obtained from patients with low viral load and no liver inflammation. As we have shown 
previously, serum IL-10 levels as well as ex vivo circulating transitional B cell frequencies 
are often at baseline levels between disease flares. Therefore, to get a true representation of 
the role of B cells in the liver, further study is required to study liver samples collected at 
timepoints of high viral load and liver inflammation, at which point we know that there is a 
non-specific cellular infiltrate into the liver and, in the periphery at least, an enrichment of 
ex vivo transitional cell frequencies and serum IL-10 production. 198 
 
 
 
Figure 6.8: Transitional B cells are present in an HBV liver.  Dot plots are shown to 
illustrate the proportions of total and mature/memory/transitional B cells in the periphery 
and liver of a representative patient with low viral load (right panels) following dual gating 
on lymphocyte and CD19+ populations. 199 
 
6.9 Depletion of B cells enhances virus specific CD8 T cell responses 
To determine whether B cells regulate CD8 T cell function, we initially studied the impact 
of depletion of the total B cell population on the magnitude of CD8 T cell responses 
against a variety of HLA-A2 restricted viral peptides. Shown in figure 6.9.1a are 
representative examples of CMV, EBV, FLU and HBV pool responses from a healthy 
donor, patient with low viral load and patient with high viral load. Upon depletion of B 
cells, there was a marked recovery of CD8 T cell responses to flu peptide in all 3 subjects, 
however in individual cases CMV, EBV and HBV pool responses were also significantly 
recovered. These data may suggest therefore that B cells maintain a constitutive low level 
suppression of virus specific T cell responses. Indeed, as shown in figure 6.9.1b, when B 
cells were added back to CD19 depleted PBMC, there was a dose dependent suppression 
of the CD8 T cell response against CMV peptide in a healthy donor. 
An impairment of the CD8 T cell response to peptide stimulation due to addition of B cells 
could be due two potential mechanisms. Either 1) addition of extra lymphocytes during 
culture increases competition for space and nutrients, therefore limits the expansive 
capacity of virus specific CD8 T cell responses or 2) a population of B cells actively 
suppresses virus specific responses. The putative regulatory transitional B cells could 
potentially mediate this latter effect. 
To determine more specifically whether transitional regulatory B cells could dampen virus 
specific CD8 T cell responses, the above experiments were repeated with the exception 
that only transitional B cells were depleted. Since we have observed previously that during 
disease flares, there is a cluster of IL-10 producing B cells at the mature-transitional border 
(fig 6.7a), we extended our gate slightly during cell sorting to further deplete this 
intermediate population also. To do this, PBMC from three HLA-A2 positive patients were 
stained for surface markers CD24, CD38 and CD19 and cells were then passed through a 
cell sorter. By manually drawing a gate encompassing both the CD24
highCD38
high and 
intermediate populations, these cells could be selectively depleted from the whole PBMC 
population. Dot plots in figure 6.9.2a show the gating strategies used to subdivide the B 
cell populations. The purity of the transitional cell depleted PBMC fraction is shown in 
6.9.2a (right panel). Upon cell sorting, only a small fraction of transitional cells remained 
(1.67% of total B cells) compared to whole PBMC (30.9% of total B cells) from the same 
individual passed through the cell sorter as a control. 200 
 
As shown in 6.9.2b, depletion of transitional cells resulted in nearly a 4 fold increase in the 
magnitude of the CD8 T cell response to a pool of HBV peptides in one patient (from 
0.06% to 0.23%). Interestingly, there was no significant recovery of CMV response in the 
same individual.  When transitional cells were added back (unstimulated or following short 
term activation with PMA/ionomycin for 5 hours) to depleted PBMC in a 1 
(Transitional):4 (PBMC) ratio, in all three patients, there was a notable suppression of the 
HBV-specific response. Furthermore, in patient 3, transitional cells were added back to 
PBMC without prior stimulation and still suppressed HBV-specific CD8 T cell responses. 
On simultaneous blockade of IL-10 and its receptor, this suppression was partially relieved 
(fig 6.9.2c). Although further experiments are required to increase the sample sizes and 
confirm these findings, these preliminary data at least suggest that transitional cells may 
have the capacity to suppress HBV-specific CD8 T cell responses by IL-10. 201 
 
      
 
Figure 6.9.1: Depletion of B cells enhances virus specific CD8 T cell responses. PBMC 
from a healthy donor, patient with low viral load and patient with high viral load were 
depleted of CD19+ B cells via positive magnetic bead selection, and CD8 T cell responses 
to different viral peptides were determined by IFN-γ production with or without CD19+ B 
cells present. a) Graphs show the change in frequency of virus specific CD8 T cell 
responses upon depletion of B cells following stimulation with either a pool of HBV 
peptides, or those towards CMV, EBV or FLU. Green bars represent an increase in 
response upon CD19+ depletion. Red bars represent a decrease or no change in the 
response. b) CD19+ B cells were then titrated back at increasing concentrations onto 
PBMC and the effect on the CD8 T cell response to CMV in a healthy donor was 
measured. 
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Figure 6.9.2: Suppression of HBV-specific CD8 T cell responses by transitional B cells. 
PBMC from HLA-A2 positive donors were depleted of CD24
highCD38
high transitional B 
cells using cell sorting. a) A representative dot plot shows the gates used to separate the 
different subsets and the purity of the cell sort in a representative patient with low viral 
load. b) PBMC were stimulated with a pool of HBV peptides and the frequency of IFNγ 
producing cells was determined after 10 days of culture with or without the presence of 
transitional cells; (left- PBMC alone, middle-PBMC depleted of transitional B cells,right-
PBMC:transitional at a 4:1 ratio). Background values derived from the unstimulated 
control samples were subtracted. c) Summary data shows the effect of transitional cell 
depletion/addition on the HBV-specific CD8 T cell responses in two patients with CHB 
(left side). An example of the effect of transitional cell depletion on CMV-specific 203 
 
responses is shown on the right side for patient 1. d) flow cytometric dot plots show the 
effect of adding back in unstimulated transitional cells (Tr.) on HBV-specific CD8 T cell 
responses, with or without IL-10 blockade. 204 
 
6.10 IL-10 blockade preferentially rescues HBV specific T cell responses 
Regulatory B cells modulate immune responses primarily through production of 
immunosuppressive IL-10. To investigate what impact IL-10 may have on virus specific 
CD8 T cell responses, PBMC from HLA-A2+ individuals were isolated and stimulated 
with viral peptides (CMV, FLU or HBV peptide pool) in the presence or absence of anti-
IL10 or anti-IL-10 receptor. Following short term in vitro culture, the magnitude of virus-
specific responses was then quantified as the number of IFN-γ-producing CD8 T cells. 
Upon stimulation with a pool of HBV peptides, there was little response above background 
in patients with high viral load (range 0-0.27%) (representative example of high level 
carrier shown in 6.10a, summary data; 6.10b). This is fitting with previous data which have 
characterised profound qualitative and quantitative defects within HBV-specific CD8 T 
cells (Boni et al. 2007;Maini et al. 2000). Upon addition of anti-IL-10 alone, HBV specific 
responses were rescued in 2/4 low level carriers and 4/7 high level carriers. In four 
individuals, blockade of IL-10 revealed new HBV-specific CD8 T cell responses which 
were previously undetectable. This data implies that certain populations of HBV-specific 
CD8 T cells, which were previously thought to be deleted in patients with high viral load, 
may instead have been present in the circulation under a state of constitutive tolerance 
induced by IL-10. IL-10 blockade was also able to rescue responses to other viral peptides 
(CMV and FLU) in patients with high viral load. 
Interestingly, in resolved individuals there was a preferential rescue of HBV-specific CD8 
T cell responses, whereas no CMV or FLU responses from the same individuals were 
rescued. This may suggest that HBV-specific CD8 T cell responses were preferentially 
sensitive to the effects of IL-10. This may be because of differential expression of IL-10R 
on their surface or because the HBV-specific responses tended to much lower than both 
CMV and FLU responses, and thus lower concentrations of IL-10 were sufficient for their 
suppression. From our data, we have found that IL-10 levels in resolved individuals 
resembled that of controls (data not shown), therefore the fact that IL-10 blockade can still 
rescue HBV-specific responses suggests a greater propensity of these cells to respond to 
this cytokine. To determine whether certain specificities of HBV-specific CD8 T cells 
were more susceptible than others to the effects of IL-10, IL-10 blocking experiments were 
carried out following stimulation of PBMC with overlapping peptides spanning the whole 
HBV genome. Shown in figure 6.10c are data from two patients with high viral load. In 205 
 
both these individuals, there was preferential rescue of responses against X and P1 peptide 
pools, and not against other pools (e.g. Core and envelope) encompassing 
immunodominant HBV epitopes.  A further cross-sectional study is required  to elaborate 
on these preliminary suggestive findings. 
To induce a more complete blockade of IL-10, PBMC were also treated with anti-IL-
10Receptor in addition to anti-IL-10. The effect on HBV responses in both resolved and 
chronic individuals is summarized in 6.10d. Upon blockade of IL-10 and its receptor 
together, in 4/7 CHB patients, there was a profound synergistic effect on HBV-specific 
responses. Therefore, these data confirm that IL-10 can potently suppress HBV specific 
CD8 T cell responses and may thus impede virus control. 
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Figure 6.10 Blockade of IL-10 rescues virus specific CD8 T cell responses. PBMC from 
HLA-A2 individuals were stimulated with viral peptides to CMV, FLU and a pool of HBV 
peptides with or without blockade of IL-10 and its receptor. a) Representative example of 
CD8+IFN-γ responses to HBV pool are shown for a high level carrier. b) cross-sectional 207 
 
data summarises the change in frequency of CD8+IFN-γ cells upon IL-10 blockade alone. 
(hc=healthy control, r=resolved, l=low viral load, h=high viral load. In all cases green bars 
represent rescue of response and red bars represent no change or decline of responses upon 
IL-10 blockade. c) PBMC from two patients were stimulated with pools of overlapping 
peptides spanning the HBV genome and the effect of IL-10 blockade is shown for each 
response d) PBMC were additionally treated with anti-IL-10R along with anti-IL-10 in 2 
resolved and 7 patients with CHB. The effects of dual blockade is shown. 
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Discussion 
In this study we found that IL-10 was raised in the circulation of patients with CHB, and its 
levels correlated temporally with flares of disease in patients with HBeAg negative 
disease. Blockade of IL-10 in vitro was able to rescue virus-specific CD8 T cell responses 
to different viral peptides (CMV, FLU, HBV pool) in patients with high viral load 
suggesting a functional suppressive role for this cytokine on the immune response. 
Furthermore, we showed that regulatory B cells were a potential source of this IL-10, as 
they were enriched in patients with CHB compared to controls upon CpG stimulation. 
Upon phenotypic characterisation, these B cells were dispersed between the mature and 
transitional B cell subsets, however only the transitional B cells were shown to correlate 
temporally with chronic flares of disease in patients with HBeAg negative hepatitis, 
suggesting that these were the putative regulatory subset in CHB. Indeed, preliminary data 
showed that selective depletion of these cells rescued CD8 T cell responses to HBV 
peptides confirming that these transitional IL-10 producing B cells could suppress and 
regulate CD8 T cell responses, at least in vitro. These data suggest that IL-10 from 
regulatory B cells may impede virus control in chronic HBV, and in this setting be 
pathogenic. 
IL-10 is a pleiotropic cytokine which regulates immune responses during bacterial, 
parasitic and viral infections (Couper et al. 2008). The overall effect it has on the outcome 
of disease depends on the timing of secretion and the pathogen involved. In Toxoplasma 
gondii infection, blockade of IL-10 signalling results in severe immunopathology due to an 
overzealous Th1 pro-inflammatory response mediated by IFN-γ and TNF-α (Gazzinelli et 
al. 1996). Conversely, during infection with LCMV in mice, blockade of IL-10R is able to 
ameriolate disease and leads to resolution of infection (Brooks et al. 2006;Ejrnaes et al. 
2006). Therefore by maintaining a fine balance between protection from immunopathology 
and impedance of viral control, IL-10 can have a potent effect on the ultimate outcome of 
disease.  
To investigate the role of IL-10 in chronic HBV infection, we first compared the 
circulating serum levels in patients and healthy donors in a cross-sectional study. From 
these data, we found that IL-10 was raised in patients, and furthermore its levels correlated 
with viral load and liver inflammation. Further possibilities for differences in IL-10 could 
be related to genetic factors such as polymorphisms associated with elevated IL-10 209 
 
production (Cheong et al. 2006;Miyazoe et al. 2002), however, the dynamic temporal 
changes in serum IL-10 we have seen over condensed periods of disease activity, are 
against this interpretation. 
To dissect the kinetics of this IL-10 production, we next studied the longitudinal 
fluctuations of this cytokine over the course of hepatic flares in patients with HBeAg 
negative hepatitis. These individuals are susceptible to recurrent spontaneous flares of 
hepatic inflammation, which provides a window of opportunity to study rapid fluctuations 
of disease over a condensed timeframe. This analysis revealed a strong temporal 
correlation between IL-10 and both viral load and ALT in the majority of patients studied. 
Interestingly, as ALT and viral load peaked appeared to peak simultaneously during flares 
of disease in most individuals, it was hard to determine which variable the IL-10 was most 
closely linked to. On the one hand, at least in some cases, IL-10 levels correlated better 
with liver inflammation whilst viral load was relatively static. In this setting, one could 
hypothesize that induction of IL-10 could be a protective strategy by the immune response 
to protect from immunopathology. During infection with Trypanosoma cruzi for example, 
inoculation of IL-10 knockout mice with the virulent Tulahuen strain resulted in early 
mortality associated with CD4+ T cells and IL-12-mediated immunopathology. This effect 
could be reversed by administration of recombinant IL-10, showing its protective role in 
this case. (Hunter et al. 1997).  On the other hand, in two cases, IL-10 levels peaked with 
viral load preceding the flare in ALT. This suggested a closer correlation with viral factors. 
In support of this, we showed that upon anti-viral therapy and suppression of viral load to 
low/below quantifiable levels in all 15 of our treated subjects, there was a return of IL-10 
levels to baseline. Based on this potential association between IL-10 levels and viral load, 
it is tempting to suggest that IL-10 may be a viral escape mechanism in this case. In 
support of this theory, CMV and EBV viruses have been shown to produce their own IL-
10, with up to 84% sequence homology to that in humans (Kotenko et al. 2000;Moore et 
al. 1990) that can bind the human IL-10 receptor and may therefore directly subvert anti-
viral immune responses. Furthermore, studies in HBV and HCV infection have suggested 
that HBV core and HCV NS4 antigens themselves induce IL-10 production from 
peripheral blood leucocytes, which could help to suppress immune responses (Brady et al. 
2003;Hyodo et al. 2003;Hyodo et al. 2004). Finally, preliminary data from our group 
(Dunn et al. unpublished) have shown that in early acute pre-symptomatic HBV infection, 
there is a peak in IL-10 production associated with the rise in viraemia preceding onset of 210 
 
liver inflammation. Although the cellular source of this IL-10 is still to be investigated, it is 
tempting to hypothesize that perhaps an active IL-10 mediated suppression of the innate 
immune response may be an early viral evasion strategy. These data suggest that both liver 
inflammation and viral load may have an important role in IL-10 induction. Perhaps 
comparison of these patients with a cohort of individuals with non-viral liver disease with 
the presence of liver inflammation could further help to define these associations. 
In this study we have investigated the role of regulatory B cells as a potential source of IL-
10 production in CHB. These regulatory B cells have been shown in murine models of 
chronic inflammation to suppress T cell responses either directly or indirectly through 
interference with APC function (Moore et al. 2001). Depletion of these regulatory B cells 
resulted in exacerbation of Th1 type inflammatory cascades in collagen induced arthritis 
(Mauri et al. 2003) and EAE (Fillatreau et al. 2002) and  IL-1 dependent inflammatory 
cascades in the GALT of mice with chronic intestinal inflammation (Mizoguchi et al. 
2002). Therefore, in these settings, regulatory B cells had a protective role. What role 
regulatory B cells may play in HBV infection in humans, as well as in the setting of 
chronic viral infection as a whole is as yet unclear and was investigated here. 
We showed firstly that upon stimulation with the toll like receptor ligand CpG, there was a 
greater proportion of IL-10 producing B cells in patients compared to healthy donors. The 
ability of TLR ligands to induce IL-10 producing B cells has been shown by 
Lampropoulou et al in a mouse model of EAE. In this study it was shown that upon CpG 
or LPS stimulation, naïve B cells produced IL-10 and were able to suppress Th1/Th17 
mediated inflammation indirectly by downregulating production of cytokines (IL-6, IL-12, 
IL-23) by dendritic cells (Lampropoulou et al. 2008). Therefore it is feasible in our model 
that TLR stimulation, especially in the liver where there is an enrichment of ligands 
derived from gut derived bacteria, could be inducing a similar regulatory IL-10 producing 
B cell population in vivo. However, this is unlikely the sole mechanism of IL-10 induction 
as it cannot explain the preferential enrichment of these B cells in patients with HBV 
infection. This suggested the presence of an HBV-specific stimulus also. 
Previous reports have shown that the HBV core antigen, an icosahedral nucleocapsid made 
up of 180-240 core protein, was able to activate naïve B cells in mice by binding directly to 
and cross-linking B cell receptors (Lazdina et al. 2001). This was however not the case for 
HBeAg, a secreted protein produced by the virus at high quantities. Similarly, Cao et al 211 
 
showed in human peripheral blood leucocyte NOD/SCID mice that HBcAg could bind 
human B cell receptor in a T cell independent fashion (Cao et al. 2001). Although these 
studies were not directly looking at the ability for HBcAg to induce IL-10, they showed at 
least that HBV particles had the potential to activate B cells. Taking this one step further, 
we investigated whether HBcAg could act as an antigen specific stimulus to induce IL-10 
production in vitro by B cells. Our results showed that upon stimulation with HBcAg for 4 
days and a short restimulation with PMA/ionomycin, there was production of a low 
frequency of IL-10 producing single positive cells, and TNF-α producing single positive B 
cells but no dual positive populations by HBcAg, indicating the presence of antigen 
specific B cells in HBV. Of note, stimulation with HBsAg at different concentrations was 
not able to induce IL-10 production either by ELISA or by intracellular cytokine staining, 
further suggesting the preferential effect of HBcAg on B cells. As both core and surface 
antigen stocks were produced by the same company at the same time, it is unlikely 
therefore that the effects seen with HBcAg were due to LPS contamination, as the same 
effect would have been seen with HBsAg, and LPS does not induce regulatory B cell IL-10 
production (Mauri C. personal communication). The ability of HBcAg to stimulate IL-10 
by PBMC has been demonstrated in HBV. In these studies, however, T cells and 
monocytes were the main producers of IL-10 production, whereas only a minority of 
HBcAg specific IL-10 was from B cells (Hyodo et al. 2003;Hyodo et al. 2004).  
It is unlikely therefore that HBcAg alone could be stimulating IL-10 production in B cells, 
and other viral factors in addition to the cytokine milieu and inflammatory mediators could 
be having an effect. IL-10, which is raised during flares of HBV, has been shown to induce 
IL-10 production by B cells and other lymphocytes. Interestingly, Lampropoulou have 
suggested a two step model of induction for IL-10 regulatory cells in EAE, by which initial 
stimulation with TLR ligands induced a pool of IL-10 producing B cells which were then 
further stimulated with autoantigen and CD40 to become antigen-specific IL-10 regulatory 
B cells, required for remission of EAE. In chronic HBV infection, ability of HBcAg to 
induce IL-10 may similarly partially be dependent on whether B cells have been primed 
towards IL-10 production, perhaps by TLR stimulation (Lampropoulou et al. 2008). 
In order to better characterise these regulatory B cell populations, we have in addition 
determined the phenotypic profile of these cells. Studies by Carsetti et al. have shown that 
human peripheral B cells can be subdivided into fractions; mature, transitional and 212 
 
memory, dependent on surface expression of markers CD24 and CD38 (Carsetti et al. 
2004). Based on this classification we showed that following stimulation with CpG as well 
as directly ex vivo, the majority of IL-10 producing cells were of transitional or mature 
phenotype. This is similar to the observations by Lampropoulou et al who also determined 
that TLR stimulation induced mainly naïve B cell IL-10 production and Duddy et al who 
have showed that naïve, not memory, B cells produced IL-10 on stimulation with CD40 
and through the B cell receptor (Duddy et al. 2007;Lampropoulou et al. 2008). Making use 
of serially stored PBMC collected before, during and after chronic flares of liver 
inflammation, we next studied the temporal correlations of these cell types over chronic 
flares of disease. This analysis showed that the transitional B cells, but not the mature or 
memory correlated temporally with disease flares, suggesting that these cells were the 
putative regulatory subset.  
To address whether these IL-10 B cells regulate immune responses in HBV, we selectively 
depleted out B cells which we had previously identified phenotypically as the regulatory B 
cells, and showed that HBV-specific responses were rescued in the three patients studied. 
Thus, these transitional B cell subsets had the capability to directly suppress virus-specific 
responses. Similar phenotypic populations of  marginal zone B cells upon stimulation with 
CpG have been shown to suppress SLE in vivo via IL-10 (Brummel & Lenert 2005;Lenert 
et al. 2005), and transitional zone MZ precursor 2 B cells mediate the same suppressive 
effects in collagen induced arthiritis (Evans et al. 2007). How they might mediate this 
effect in vivo within the liver, the site of highest liver inflammation and viral load, is still 
open to speculation. In previous reports, IL-10 production from regulatory B cells has been 
shown to both directly and indirectly suppress T cell responses by interference with 
expression of costimulatory molecule expression on APC and cytokine and chemokine 
production (Brummel & Lenert 2005). Thus it is likely that regulatory B cells use a multi-
faceted approach in their regulation. Firstly, these cells have been shown to induce 
regulatory T cell populations, which have previously been shown to be enriched in patients 
with severe chronic HBV infection (Xu et al. 2006). This could potentially be through IL-
10 production, although previous studies have shown that B cells can induce T cell 
regulatory activity instead by acting as inefficient antigen presenting cells (Reichardt et al. 
2007). In the anterior chamber of the eye, for example, simultaneous presentation of 
antigens on MHC Class I and II has been shown to induce both CD4 and CD8 regulatory T 
cell activity associated with peripheral tolerance. (Ashour & Niederkorn 2006). 213 
 
Furthermore, in a model of colitis, protective transfer of mesenteric lymph node B cells 
was associated with increased CD3+NK1.1+T cells in the mesenteric lymph nodes and an 
increase in regulatory CD4+CD8a+T cells among intraepithelial lymphocytes (Wei et al. 
2005). Therefore, induction of these populations may amplify the regulatory potential of B 
cells, although Fillatreau et al show in a bone marrow chimeric model in EAE where only 
B cells but not T cells are IL-10 deficent, that there is no resolution of infection. Therefore, 
B cells may indeed have their own direct effects as well (Fillatreau et al. 2002). Overall, 
from the previous literature it is evident that multiple sources of IL-10 are available, 
especially within the HBV infected liver and not only resident Kupffer cells but infiltrating 
monocytes, macrophages and T cells can respond to TLR ligands within the local 
environment to elaborate IL-10 (Boonstra et al. 2006). Therefore, although B cells are not 
the dominant source, they may still have potent action by amplifying their function by 
recruiting other cells within the regulatory framework. Furthermore, greater study is 
needed to characterise the proportion of regulatory B cells in livers with high viral load and 
ongoing liver inflammation, as from the evidence in peripheral B cells, it is at these 
timepoints that regulatory B cells are enriched over other B cell fractions, and may 
contribute significantly. 
We have established that IL-10 is raised in patients with CHB, but what are the functional 
implications of this? To investigate this, we next studied the impact of IL-10 blockade in 
vitro on the magnitude of virus-specific responses. We observed that blockade of IL-10 in 
vitro was able to rescue HBV-specific CD8 T cell responses. A more comprehensive 
blockade with IL-10 receptor as well had a synergistic effect on the enhancement of 
responses. Furthermore, in some cases, new HBV-specific CD8 T cell responses were 
revealed whereas they were previously undetectable. This suggested that CD8+ specific 
responses may be under constitutive suppression by the elevated IL-10 levels in these 
individuals. Interestingly, in resolved individuals, HBV specific responses were rescued 
preferentially to CMV or FLU responses from the same individuals. In these individuals, 
serum IL-10 levels were not significantly different compared to healthy donors. This may 
imply that HBV specific responses are more sensitive to the effects of IL-10, possibly due 
to differential expression of IL-10 receptor although this remains to be investigated. Thus 
in resolved individuals, any IL-10 present could possibly modulate HBV specific responses 
but not be sufficient to significantly modulate the more robust responses to CMV and FLU 
viruses. 214 
 
In previous chapters we showed that CD8 T cells from patients with high viral load 
displayed a marked global dysfunction in their ability to produce IL-2 and proliferate. 
Based on our observations that blockade of IL-10 can rescue not only HBV-specific but 
other viral responses, we suggest that IL-10 may be a possible mechanism for this pan-
CD8 T cell dysfunction seen. In support of these data, a study in HIV infection showed that 
IL-10-producing gag-specific CD8 T cells could suppress IL-2 production and cytolysis 
from antigen-stimulated CD8 T cells.  Furthermore, depletion of these IL-10-producing 
CD8 T cells resulted in a recovery of IL-2 but not IFNγ production by both CMV and HIV 
specific CD8 T cells (Elrefaei et al. 2007). This is congruent with our identification of CD8 
T cells that maintain their ability to produce IFN-γ, in the face of IL-2 loss. Similarly, in 
the LCMV mouse model, blockade of IL-10 production was associated with recovery of T 
cell IL-2 production and subsequent viral clearance (Brooks et al. 2006). 
We have also shown that CD8 T cells isolated from the liver of patients with HBV, have 
the greatest impairment in their production of IL-2. This disparity in function between the 
peripheral blood and intahepatic lymphocytes could again be partially explained by IL-10. 
In recent reports, it has been shown that Kupffer cells may constitutively produce IL-10 in 
the liver in responses to Toll like receptor ligands such as LPS derived from gut derived 
bacteria (Tu et al. 2008a). This resting state of IL-10, we hypothesize, could further induce 
IL-10 production by regulatory B cells initiating a regulatory cascade which could 
contribute to heightened local suppression of HBV-specific CD8 T cell responses. Indeed, 
localised IL-10 mediated tolerance of anti-viral responses has been associated with viral 
persistence in other organs such as the salivary glands and the spleen. Persistence of 
MCMV in salivary glands has been associated with the presence of IL-10 producing CD4 
T cells specifically within this organ, but not elsewhere. Blockade of IL-10R resulted in an 
increased accumulation of IFNγ producing CD4 T cells and concurrent clearance of 
infection (Humphreys et al. 2007). Similarly, high levels of IL-10mRNA was detected in 
splenic CD25 negative T cells, and associated with persistence of human Visceral 
leishmaniasis in the spleen (Nylen et al. 2007). These data support the idea that IL-10 
mediated local tolerance may facilitate loss of viral control, however this is only a 
contributory mechanism, and other factors have been described. For example, in previous 
chapters we have alluded to the role of L-arginine depletion and resultant CD3ζ chain 
downregulation which could influence the capacity of global CD8 T cell IL-2 production 215 
 
and proliferation. Additionally, there is accumulating evidence for the role of other 
cytokines such as TGF-β in the regulation of immune responses. In patients with 
HIV/HCV coinfection or HCV monoinfection for example, blockade of TGF β enhanced 
both CD4 and CD8 T cell production of IFN-γ on ELISPOT analysis in response to a pool 
of HCV core peptides. In this case, HCV specific CD8+CD25- T cells were a potential 
source of this regulatory cytokine. Interestingly, blockade of TGF-β or IL-10 did not 
significantly alter IFN-γ responses following stimulation with CEF (comprised for a pool 
for 23 major histocompatability compex class I restricted T cell 11-18mer peptides from 
CMV, EBV and FLU viruses). This was against global CD8 T cell dysfunction, however 
due to the fact that the magnitude of responses (number of spot forming units) was upto 
1000 times greater with this more robust stimulus, effect of IL-10/TGF-β may have been 
more negligible and difficult to detect (Alatrakchi et al. 2007b).  
We have shown in this study that IL-10 actively fluctuates in chronic HBV infection and is 
associated temporally with disease flares. Blockade of IL-10 and its receptor significantly 
rescues virus specific responses thus suggesting that IL-10 is able to suppress T cell 
responses within these individuals. This could serve as a partial mechanism for the global 
functional defects we have observed in previous chapters. Furthermore, we show that IL-
10 producing B cells exist in chronic HBV infection and correlate temporally with disease 
activity. These B cells have direct suppressive capacity in vitro at least implicating them as 
potential suppressors of viral control and mediators of pathogenesis in HBV. 216 
 
Future directions 
The data presented in this thesis contribute to the understanding of CD8 T cell inefficiency 
and potential mechanisms for perpetuation of chronic HBV infection. In this section, I will 
discuss some of the future plans for this work, as well as its potential implications for the 
design of immunotherapeutic agents, and its limitations. 
In chapter three, we identified a global CD8 T cell defect in IL-2 production and 
proliferation in HBeAg positive patients with high viral load and liver inflammation. Since 
the majority of patients with high viral load frequently also have co-existing liver 
inflammation and are HBeAg positive, it is difficult to distinguish cause from effect in the 
observed association between disease variables in CHB and the functional/phenotypic 
parameters investigated in CD8 T cells. It would be useful to dissect this relationship 
further and determine whether one disease variable was more influential than the others at 
inducing loss of IL-2. One potential way to test this would be to compare the function of 
intrahepatic global CD8 T cells isolated from HBV inflamed livers vs. non-HBV inflamed 
liver. Patients with alcoholic hepatitis may be recruited, as there is no underlying viral 
pathology, yet liver inflammation is still present. This would help to determine whether 
inflammation alone can induce loss of CD8 T cell function, and what contributory role 
virus/secreted viral antigens may have in inducing T cell hyporesponsiveness. 
Alternatively, it is also feasible to study longitudinal changes in CD8 T cell IL-2 
production before, during and after HBeAg negative flares of liver disease, in which there 
are intermittent peaks of disease activity over a relatively condensed timeframe. These data 
may reveal whether fluctuations in CD8 T cell effector function are related temporally to 
HBV DNA, ALT or both. 
An ongoing study in our group (Khanna et al.) is comparing the function of global and 
virus-specific CD8 T cells in treated vs. untreated patients with CHB. Anti-viral 
treatments, to date, had the capacity to suppress HBV viral load in patients, however this 
was not maintained on cessation of therapy suggesting that immune function was not 
recovered. A range of novel more potent anti-viral drugs are now licensed for use; their 
efficacy in reversing or boosting immune function will be a focus of this study. This 
knowledge will facilitate the timely delivery of the most potent agents to maximally boost 
the immune response, with an aim of regaining immune control and viral clearance. 217 
 
 
In the initial cross-sectional study design, parameters being compared between the groups 
include CD8 and CD4 T cell production of cytokines (IL-2, TNF, IFNγ), cytolytic ability 
and proliferation. Furthermore, the frequency of virus-specific CD8 T cells expressing the 
pro-apoptotic molecule Bim, which is upregulated in HBV-specific CD8 T cells and 
associated with their attrition during CHB (Lopes et al. 2008), is being compared between 
the groups. Effector function and Bim expression will also be characterised longitudinally 
in serial PBMC samples isolated from patients at pre and post treatment timepoints, to 
determine whether impaired effector function in CD8 T cells can be recovered upon 
sustained reduction of viral load and ALT on antiviral therapy.  
In chapter four, we showed that in the absence of L-arginine, CD8 T cells were unable to 
upregulate CD3ζ in vitro. Furthermore, serum L-arginine levels were depleted in vivo in 
patients with high liver inflammation, and arginase activity was elevated in the livers of 
patients with CHB compared to non-viral liver disease. We hypothesized therefore that 
arginase-1 mediated L-arginine depletion could be partially responsible for 
hyporesponsiveness of CD8 T cells in CHB. These data raise the following questions; 
1.  What is the source of arginase-1 in the HBV inflamed liver? 
2.  Can depletion of other non-essential amino acids have the same effect on T cell 
responses? 
One potent source of arginase which has not been investigated in this study is myeloid-
derived suppressor cells. These cells were first described in the 1970’s as natural-
suppressor cells, and have the capability to suppress T cell responses, partially by 
upregulation of arginase-1 and catabolism of extracellular arginine (Bronte & Zanovello 
2005). They have been shown to accumulate in cancer (Zea et al. 2005), autoimmune 
disease, in situations of immune stress or trauma (Serafini et al. 2004), and during certain 
acute or chronic fungal (Mencacci et al. 2002) or parasitic infections (Goni et al. 2002), 
where they mediate immunosuppression. They are regarded as immature cells from the 
myeloid lineage, and in mice, are phenotypically heterogenous. In mice with subcutaneous 
implants of colon carcinoma, MDSC were CD11b+GR1+ and upregulated iNOS and 
arginase-1 which can both catabolise L-arginine (Ochoa et al. 2007). In murine lung 218 
 
carcinoma however, MDSC expressed macrophage markers CD11b+GR1-CD68+ and had 
high arginase-1 activity (Rodriguez et al. 2004).  
In humans, Filipazzi et al. found that a population of CD14+HLA DR (negative/low) cells 
were enriched in all metastatic melanoma patients but undetectable in healthy donors and 
were potently capable of suppressing lymphocyte function. However, this was mediated by 
TGF−β and not NOS/arginase (Filipazzi et al. 2007). In a more recent study however, 
Hoechst et al. demonstrated that the same phenotypic subset of MDSC were enriched in 
the periphery of patients with hepatocellular carcinoma compared to healthy donors, had 
high arginase activity, and suppressed autologous T cell proliferation (Hoechst et al. 2008). 
Although these studies agree on the phenotypic characterisation of a subset of MDSC in 
humans, there is some debate as to whether their influence on T cell responses is mediated 
by arginase activity or not. 
In patients with metastatic renal cell carcinoma, Zea et al. showed that PBMC had a 6-8 
fold higher arginase activity compared to those isolated from healthy donors. This 
correlated with reduced serum L-arginine levels, high plasma ornithine (the breakdown 
product of L-arginine when metabolised by arginase-1), and low cytokine production and 
CD3ζ downregulation in T cells. Cell separation studies showed that elevated arginase 
activity was limited to a subset of CD11b+CD14-CD15+ cells with a polymorphonuclear 
granulocyte morphology, and the percentage of these cells directly correlated with arginase 
activity in PBMC (r
2=0.9327). Phenotypically, these cells also expressed CD80, CD83, 
CD86, MHC II and CD11a. Importantly, depletion of these MDSC upregulated CD3ζ and 
recovered proliferative capacity in T cells, suggesting that MDSCs were suppressing T cell 
function through arginase (Zea et al. 2005). 
It is feasible that selective accumulation of the MDSC in the liver (possibly recruited by 
IFNγ induced chemokine release (Kakimi et al. 2001b)) and periphery of patients with 
CHB may contribute to suppression of global CD8 T cell IL-2 production and 
proliferation, and thus potentially impair viral control. According to the above literature, 
MDSC in humans may be identified by their expression of markers such as CD14 and 
CD11b, as shown in mice. Using a cross-sectional study design, the frequency of these 
cells could be quantitated by surface staining and flow cytometry in peripheral blood and 
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healthy donors. Furthermore, the capacity of these cells to suppress both HBV-specific and 
other control virus-specific CD8 T cell responses could be determined by co-culture of 
isolated MDSC with PBMC stimulated with HLA-A2 restricted viral peptides. Addition of 
arginase inhibitors (nor-NOHA) may further help to determine whether any observed 
suppression was mediated through arginase activity or not. These experiments would help 
strengthen our current findings and provide additional mechanisms for global and HBV-
specific CD8 T cell dysfunction during CHB. 
In addition to depletion of L-arginine, studies have shown that depletion of tryptophan and 
accumulation of its toxic metabolites is associated with CD3ζ downregulation and 
impaired T cell proliferation (Fallarino et al. 2006;Frumento et al. 2002), although this is 
not true for all non-essential amino acids, as depletion of L-glutamine does not have this 
effect (Rodriguez et al. 2002). By obtaining tryptophan depleted medium, it would be 
possible to study whether depletion of this amino acid may also contribute to CD8 T cell 
dysfunction during CHB. 
Normal serum concentrations of L-arginine range from 50-150μmol/L (Ochoa et al. 2007). 
During trauma, studies have reported that rapid release of arginase can significantly 
deplete serum L-arginine levels to below 50μmol/L, which is associated with CD3ζ 
downregulation and T cell anergy (Bernard et al. 2001;Ichihara et al. 1999). In our cross-
sectional study, 3 patients had serum L-arginine levels below 50μmol/L, and in a further 6 
patients, serum L-arginine levels were at the lower end of normal range, below 75μmol/L 
(figure 4.9). L-arginine levels may be even lower in the liver, where we have shown 
arginase to be upregulated. In these individuals, an insufficient supply of L-arginine may 
hamper the ability of HBV-specific CD8 T cells to respond to antigenic stimulation 
through the TCR. This could potentially hinder the efficacy of immunotherapeutic vaccines 
which aim to boost HBV-specific CD8 T cell responses. Dietary L-arginine has been 
shown to protect against infection in trauma patients, however in one study, it was also 
shown to stimulate tumours in patients with breast cancer (Park et al. 1992). Other 
potential therapies may include drugs such as sildenafil, which have known safety and 
pharmokinetics, and may boost T cell responses by downregulating arginase and iNOS 
activity, primarily in MDSC (Serafini et al. 2006). 220 
 
In chapter five, we showed that global CD8 T cells were more differentiated in patients 
with CHB and had shorter telomeres within the CD27 negative fraction. Furthermore, 
telomere length was even shorter in HBV-specific CD8 T cells. These latter experiments 
were done in a limited number of patients for the following reasons; 
1.  Ex vivo circulating frequencies of HBV-specific CD8 T cells are barely detectable 
in patients with high viral load, therefore are difficult to study. 
 
2.  Expansion of these HBV-specific CD8 T cells in vitro grossly increases telomere 
length in all CD8 T cells, suggesting that this was an artefact of cell culture. 
 
3.  Virus-specific CD8 populations have been identified by measuring the production 
of IFN-γ production by these cells. Staining the cells with IFN-γ occurred prior to 
hybridisation of PBMC in the flow FISH assay. Heating of the conjugated antibody 
to 82
oC results in degradation of the fluorochrome, weakening the fluorescence 
signal and making it even more difficult to detect HBV-specific populations. 
In future experiments, these assays could be repeated with the use of Quantum Dot 
nanocrystal primary antibody conjugates, which are more heat stable, brighter and 
photostable than organic fluorophores. These reagents are being routinely used now by our 
collaborators at the Department of Medicine, Addenbrooke’s Hospital, Cambridge. 
In addition to studying telomere length in CD8 T cells, an additional marker associated 
with replicative senescence is phosphorylated histone H2AX. When telomeres reach a 
critical length, DNA double strand breaks trigger cell cycle arrest. This DNA damage 
response involves phosphorylation of histone H2AX, which initiates a cascade of events 
resulting in cell senescence (d'Adda et al. 2003). Accumulation of phosphorylated histone 
H2AX has been found in colonocytes in patients with Ulcerative Colitis compared to 
controls in a recent study and this DNA damage signal can be measured by flow cytometry 
(Risques et al. 2008). It is feasible therefore in future studies to determine the fluorescence 
of phosphorylated histone H2AX in PBMC from patients with CHB, as a measure of DNA 
damage and replicative senescence in these cells. 
Telomere shortening and replicative senescence can be delayed by the action of 
telomerase, which can add telomeric repeats back on to the ends of chromosomes (Akbar 221 
 
& Vukmanovic-Stejic 2007;Zajac et al. 1998). In future studies, we aim to study whether 
aberrant expression of telomerase in lymphocytes may partially explain why telomere 
length is shorter in CD8 T cells from patients with high viral load compared to patients 
with low viral load and healthy donors. This would involve extending the preliminary 
cross-sectional study shown in figure 5.10. In addition, future studies would also 
investigate the in vitro effect of IFNα on telomerase activity on CD8 T cells from patients 
with CHB, as this has been previously reported to inhibit telomerase (Reed et al. 2004). 
Interestingly, previous data from our group has demonstrated that IFNα levels in the serum 
correlated temporally with disease activity during flares of HBeAg negative hepatitis 
(Dunn et al. 2007). Longitudinal determination of telomerase activity derived from PBMC 
cell extracts available from timepoints before, during and after such flares, would allow 
correlation of telomerase activity with IFNα levels in vivo. Furthermore, the effect of 
IFNα therapy on telomerase activity in patients with CHB may also be determined. 
In chapter six we suggested a novel role for B cells in regulating the immune response 
during human chronic viral infection through production of IL-10. We showed that a 
subset of transitional B cells fluctuated with disease activity ex vivo in patients undergoing 
HBeAg negative flares of liver disease, and depletion of these cells rescued HBV but not 
CMV-specific CD8 T cell responses in vitro. Additionally, suppression by transitional cells 
was mediated partially by IL-10 production; blockade of IL-10 and its receptor rescued 
HBV-specific CD8 T cell responses. A number of questions are raised by our findings 
which can be addressed in future work. 
The ability of B cells to regulate human viral infections is a new emerging field of 
research. No phenotypic markers have yet been published to identify IL-10 producing 
regulatory B cells in humans. In mice, Evans et al. showed that MZ-transitional 2 B cells 
were selectively responsible for IL-10 mediated suppression of autoimmunity (Evans et al. 
2007). Work from the same group has provided evidence that human transitional B cells 
may have the same regulatory capabilities (Paul Blair et al, manuscript submitted). On the 
basis of this work, and our own observations that IL-10 is produced exclusively by 
transitional and mature B cells upon CpG stimulation, we investigated 
CD24hiCD38hiCD19+ B cells as the putative regulatory subset. Additional phenotypic 
markers which may be useful to characterise these cells in the future include CD1d; a 
marker found of CD19+ positive B cells which were enriched in gut-associated lymphoid 222 
 
tissue of mice and regulated inflammation through production of IL-10 (Mizoguchi et al. 
2002). 
In this work, we have studied the phenotypic properties of B cells after 4 days stimulation 
with CpG. These data have also been repeated in a limited number of patients ex vivo and 
show a trend towards an increase in transitional cells with viral load (work by Gidon Ellis). 
In future work, this phenotypic study can be extended. Phenotypic markers may also be 
used to look at the proportion of regulatory B cells within HBV and non-HBV livers. 
Through our collaborators, we have access to a large library of paraffin embedded samples, 
which may be stained by immunohistochemistry for B cell and T cell markers. 
We have functionally identified regulatory B cells through their ability to produce IL-10 
following stimulation with CpG and the mitogen PMA. In our cross-sectional study, the 
proportion of IL-10 producing B cells was raised in CHB compared to controls. However, 
it is not clear whether HBV signals through toll like receptors, and whether it contains 
unmethylated CpG motifs which would be capable of ligating TLR9 on B cells in vivo. It 
would be important in future studies to investigate whether IL-10 could be induced in these 
subsets by a more physiological stimulus. Candidate stimuli include the recombinant 
surface and core antigens of HBV. HBsAg is released at milligram quantities in patients 
with CHB, and HBeAg (the cleaved form of HBcAg), is produced during active disease 
and has no known role in viral replication, but instead has been suggested to be a tolerogen 
(Milich et al. 1990). In preliminary data, we have shown that stimulation of PBMC with 
HBcAg for four days induced IL-10 and TNFα single positive subsets in CD19+ B cells 
from patients with CHB. HBsAg did not have the same effect in our study. Observations 
by Dunn et al., who quantified supernatant IL-10 by ELISA following stimulation of 
PBMC from acute patients with the same HBcAg or HBsAg preparations (Dunn et al. 
manuscript submitted), also found IL-10 induction only by nucleocapsid antigen. 
Comparison of the proportion of IL-10 producing B cells stimulated with HBcAg between 
patients and healthy donors may help to confirm our observations with the CpG stimulus.  
In addition to the above experiments, there are further lines of work which may be 
pursued. They are outlined in brief here. 
1)  We observed that HBV-specific CD8 T cell responses may be more sensitive to IL-
10 blockade than CMV or FLU-specific responses from the same individuals. This 223 
 
differential sensitivity to the effects of IL-10 could reflect distinct expression of IL-
10 receptor on different populations of virus-specific CD8 T cells. In future studies, 
we could therefore study expression of IL-10R on the surface of CD8 T cells 
directed against different viruses. 
 
2)  We now have access to longitudinal PBMC and serum samples taken from patients 
before and after initiation of anti-viral therapy. In these individuals, it will be 
possible to study the effect of therapy and reduction in viral load on serum IL-10 
concentration and ex vivo frequencies of transitional B cells.  
 
3)  Regulatory B cells may additionally suppress HBV-specific CD8 T cell responses 
by mechanisms independent of IL-10. This was suggested by our observation that 
transitional cells partially suppressed HBV-specific responses upon IL-10 
blockade. We hypothesize that this could be mediated through release of cytokines 
such as TGF-β, blockade of which can rescue both HBV (Lopes and Khanna 
unpublished data) and HCV-specific CD8 T cell responses in vitro (Alatrakchi et 
al. 2007a), or through triggering of a regulatory network, including regulatory T 
cells, which may futher amplify suppression. B cell deficiency, during EAE 
infection of mice, delayed the emergence of Foxp3+ IL-10 producing regulatory T 
cells in the CNS. Regulation of CD4+CD25+ T regs by B cells was mediated 
through the costimulatory molecule B7 (Mann et al. 2007). 
 
4)  We aim to investigate the potential for HBV-specific B cells to regulate the 
immune response during CHB. Recently it was demonstrated by Ward et al. that 
HBsAg specific memory B cells could be isolated ex vivo with a novel two-step 
immunomagnetic protocol (Ward et al. 2008). This method could be used to 
quantify and compare the frequency of HBV-specific B cells in patients with low 
and high levels of serum IL-10, and also to determine their functional capacity in 
vitro. 
Two recent studies in murine models of LCMV have shown that blockade of IL-10 
receptor can mediate clearance of virus in vivo (Brooks et al. 2006;Ejrnaes et al. 2006). 
More recently, the same group showed that blockade of IL-10 enhanced the function of a 
previously ineffective therapeutic DNA vaccine to boost antiviral immune responses 224 
 
(Brooks et al. 2008). In our study, we have shown in vitro that blockade of IL-10 and its 
receptor can rescue HBV-specific CD8 T cell responses. Neutralising antibodies against 
IL-10 may potentially boost HBV-specific CD8 T cell responses in vivo. However, the 
kinetics of IL-10 administration may be critical in determining its efficacy. In a normal 
immune response, IL-10 production may serve as a physiological brake to prevent an over-
reactive immune response (Martinic & von Herrath 2008). Any potential side effects also 
have to be taken into account. IL-10 deficient mice have been shown to develop 
enterocolitis in the presence of normal gut flora (Kuhn et al. 1993). 
In addition to blockade of IL-10 signalling, studies in mice with chronic LCMV infection 
have also highlighted other promising, potentially complementary, strategies; blockade of 
PD-1/PD L1 and treatment with FTY720, a novel class of immunosuppressive drug. As 
discussed in chapter five, PD-1 is a negative regulator of T cell signalling and has been 
shown to be hyper-expressed on exhausted LCMV specific CD8 T cells (Barber et al. 
2006). In patients with CHB, PD-1 expression was shown to be raised both on HBV-
specific (Boni et al. 2007) and global CD8 T cells (Evans et al. 2008;Peng et al. 2008b). 
Blockade of PD-1/PD-L1 signalling was able to recover core and polymerase, but not 
envelope specific CD8 T cell responses in vitro (Boni et al. 2007). Antiviral treatment 
reduced PD-1 expression on both global and HBV-specific CD8 T cells and was associated 
with recovery in the frequency of IFN-γ producing T cells (Evans et al. 2008).  Medarex 
and Ono Pharmaceuticals have tested the safety of MDX-1106, a fully human anti-PD-1 
antibody, in a Phase I study in patients with recurrent or treatment refractory cancer. More 
recently, they launched a double-blind, randomized, placebo controlled, single-dose, dose-
escalation, safety and pharmokinetic study of MDX-1106 for the treatment of HCV 
infection.  
In the last month, Premenko-Lanier et al. have showed that FTY720, an 
immunosuppressive agent trialed in humans for treatment of relapsing multiple sclerosis 
and prevention of kidney transplant rejection was able to clear already established chronic 
LCMV infection in mice (Premenko-Lanier et al. 2008). During murine LCMV infection, 
it is well characterised that infection with the Armstrong strain of virus results in acute 
infection and viral resolution, whereas infection with the clone 13 strain instead favours 
viral persistence. Premenko-Lanier et al. noted that following infection with the Armstrong 
strain, there was a profound lymphopenia 1-3 days post infection which was much less 225 
 
marked during infection with the clone 13 variant. These lymphocytes were found to be 
sequestered within the lymph nodes during this period. By treating clone 13 variant mice 
with FTY720, which is known to sequester lymphocytes to lymph nodes and Peyer’s 
patches, the authors observed that by day 8, clone 13 titres were undetectable in brain and 
kidneys, and virus was cleared by day 30. Furthermore, administration of FTY720 at days 
30, 31 and 32 of established infection, resulted in clearance of virus by day 60. FTY720 
did not have a direct anti-viral effect, and required the presence of CD4 T cells, suggesting 
that it had an immunomodulatory role. Both glycoprotein (GP)33-41 and  nucleoprotein 
(NP)396-404 specific CD8 T cells in FTY720 treated mice were functional, whereas 
(NP)396-404 specific CD8 T cells have previously been described to be deleted during 
chronic LCMV infection with clone 13 variant (Zajac et al. 1998). This study has used a 
drug which is already used in humans for the clearance of chronic LCMV infection. Such 
therapy may also have efficacy in patients with CHB, although the mechanism of action is 
not yet fully clear. In the interim period, it would be interesting to investigate patients who 
are currently under FTY20 therapy for diseases such as multiple sclerosis, who may be 
also co-infected with chronic persistent viruses such as HBV/HIV or HCV. 
A number of new targets for immunotherapy have been identified in mice and human 
chronic viral infections. Development of some of these agents for treatment of human 
disease is in progress, and will be complimentary to the existing anti-viral therapy regimes. 
Together, these strategies may be more efficacious and provide a means to help reduce the 
global burden of CHB worldwide. 
We have described three novel mechanisms that may contribute to inefficient T cell 
function in CHB; downregulation of the TCR-associated signalling molecule CD3ζ, 
partially attributable to arginase-1 mediated L-arginine depletion, regulation by transitional 
B cell IL-10 and premature ageing of global CD8 T cells. We propose that these 
mechanisms in combination may act to disable CD8 T cell responses, and in addition, 
contribute to the pro-inflammatory cytokine environment and immune mediated pathology. 
In conclusion, these data provide new avenues for immunotherapeutic intervention in 
CHB, which may boost the body’s natural ability to control this virus.  
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